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 The work in this thesis details the design, synthesis, and biological evaluation of 
molecular inhibitors for the inhibition of biologically relevant enzymes.  The first three 
chapters of this thesis concern the polyphenol resveratrol and its inhibition of the quinone 
reductase 2 (QR2) enzyme.  The work on this subject resulted in the complete design, 
synthesis, biological and structural evaluation of a second generation library of 
resveratrol analogues.  From this work we identified a novel resveratrol analogue that 
inhibits QR2 in a previously unknown binding orientation.  The fourth chapter of this 
thesis details the de novo design of molecules for the inhibition of the Class II HMGR 
enzyme.  The work on this subject involved the de novo design and in silico screening of 
a set of phenothiazine molecules for the inhibition of II-HMGR.  These molecules were 
synthesized and assayed against II-HMGR, resulting in the identification of a substituted 
phenothiazine compound found to inhibit II-HMGR with an IC50 of 130 µM.  This work 
resulted in a successful strategy for the identification of II-HMGR inhibitors.    
	 1
CHAPTER ONE: 






Many epidemiological studies have implicated the positive correlation between 
heightened consumption of total fat, saturated fat, cholesterol, and total caloric intake 
with mortality from heart disease.  This trend has been found in most developed nations, 
with the exception of France; where mortality rates from coronary heart disease (CHD) 
are a third lower than comparable nations, including the United States and the United 
Kingdom, that have similar dietary fat intakes.1  This finding, coined the “French 
paradox,” has been partially attributed to the increased consumption of red wine by the 
French.  Red wine contains higher concentrations of polyphenols than white wine and 
other alcoholic beverages.2  Polyphenols such as resveratrol, quercetin, catechin, and 
proanthocyanidins are abundant in the seeds and skins of grapes and have the ability to 
function as antioxidants, protecting low-density lipoproteins (LDL) from oxidation and 
inhibiting platelet aggregation.3  Understanding of the French paradox has stimulated 
further investigations questioning whether the polyphenolic compounds found in red 




Resveratrol (3,5,4’-trihydroxystilbene) is a naturally occurring polyphenol that 
was discovered in 1940 when it was isolated from the roots of white hellebore (Veratrum 
grandiflorum O. Loes) by Takaoka and coworkers (Figure 1.1).4  Initially there was little 
interest in the molecule as it was characterized as a phytoalexin.5, 6  However, in 1992 
Siemann and coworkers proposed that resveratrol was behind the cardioprotective effects 
of red wine and the French paradox; since that time, interest in resveratrol has sky-
rocketed.7  Subsequently, numerous reports have indicated that resveratrol can prevent or 
retard the progression various disease states, including cancer, cardiovascular disease, 
ischemic injuries, and diabetes.8-12  Resveratrol has even been shown to extend the 









1.2.1. Dietary Sources of Resveratrol 
Since the time of its discovery, resveratrol has been isolated from over 70 
different plant species including blueberries, peanuts, pistachios, rhubarb, hops, and most 
importantly, grapes (Table 1.1).15  A survey of just a few of resveratrol’s dietary sources 
proves that the highest concentration of dietary resveratrol is found in red wine, and the 
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concentration of resveratrol found in red wine is significantly higher than that in white 
wine.  Because resveratrol is found in the skins and seeds of grapes, and not the flesh, this 
finding can be largely attributed to the wine making techniques.  White wine is pressed 
lightly and spends less time in contact with the skins of the grapes.  In contrast, red wine 
is often fermented on the skins of the grapes, allowing more time to extract resveratrol.7  
The geographical growing region of the grapes also has an effect on the concentration of 
resveratrol found in red wines.  As a phytoalexin, higher concentrations of resveratrol are 
produced by plants growing under stressful conditions. 
 
 
Table 1.1. Dietary sources of resveratrol. 
 
Dietary Source of Resveratrol Trans-Resveratrol Concentration 
Red wines 0.1 to 14.3 mg/L16-18 
White wines <0.1 to 2.1 mg/L16, 19 
Grapes 0.16 to 3.54 µg/g20, 21 
Raw cranberry juice 0.2 mg/L22 
Blueberries 32 ng/g23 
Peanuts 0.02 to 1.92 µg/g24 
Peanut Butter 0.3 to 0.65 µg/g25 
Pistachios 0.09 to 1.67 µg/g26 




1.2.2. Resveratrol and Carcinogenesis 
 In 1997, a ground-breaking study was published by Jang and coworkers that 
indicated resveratrol could prevent the three major stages of carcinogenesis, inhibiting 
cellular events related to tumor initiation, promotion, and progression.8  Resveratrol has 
been found to relieve events that are associated with tumor initiation by functioning as an 
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antioxidant.  For example, resveratrol was found to inhibit free radical formation upon 
treating human promyelocytic leukemia cells (HL-60) with 12-O-tetradecanoylphorbol-
13-acetate (TPA) with an ED50 of 27 µM.28  Additionally, Prochaska and colleagues 
found that resveratrol was able to induce quinone reductase-1 (QR1) activity with 
cultured mouse hepatoma cells (Hepa 1c1c7), where a concentration of 21 µM was 
required to double QR1 activity.29  This finding is relevant as QR1 is a phase II enzyme 
that is able to metabolically deactivate carcinogens, functioning in chemoprevention.  
Resveratrol’s inhibition of tumor promotion stems from its ability to inhibit 
cyclooxygenase-1 (COX1), an enzyme that catalyzes the conversion of arachidonic acid 
to prostaglandins, which are compounds capable of stimulating tumor cell growth.  
COX1 has also been shown to activate various carcinogens, resulting in reactive forms 
that have the ability to damage DNA.  Resveratrol was found to inhibit tumor promotion 
by Jang and colleagues.  In an 18-week study of mice where 7,12-
dimethylbenzanthracene (DMBA) was used as a tumor initiator and TPA was used as a 
tumor promoter, the topical application of 1, 5, 10, or 25 µmol of resveratrol together 
with TPA twice a week reduced the number of skin tumors per mouse by 68, 81, 76, or 
98%, respectively.8         
 
1.2.3. Resveratrol and Cardiovascular Disease 
  Systemic administration of resveratrol to rabbits fed a hypercholesterolaemic diet 
was found to inhibit the induced increase of platelet aggregation by Wang and 
coworkers.30  Zini and coworkers found that resveratrol was capable of reducing the 
atherosclerotic area and the size of the blood clot produced by laser-induced damage of 
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the endothelium in mice that were genetically hyperchloesterolaemic.31  The mechanism 
by which resveratrol exerts these helpful effects is not known; however, it may involve 
the preferential inhibition of COX1 over COX2 by resveratrol.  The constitutive form of 
the enzyme, COX1, synthesizes thromboxane A2 (TxA2) in platelets, and is a powerful 
inducer of platelet aggregation and also a vasoconstrictor.32  The inducible form of the 
enzyme, COX2, synthesizes prostacyclin in vascular endothielial cells, and is an 
antiplatelet aggregator and also a vasodilator.33  Thus, selective inhibition of COX1 by 
resveratrol may promote blood flow and decrease thrombus formation.  
 
1.2.4. Resveratrol and Longevity 
 Perhaps the most intriguing effect of resveratrol is its ability to affect lifespan 
extension in a variety of organisms, resulting in it being termed the “molecular fountain 
of youth.”  Many reports have implicated that resveratrol functions similarly to caloric 
restriction as it pertains to lifespan extension.  Caloric restriction has been extensively 
studied in the past 70 years and is largely held as the most robust and reproducible 
method for the retardation of aging and age-related diseases.34  Resveratrol has been 
postulated to function as a caloric restriction mimetic because an array of evidence exists 
that links resveratrol to the activation of sirtuin proteins. 
 The sirtuins are a family of conserved NAD+-dependent deacetylases that have 
been named after the Saccharomyces cerevisiae silent information regulator 2 (Sir2) 
protein, which is the founding member of the family.35  There exist seven mammalian 
sirtuins SIRT1-7, where SIRT1 is the closest homolog of Sir2.  In 2000, Lin and 
coworkers published a seminal report detailing that the increased longevity resulting from 
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caloric restriction is dependent on the activation of Sir2 by NAD.36  Extra copies of the 
genes that encode for the sirtuin proteins in yeast, worms, and flies have also been 
associated with lifespan extension.37-39  In 2003, Howitz and colleagues showed that 
resveratrol was capable of activating Sir2 in Saccharomyces cerevisiae and linked it to 
extending the lifespan of the yeast by 70%.13  Since then, a host of studies have been 
performed investigating the link between SIRT1 and various diseases.  Overexpression of 
SIRT1 in mice has been shown to protect mice from aging-related phenotypes 
comparable to type 2 diabetes,40 cancer,41 and Alzheimer’s disease;42 however, 
overexperssion of SIRT1 has not been found to extend the lifespan of mice.  Long term 
administration of resveratrol to mice induced gene expression that mimicked the effects 
of caloric restriction and retarded aging-related diseases.43 
 Whether or not resveratrol is exerting these anti-aging effects by activation of the 
sirtuins is still unclear.  The original findings of Howitz have been called into question as 
at least two reports have shown that the activation of Sir2 and SIRT1 by resveratrol is 
substrate specific.  In vitro resveratrol was found to enhance the binding and 
deacetylation of peptide substrates that contained the non-physiological fluorescent 
moiety, Fluor de Lys, which was used by Howitz and colleagues in their original study.   
Resveratrol was found to have no activation effect on the binding and deacetylation of 
peptides lacking Fluor de Lys.44  Borra and coworkers investigated the activation of Sir2, 
SIRT1, and SIRT2 by resveratrol and found only SIRT1 was significantly activated by 
resveratrol using a commercially available Fluor de Lys kit.  Moreover, two other 
fluorophores were examined: 7-amino-4-methylcoumarin and rhodamine 110.  It was 
found that peptides containing a fluorophore had a decreased ability to bind SIRT1 and 
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that the presence of resveratrol increased the ability of fluorophore-containing peptides to 
bind SIRT1, indicating that interaction of resveratrol with SIRT1 induces a 
conformational change that better accommodates the fluorophore.45       
 Recently, a new mechanism for the activation of SIRT1 by resveratrol has been 
proposed by Park and colleagues.46  Resveratrol was found to competitively inhibit 
cAMP-degrading phosphodiesterases, resulting in an increase in cAMP concentrations.  
Increased concentrations of cAMP subsequently activate Epac1, a cAMP-regulated 
guanine nucleotide exchange factor, which results in an increase in intracellular Ca2+ 
concentrations.  Increase in Ca2+ levels activates the CamKKβ-AMPK pathway through 
phospholipase C and the ryanodine receptor Ca2+-release channel.  Overall, resveratrol 
increases the concentration of NAD+ and the activity of SIRT1.  Therefore, resveratrol 
may not directly increase the activity of SIRT1, but solid evidence exists that it does so 
indirectly through the cascade mechanism detailed above.  In further support of this 
mechanism of indirect activation of SIRT1 by resveratrol, inhibition of the 
phosphodiesterase PDE4 with rolipram was found to mimic all of the effects of 
resveratrol including prevention of obesity despite a high-fat diet, increased 
mitochondrial function, increased physical stamina, and glucose tolerance in a mouse 
model.      
 
1.2.5. Biological Availability of Resveratrol 
One of the main issues complicating the use of resveratrol as a therapeutic lead is 
its low bioavailability.  Circulating resveratrol has a half-life of 8-14 minutes because it is 
rapidly metabolized in the liver and gut by sulfation and glucuronation.  This metabolism 
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results in the formation of 3- and 4’-O-sulfate and 3-O-glucuronide conjugates and 
reduces the circulating plasma concentration of resveratrol (Figure 1.2).47-50  These 
primary metabolites of resveratrol have been shown to have far lower affinity for certain 
targets in vitro.  For instance, COX1, COX2, and quinone reductase 2 (QR2) are inhibited 
by resveratrol; however, only COX1 and COX2 are inhibited by resveratrol-4’-O-sulfate.  
The resveratrol-3-O-sulfate and -3-O-glucuronide metabolites were found to only weakly 
inhibit COX1 and COX2, while none of the metabolites were found to inhibit QR2.47  
The serum half-life of total resveratrol metabolites was found to be 9.2 hours by Walle 
and colleagues, signifying that the in vivo exposure to metabolite forms of resveratrol is 
















resveratrol-3-O-sulfate resveratrol-4'-O-sulfate resveratrol-3-O-glucuronide  
 




1.2.6. Targets of Resveratrol 
Though resveratrol exerts a host of beneficial health effects, and there is a 
plethora of convoluted research about its targets and mechanisms, the complete story is 
still a mystery.  The search for targets of resveratrol has been met with almost universal 
success; consequently, resveratrol has been shown to either inhibit or activate a variety of 
different enzymes and biological pathways.52  For example, resveratrol’s anti-
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inflammatory, cardioprotective, and chemopreventative activity has been linked to its 
ability to inhibit cyclo- and lipooxygenases,8, 53 while activation of Sir2/SIRT1 by 
resveratrol has been proposed to explain lifespan prolongation.13, 54  A sample of 
resveratrol’s identified targets is shown in Table 1.2.   
Because of the many direct targets of resveratrol that have been identified, 
elucidating which target is implicated in the treatment of a given disease state is unclear, 
complicating its use as a therapeutic lead.  Additionally, resveratrol typically acts on its 
targets with concentrations in the micromolar range, and in many cases those targets may 
be acted on by other molecules with nanomolar concentrations.52  As an example, 
resveratrol inhibits cyclooxygenase-1 (COX1) with an IC50 of 15 μM, while the 
diarylpyrazole SC-560 inhibits COX1 with an IC50 of 9 nM.55  To date, the highest 
affinity target of resveratrol identified is the enzyme quinone reductase 2 (QR2), which 
resveratrol binds to with a dissociation constant (Ki) of 35 nM.56    
 
 
Table 1.2. Activity of resveratrol on various enzymes. 
 
Enzyme Inhibited by Resveratrol Enzymes Activated by Resveratrol 
Cyclooxygenase-1 (ED50 = 15 µM)8 Quinone Reductase-1 (27 µM*)29 
Cyclooxygenase-2 (IC50 = 32 µM)57 Sir2/SIRT1 (100 µM**)13 
Lipooxygenases (IC50 = 3.7 µM)52 AMP kinase (50 µM**)58 
Protein kinase C (IC50 = 40 µM)59 Adenylyl cyclase (0.8 µM**)60 
IKKβ (IC50 = 1 µM)61  
Ribonucleotide reductase (IC50 = 50 µM)62  
NF-κB (IC50 = 30 µM)63  
Quinone reductase 2 (Ki = 35 nM)56  
Aromatase (IC50 = 25 µM)64  
*concentration required to double activity, **resveratrol concentration tested 
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1.3. Quinone Reductase 2 (QR2) 
Quinone reductase 2 (QR2) was discovered in 1961, when it was purified from 
bovine kidney, and is the second member of a small family of quinone reductases.65  It 
was first described as a mammalian cytosolic FAD-dependent flavoprotein that catalyzed 
the oxidation of reduced N-ribosyl- and N-dihydronicotinamides by menadione and other 
quinone substrates.65-67  Interestingly, it was not found to catalyze the oxidation of the 
more common NAD(P)H or reduced nicotinamide mononucleotide (NMnH).  After its 
initial discovery and characterization, it was generally forgotten about for the next 30 
years.  In 1990, QR2 was rediscovered by Jaiswal and coworkers in the process of their 
work cloning human QR1, when they isolated a second quinone oxidoreductase, which 
they termed NQO2.68  It was not until 1997 that QR2 and NQO2 were reconciled to be 
the same enzyme by Zhao and coworkers.69       
 
1.3.1. QR1 vs. QR2 Comparison 
The QR2 physiological homodimer of 231 amino acids per monomer is encoded 
for by the human QR2 gene located on chromosome 6p25 and is 43 residues shorter than 
QR1.70, 71  In contrast to QR1, which is known to be a cytoprotective detoxifying enzyme, 
the true in vivo function of QR2 is currently a mystery.  The characterized function of 
QR1 is the deactivation of quinones via a two-electron reduction, producing 
hydroquinones that can be conjugated with glutathione or glucuronic acid and excreted 
from the body.72  QR2 has been shown to effect either the one-, two-, or four-electron 
reductions of quinones, quinone derivatives, some anti-malarial quinolones,73, 74 and 
certain nitro-containing compounds,75 as well as being identified as the third melatonin 
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binding site.76  In some cases, QR2 has been shown to catalyze the metabolic activation 
of quinones and anti-tumor drugs, producing reactive oxygen species and leading to 
cytotoxicity and cell death.77-79  Another difference between the two reductases is their 
cosubstrate specificity; QR1 is capable of using phosphorylated dihydronicotinamides as 
cosubstrates where QR2 is not, having been shown to use the reduced N-substituted 
nicotinamide analogues in vitro.75  In addition, QR2 is a metalloenzyme, containing a 
zinc ion, the function of which has yet to be identified.69  The two enzymes also have 
different tissue distribution profiles, where QR1 is ubiquitous in all tissue types80 and 
QR2 tissue distribution appears to be highly dependent on the species investigated.  In 
humans, QR2 expression is high in both skeletal muscle and the liver.70, 81          
Yet another distinction between the two reductases is their inhibitor profiles.  A 
clear example of this is their opposite responses to resveratrol.  Prochaska and coworkers 
found that resveratrol was able to increase QR1 activity with cultured mouse hepatoma 
(Hepa 1c1c7) cells at a concentration of 21 μM to double its enzymatic acitivity.29  In 
contrast, resveratrol acts as a competitive inhibitor of QR2 against N-
methyldihydronicotinamide (NMeH) with a Ki of 80 ± 20 nM and as an uncompetitive 
inhibitor of QR2 against menadione with a Ki of 0.9 ± 0.1 μM.47   
 
1.3.2. QR2 Catalytic Mechanism 
QR2 operates via a classic ping-pong mechanism; first, the oxidized isoalloxazine 
ring of the FAD cofactor is reduced by accepting a hydride from the reduced 
nicotinamide, which forms the FADH2-QR2 enzyme complex and releases the oxidized 
nicotinamide from the active site.  The quinone substrate then enters the QR2 active site 
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and accepts a hydride from FADH2, resulting in the two-electron reduction of the quinone 
substrate (Figure 1.3).74, 82  The QR2 active site is 17 Å long by 7 Å wide; three side of 
the active site are lined with hydrophobic amino acids, while the fourth side is solvent 
exposed.  The two ends of the active site contain amino acids amenable for hydrogen 
bond formation (Gly174, Asn161, and Thr71).56  These features of the QR2 active site, its 
narrow width and hydrophobic nature, allow only for the accommodation of molecules 
similar to resveratrol, molecules that can easily occupy essentially planar conformations.  
In addition, molecules that have been identified to bind tightly to QR2 are typically 












1.3.3. Resveratrol and QR2 
The mechanism by which resveratrol inhibits QR2 has been extensively studied.  
Resveratrol binds tightly in the active site of QR2, sitting parallel to the oxidized 
isoalloxazine ring of the bound FAD cofactor, in a perfectly flat conformation (Figure 
1.4A).  It is bound deep in the QR2 dimeric interface, filling a hydrophobic cleft (Figure 
1.4B).56  Each of the hydroxyl groups of resveratrol participate in stabilizing hydrogen 
bonding interactions with residues at the termini of the active site.  The 4’-hydroxyl of 
resveratrol forms two water-mediated hydrogen bonds through ordered active site waters 
to Asp117 and Thr71.  The 3-hydroxyl forms a direct hydrogen bond to Gly174 and the 
5-hydroxyl forms a direct hydrogen bond to Asn161.  The phenyl rings of resveratrol 
participate in van der Waals interactions with neighboring residues lining the interior of 








Figure 1.4. Resveratrol-QR2 complex (PDB: 1SG0) where resveratrol is shown in green, 
colored by atom type, and shown in ball and stick representation.  Water molecules are 
shown as red spheres and distances are displayed by a grey dashed line labeled with the 
distance in Ångstroms (Å).  (A) X-ray structure of resveratrol in complex with QR2, 
showing hydrogen bond network within QR2 active site, where the position of resveratrol 
parallel to the isoalloxazine ring of the FAD cofactor is displayed; (B) Resveratrol in 
QR2 active site, where QR2 is shown in grey surface representation and colored 











1.4. Interest in Resveratrol and its Targets 
 The biological activity of resveratrol – its ability to produce a vast assortment of 
beneficial health effects, not exert any known detrimental side effects, and the fact that it 
interacts with a host of targets – makes it an incredibly interesting research subject.  
There is much to be learned about resveratrol’s interactions.  One way to accomplish this 
is to make various structural modifications to resveratrol and determine what effect those 
modifications have on the molecule’s activity.  The work in the next two chapters of this 
thesis has been accomplished in an attempt to elucidate the structural and electronic 
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2.1. Previous Work 
To begin to address the problems with using resveratrol as a therapeutic lead, 
previous Lipton Research Group member Dr. SooSung Kang synthesized a small library 
of 78 resveratrol analogues.  These resveratrol analogues were designed to probe the 
different steric and electronic requirements of the central olefin and aryl rings of 
resveratrol.  To do this, several electron-donating (OH, OMe, and NMe2) and electron-
withdrawing (F, CF3, and NO2) as well as naphthyl substituents were chosen to decorate 
the aryl rings.  Four substituents (H, Me, Et, and CF3) were chosen to investigate the 
steric and electron demands of the central olefin.  The design, synthesis, and evaluation 
of this library against COX1, COX2, and NF-κB has been previously published.1  
These analogues were tested for COX1, COX2, and NF-κB inhibition by the 
research laboratory of Prof. John Pezzuto of the Department of Medicinal Chemistry and 
Molecular Pharmacology at Purdue University.  The COX1 assay was accomplished 
using an initial screen for COX1 inhibition of each of the resveratrol analogues at a 
concentration of 10 µg/ml.  Analogues that showed at least 50% 
	 25
enzymatic inhibition of COX1 at that concentration were then reassayed in triplicate to 
determine an IC50 value and standard deviation.  The COX2 assay was carried out 
similarly to the COX1 assay.  Inhibition of NF-κB was determined using a luciferase 
reporter gene assay where the resveratrol analogues were initially screened at a 
concentration of 20 µg/ml.  The library members that showed more than 50% inhibition 
at that concentration were then reassayed in duplicate to determine an IC50 value and 
standard deviation.  Library members were tested for QR2 inhibition by Dr. Barbara 
Calamini and Prof. Andrew Mesecar of the Center for Pharmaceutical Biotechnology and 
Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy at The 
University of Illinois at Chicago.  Briefly, the enzymatic activity of QR2 at steady-state 
was determined using an assay where NMeH (N-methyldihydronicotinamide) was used 
as a co-substrate and menadione was used as the quinone substrate, and the activity of 
QR2 was followed by monitoring the decrease in absorbance of NMeH at 360 nm.  The 
resveratrol analogues were tested at 100 μM and IC50 values were determined for 
compounds that showed greater than 50% inhibition of QR2 at this concentration.  The 














L.M.a R1 R2 R3 
IC50 (μM) 
COX1 COX2 NF-κB QR2 
Res 4-OH H 3,5-(OH)2 0.83 0.99 16.1 11.5 
2.1a 4-OH H 3,4-(OH)2 -- -- 12.7 6.0 
2.1b 4-OH H 3,5-(OMe)2 0.70 0.82 19.5 5.1 
2.1c 3,4-(OH)2 H 4-OMe -- -- 12.2 9.3 
2.1d 3,4-(OH)2 H 3-F 11.5 -- 10.3 20.8 
2.1e 3,4-(OH)2 H 4-CF3 -- -- -- 14.2 
2.1f 4-OMe H 3,5-(OMe)2 -- -- 28.3 14.6 
2.1g 3,5-(OMe)2 H 3,4-(OMe)2 -- -- -- 37.1 
2.1h 3,5-(OMe)2 H 4-F -- -- 37.5 4.6 
2.1i 3,5-(OMe)2 H 2-Naphthyl -- -- 18.8 0.73 
2.1j 3,4-(OMe)2 H 3-OMe -- -- 17.3 6.8 
2.1k 3,4-(OMe)2 H 4-NMe2 -- -- -- 13.0 
2.1l 3,4-(OMe)2 H 2-Naphthyl -- -- -- 5.5 
2.1m 4-OH Me 3,5-(OH)2 1.9 1.57 -- 39.0 
2.1n 4-OH Me 4-CF3 -- -- -- 2.8 
2.1o 3,5-(OH)2 Me 4-OH 1.9 1.78 26.2 4.8 
2.1p 4-OMe Me 3,5-(OH)2 12.4 16.0 35.2 12.0 
2.1q 4-OMe Me 3,5-(OMe)2 -- -- 27.1 20.1 
2.1r 4-OMe Me 3,4-(OMe)2 -- -- -- 6.7 
2.1s 3,4-(OMe)2 Me 3,5-(OH)2 11.4 -- 13.1 33.7 
2.1t 3,4-(OMe)2 Me 3,5-(OMe)2 -- -- -- 9.9 
2.1u 3,5-(OMe)2 CF3 4-OMe 7.8 -- -- 13.0 




Table 2.1, continued 
	
L.M.a R1 R2 R3 
IC50 (μM) 
COX1 COX2 NF-κB QR2 
2.1w 3,5-(OH)2 Et 4-NMe2 0.99 -- -- 10.9 
2.1x 3,4-(OMe)2 Et 3,5-(OMe)2 -- -- 27.2 16.3 
2.1y 4-OH CF3 3,5-(OH)2 -- -- -- -- 
2.1z 4-OMe CF3 3,5-(OH)2 -- -- -- -- 
2.1aa 3-CF3 CF3 3,5-(OMe)2 -- -- 31.9 -- 
2.1ab 4-F CF3 3,5-(OMe)2 3.0 -- 39.0 -- 
2.1ac 4-OMe CF3 3,5-(OMe)2 -- -- 37.8 -- 
2.1ad 3,5-(OH)2 H 4-OMe 25.8 19.6 -- -- 
2.1ae 3,5-(OH)2 H 3,4-(OMe)2 0.29 21.3 -- -- 
2.1af 3,5-(OH)2 H 3-F 16.5 -- -- -- 
2.1ag 3,5-(OH)2 H 4-F 51.3 -- 52.1 -- 
2.1ah 3,5-(OH)2 H 4-Me2N 29.7 -- 12.9 -- 
2.1ai 3,5-(OH)2 H 4-NO2 2.2 31.6 -- -- 
2.1aj 3,5-(OH)2 H 2-Naphthyl 18.4 -- -- -- 
2.1ak 3,5-(OH)2 H 4-CF3 17.8 -- -- -- 
2.1al 3,4-(OH)2 H 4-F -- -- 17.9 -- 
2.1am 3,4-(OH)2 H 4-Me2N -- -- 14.8 -- 
2.1an 3,4-(OH)2 H 2-Naphthyl -- -- 6.9 -- 
2.1ao 4-OMe H 3,4-(OMe)2 -- -- 52.0 -- 
2.1ap 3,5-(OMe)2 H 3-F -- -- -- -- 
2.1aq 3,5-(OMe)2 H 4-Me2N -- -- -- -- 
2.1ar 3,5-(OMe)2 H 4-NO2 10.1 5.94 -- -- 
2.1as 3,5-(OMe)2 H 4-CF3 -- -- -- -- 
2.1at 3,4-(OMe)2 H 3-F 3.2 -- 38.8 -- 
2.1au 3,4-(OMe)2 H 4-NO2 -- -- -- -- 
2.1av 3,4-(OMe)2 H 4-CF3 -- -- 34.7 -- 
2.1aw 4-OH Me 3,4-(OH)2 -- -- 21.3 -- 
2.1ax 4-OH Me 3,5-(OMe)2 -- -- -- -- 
2.1ay 4-OH Me 4-Me2N 36.3 0.47 -- -- 
	
	 28
Table 2.1, continued 
	
L.M.a R1 R2 R3 
IC50 (μM) 
COX1 COX2 NF-κB QR2 
2.1az 3,5-(OH)2 Me 3,4-(OMe)2 10.6 12.8 -- 103.8 
2.1ba 3,5-(OH)2 Me 3-F 10.5 -- -- -- 
2.1bb 3,5-(OH)2 Me 4-F -- -- -- -- 
2.1bc 3,5-(OH)2 Me 4-Me2N 10.9 -- -- -- 
2.1bd 3,5-(OH)2 Me 2-Naphthyl -- -- 42.3 -- 
2.1be 3,5-(OH)2 Me 4-CF3  10.7 1.74 -- -- 
2.1bf 4-OMe Me 2-Naphthyl -- -- 48.2 -- 
2.1bg 4-Cl Me 3,5-(OH)2 5.3 -- 39.2 -- 
2.1bh 4-Cl Me 3,4-(OH)2 -- -- 37.5 -- 
2.1bi 3-F Me 3,5-(OH)2 4.9 2.54 -- -- 
2.1bj 4-Me2N Me 3,5-(OH)2 0.97 -- 34.2 -- 
2.1bk 4-Me2N Me 3,4-(OH)2 -- -- -- -- 
2.1bl 4-Me2N Me 3,5-(OMe)2 32.6 -- -- -- 
2.1bm 4-OH Et 3,5-(OH)2 -- -- -- -- 
2.1bn 4-OH Et 3,5-(OMe)2 -- -- -- -- 
2.1bo 3,5-(OH)2 Et 3,4-(OMe)2 9.7 -- -- -- 
2.1bp 3,5-(OH)2 Et 3-F 5.4 -- -- -- 
2.1bq 3,5-(OH)2 Et 4-F -- -- -- -- 
2.1br 3,5-(OH)2 Et 2-Naphthyl -- -- -- -- 
2.1bs 3,5-(OH)2 Et 4-CF3 7.4 2.2 -- -- 
2.1bt 4-Cl Et 3,5-(OH)2 11.6 -- 38.3 -- 
2.1bu 4-Cl Et 3,4-(OH)2 -- -- -- -- 
2.1bv 3-F Et 3,5-(OH)2 3.5 17.7 25.7 -- 
2.1bw 2-Naphthyl Et 3,5-(OH)2 0.17 3.3 -- -- 
2.1bx 4-CF3 Et 3,5-(OH)2 30.5 14.8 -- -- 
2.1by 4-CF3 Et 3,4-(OH)2 -- -- -- -- 





2.2. Structure-Activity Relationships (SARs) 
Twenty-five library members were found to inhibit COX1 over 50% at a 
concentration of 10 µg/ml.  Of those twenty-five, eight had IC50 values similar to or better 
than resveratrol: 2.1b, 2.1m, 2.1o, 2.1w, 2.1ae, 2.1ai, 2.1bj, and 2.1bw.  Examination of 
the potent inhibitors proves that a resorcinol ring is present in all of the compounds; 
however, in 2.1b it is methylated.  This may be a consequence of the free-hydroxyls 
forming stabilizing hydrogen-bonds within the COX1 active site.  Additionally, an 
electron-rich aryl ring may be required for potent inhibition.  Five of the eight potent 
inhibitors had substituted central alkenes, possibly indicating that a perfectly planar 
structure is not required for inhibition of COX1.  Further evidence to support this 
hypothesis comes the fact that the inhibitors 2.1o and 2.1m, which only differ by the 
location of the alkene-methyl group relative to the resorcinol ring, have the same IC50 
value of 1.90 µM.  Additional support of this hypothesis is found in the most potent 
COX1 inhibitor in the library, compound 2.1bw, which has an ethyl-group 
functionalizing its central alkene.  Comparison of 2.1bw to the compound 2.1aj, an 
analogue of 2.1bw that lacks the central-alkene ethyl substituent, proves that the ethyl 
group is required for potent inhibition as 2.1aj is 100-fold less active than 2.1bw.  
Finally, it appears that the ring opposite the resorcinol is able to tolerate a wide variety of 
substitution, albeit most of the rings are relatively electron-rich.  From these results, the 
compound 2.1bc was identified for selective inhibition of COX1.  
Seventeen library members were found to inhibit COX2 over 50% at a 
concentration of 10 µg/ml.  Of those seventeen, seven had IC50 values similar to or better 
than resveratrol: 2.1b, 2.1m, 2.1o, 2.1ay, 2.1be, 2.1bi, and 2.1bw.  Four of the analogues 
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were also good inhibitors of COX1: 2.1b, 2.1m, 2.1o, and 2.1bw.  Five of the seven 
inhibitors had a resorcinol ring; however, in 2.1b it was methylated.  Again, this may 
indicate that the free resorcinol hydroxyls are important for hydrogen-bonding within the 
active site.  Possibly of more consequence, all of the potent COX2 inhibitors have at least 
one very electron-rich aryl ring.  Six of the seven best inhibitors had a substituted central 
alkene, indicating that possibly COX2 also recognizes a form of resveratrol that is not 
completely planar.     
Twenty-six of the seventy-eight compounds tested were found in inhibit NF-κB.  
Seven of the active inhibitors had IC50 values similar to or better than resveratrol: 2.1a, 
2.1c, 2.1d, 2.1s, 2.1ah, 2.1am, and 2.1an.  Six of the most potent inhibitors had 
unsubstituted central alkenes, and the seventh (2.1s) had a methyl substituent, indicating 
that for potent inhibition of NF-κB, less steric bulk around the central olefin is required.  
Additionally, this finding points to a planar binding conformation of resveratrol.  All of 
the most active compounds were found to contain a catechol ring, and with the exception 
of 2.1s, all of the catechol hydroxyls are free.  Again, this may signify that free hydroxyls 
are required for hydrogen-bonding within the NF-κB active site.   
Twenty-six of the seventy-eight library members were found to inhibit QR2.  Of 
those twenty-six, thirteen showed inhibition similar to or better than resveratrol: 2.1a, 
2.1b, 2.1c, 2.1h, 2.1i, 2.1j, 2.1l, 2.1n, 2.1o, 2.1r, 2.1t, 2.1v, and 2.1w.  The two most 
active compounds 2.1i and 2.1v were substantially more potent than resveratrol and had 
IC50 values greater than 20 µM for COX1, COX2, and NF-κB, giving them at least 30-
fold selectivity for QR2.  Six of the thirteen potent compounds were found to have 
substituted central olefins, indicating that the active site of QR2 either (a) accommodates 
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a non-planar structure of resveratrol, or (b) the alkene-substituted molecules are able to 
adopt a different binding conformation than resveratrol.  Examination of the crystal 
structure of resveratrol bound to QR2 (Chapter 1, Figure 1.4) indicates that there may be 
room for the alkene-substituent on the solvent exposed side of the QR2 active site.  Seven 
of the most active compounds did not have free hydroxyl groups, which may imply that 
the stabilizing hydrogen-bonds resveratrol makes within the QR2 active site are not 
rigorously required for QR2 inhibition, or that the library members lacking hydroxyl 
groups that inhibit QR2 potently bind in a different conformation or location. 
These initial data from the work for Dr. SooSung Kang, the Pezzuto lab, and the 
Mesecar lab resulted in at least one compound for each enzyme target that had activity 
superior to resveratrol.  Additionally, some initial SARs for the interactions of the 
compounds with the targets were generated, producing hypothetical pharmacophore 
models.  To maximize the benefit of these SAR models, and to more fully elucidate the 
importance of the physical attributes of the analogues that increase their potency toward 
their respective targets, we set out to determine quantitative structure-activity 
relationships (QSARs) for each system.  Herein, we describe the use of QSARs and 3D-
QSARs to develop quantitative models for the interaction of the resveratrol analogues 







2.3. Quantitative Structure-Activity Relationships (QSARs) 
 Quantitative structure-activity relationships (QSARs) use the similarity principle, 
the observation that chemically similar compounds tend to have similar biological 
activity, to try and understand the quantitative correlation between the structural and 
electronic elements of molecules that dictate their biological activities.  In order to do 
this, various molecular descriptors are used.  Molecular descriptors are the structural and 
electronic factors of a compound that can be quantified to describe a specific molecular 
property of the compound.  The molecular descriptors chosen for the analysis of the 
seventy-eight resveratrol analogues were the Hammett parameter (σ), the Taft steric 
parameter (ES), and the hydrophobic parameter (π).  These parameters were chosen to 
describe the electronic, steric, and hydrophobic properties of the compounds, 
respectively.  Stepwise regression was then used to determine QSARs.   
 
2.3.1. Molecular Descriptors 
      The Hammett parameter (σ) was originally described by Louis P. Hammett in 
1937.2  Hammett observed that the position and electronic nature of a benzoic acid 
substituent had a measurable effect on the acidity of benzoic acid; when a substituent was 
electron donating, acidity decreased, and when a substituent was electron withdrawing, 
acidity increased.  Hammett was able to quantify this effect with the parameters σmeta and 
σpara, where σ = log(Ka/Kao) and Ka is the acidity constant of the substituted benzoic acid, 
Kao is the acidity constant of unsubstituted benzoic acid (Figure 2.1).  Negative values of 
σ indicate a substituent is electron-donating, while positive values of σ indicate a 
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Figure 2.1. Determination of Hammett parameter. 
 
 
 The Taft steric parameter (ES) was described by Robert W. Taft Jr. in 1952.3, 4  
Taft proposed his parameter as a modification to the Hammett equation, as a way to 
factor in the effect of steric bulk of a substituent on reaction rate.  To determine ES, Taft 
investigated the rate of acid-catalyzed methyl ester hydrolysis (Figure 2.2), where ES = 
(1/δ)log(ks/kCH3) and δ is the reaction constant describing susceptibility to steric effects (δ 
= 1 for reference reaction (R = CH3)), ks is the rate of the investigated reaction, kCH3 is the 
rate of the reference reaction.  All substituents have a negative value of ES except 











 The hydrophobic parameter (π) describes how hydrophobic or hydrophilic a 
particular substituent is.  The hydrophobic parameter is defined from the partition 
coefficient (P) of a molecule, where P = [drug]octanol/[drug]water.  Applying the logarithm, 
this equation becomes: logP = log[drug]octanol – [drug]water.  The particular contribution of 
a substituent, the hydrophobic parameter (π), is arrived then arrived at by the equation: πx 
= logPsubstituted compound – logPparent compound, or πx = log(PRX/PRH).  Positive values of π 
indicate a substituent that is more hydrophobic than hydrogen, negative values of π 
indicate a substituent that is less hydrophobic than hydrogen, where π = 0 for hydrogen.  
Table 2.2 is a compilation of the molecular descriptors used in the determination of 
QSAR models. 
 
Table 2.2. Molecular descriptors used for the construction of QSAR models. 
 
Substituent σm σp ES π 
OH 0.12 -0.37 -0.55 -0.67 
OMe 0.12 -0.27 -0.55 -0.02 
NMe2 -0.16 -0.83 -1.71* 0.18 
F 0.34 0.06 -0.55 0.14 
Cl 0.37 0.23 -0.97 0.71 
CF3 0.43 0.54 -2.4 0.88 
NO2 0.71 0.78 -2.52 -0.28 
H 0 0 0 0 
Me -0.07 -0.17 -1.24 0.56 
Et -0.07 -0.15 -1.31 1.02 
2-Napthyl 0.04 0.04 -1.31** 1.32 
*ES unavailable for NMe2, ES for i-Pr was used, ** ES unavailable for 2-Naphthyl, ES for            





2.3.2. Stepwise Regression 
 Each resveratrol analogue in the library had seven possible positions of 
substitution and each position had three molecular descriptors, resulting in a total of 
twenty-one descriptors per analogue (Figure 2.3).  Because of the way the compounds 
were tested for inhibition of each enzyme, IC50 data was only available for compounds 
that were moderate to good inhibitors of each enzyme – and not for the compounds that 
inhibited each enzyme poorly or not at all.  This was unfortunate because information 
about molecules that show poor inhibition is of equal importance as information about 








Stepwise regression is a regression model that selects the included predictive 
variables by forward selection, backward elimination, or bidirectional elimination.  The 
QSARs reported herein were determined by the use of forward selection stepwise 
regression.  This was done to preclude a QSAR that was overdetermined, as there were a 
large number of descriptors for each system (twenty-one) and a small number of 
molecules in each set.  In general, each QSAR was arrived at by testing each variable 
individually.  For each QSAR, the variable that gave the best correlation with the data 
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was used as the starting variable.  An iterative process followed in which every variable 
was tested and the variable that gave the best correlation was added to the QSAR.  This 
process was continued until there was either no improvement in the QSAR or until the F-
test determined the correlation was not meaningful at a 95% confidence interval.  For 
every QSAR, the figures in parentheses are the standard errors associated with the 
coefficients, n represents the number of data points upon which the equation is based, r is 
the correlation coefficient, and s is the standard deviation from the regression equation. 
  
2.3.3. COX1 QSAR 
 Of the thirty-six resveratrol analogues that were found in inhibit COX1, thirty-
three contained a resorcinol or methylated resorcinol ring.  For this reason, the 
distribution of values of the molecular descriptors in some positions on the resveratrol 
skeleton was not great enough to establish a meaningful correlation with the IC50 data.  
To circumvent this issue, we attempted aligning the compounds in such a way as to place 
all of the resorcinol rings in the same chemical space and only examine the effect of 
substitution on one ring and the central alkene; however, this attempt was not a success as 
the position of the alkene substituent varied with respect to the resorcinol ring. 
 
2.3.4. COX2 QSAR 
Stepwise regression on the molecular descriptors of the seventeen molecules that 
were found to inhibit COX2 resulted in the QSAR model, Equation 2.1.   
 
	 37
log(1/IC50) = 1.77(±0.67)R1,3π + 1.97(±1.11)R1,4σp – 1.36(±0.65)R1,4π – 0.92(±0.78)R1,5π 
– 16.6(±3.22)R1,5ES – 1.27(±0.65)R2π – 0.57(±0.38)R2ES – 8.55(±1.66)R3,4σp – 
4.40(±0.88)R3,4ES  – 20.7(±4.33)R3,5π  – 14.5(±2.75) 
n = 17, r2 = 0.91, s = 0.29, F = 5.929, F0.05(10, 6) = 4.06            Eq.  2.1. COX2 QSAR 
 
 The QSAR model derived for COX2 signified that substitution at the 3,3 position 
of the “B” ring of the analogue was not required for good inhibition.  Additionally, the 
initial SARs were supported in the QSAR.  First, the QSAR model indicated that a 
relatively large, hydrophobic alkene substituent will increase inhibition of COX2.  
Second, the QSAR model indicated an electron-donating substituent was important at the 
3,4 position of the “B” ring, supporting our observation that at least one electron rich ring 
is required for good inhibition.  A pictorial representation of the COX2 QSAR result is 













2.3.5. NF-κB QSAR 
Stepwise regression on the molecular descriptors of the thirty-four molecules that 
were found to inhibit NF-κB resulted in the QSAR model, Equation 2.2. 
 
 
log(1/IC50) = – 0.16(±0.05)R1,3ES – 0.19(±0.09)R1,4σp + 0.11(±0.04)R2ES – 
1.55(±1.22)R3,3σm – 0.63(±0.25)R3,3ES + 0.52(±0.32)R3,4σp – 0.60(±0.17)R3,4π – 
1.58(±0.17)  
n = 34, r2 = 0.66, s = 0.15, F = 7.08, F0.05(7, 26) = 2.39            Eq. 2.2. NF-κB QSAR 
 
 
 The QSAR model derived for NF-κB inhibition supports some of our initial 
SARs.  First, it appears substitution at the 1,5 position of the “A” ring is not required for 
good inhibition of NF-κB.  This finding from the QSAR model is supported by the trend 
in the inhibitory data, where all of the most active NF-κB inhibitors had a catechol ring.  
Second, in support of our initial SAR observation that an unsubstituted central-olefin is 
preferred, the QSAR for NF-κB indicates that a small alkene-substituent will increase 
inhibition of NF-κB.  A pictorial representation of the NF-κB QSAR result is shown in 









2.3.6. QR2 QSAR 
Stepwise regression on the molecular descriptors of the twenty-six molecules that 
were found to inhibit QR2 resulted in the QSAR model, Equation 2.3. 
 
 
log(1/IC50) = 1.08(±0.31)R1,3π + 0.31(±0.27) R1,3ES – 0.47(±0.30)R1,4π + 
3.01(±1.43)R2σm + 11.9(±5.79)R3,3σm + 4.36(±1.28)R3,3π – 3.90(±1.21)R3,4π – 
2.74(±0.94)R3,4ES + 12.4(±4.92)R3,5σm – 3.75(±1.36)R3,5π – 3.78(±1.13) 
n = 26, r2 = 0.75, s = 0.36, F = 4.40, F0.05(10, 15) = 2.54                Eq. 2.3. QR2 QSAR 
 
 
 The QSAR model determined for QR2 indicates that it is important that one side 
of the analogue have hydrophilic residues and the other hydrophobic residues.  The way 
the QSAR data was input, the positions 1,3 and 3,3 positions appear to dictate 
hydrophobic substituents.  Taking into consideration the known structure of the QR2 
active site, rotation about the central sp3 bonds of the stilbene model yields a 
conformation of the analogues that agrees with the known structural information (Figure 
2.6).  Thus, the QSAR model dictates that small hydrophobic substituents should be 
placed on the side of the stilbene that will interact with the hydrophobic side of the active 
site and hydrophilic substituents should be placed on the side of the stilbene that will 
interact with the solvent exposed side of the QR2 active site.  The QSAR model also 
signifies that an electron-withdrawing substituent is preferred on the central alkene, 









 Though the developed QSAR models resulted in some preliminary correlations 
between the structural elements of our analogues and their biological activities, as well as 
supporting our observed SARs, they were by no means conclusive.  The QSARs were 
constructed using only the compounds that had inhibitory concentrations within a range 
of 0.17 to 103.8 µM, as the enzymatic inhibition data for the less active analogues was 
not available.  Each QSAR was derived from a small set of structurally similar 
compounds, where the true alignment of the rings, and the substituents on the rings, in 
each of the enzyme’s active sites was unknown.  These facts greatly increased the 
likelihood of chance correlations within each of the models.  Additionally, the 1D-
QSARs generated were not able to account for any conformational effects that may be 
critical for protein-ligand association. 
 In an attempt to further clarify the properties of the analogues that dictated their 
biological activity toward the given targets, we turned our attention to the development of 
3D-QSAR models.  3D-QSARs are incredibly useful for representing the binding site of a 
target by mapping the physicochemical properties of the ligands onto a surface or grid 
	 41
that surrounds the ligand molecules, which are superimposed in 3D space.  This type of 
3D-QSAR model interacts simultaneously with all ligands and represents an average of 
all of the modeled compounds.  Implementing 3D-QSARs was of particular interest to us 
as we reasoned they would generate 3D models of the binding sites of COX1, COX2, and 
NF-κB by looking at 3D properties of the ligands.  Additionally, 3D-QSARs would 
facilitate quantification of the interactions between the analogues and protein at an atomic 
level by modeling the electrostatic forces, hydrogen bonds, and van der Waals 
interactions that were important in the ligands. 
 We set out to determine 3D-QSARs in collaboration with Gregory Wilson and 
Prof. Markus Lill of the Department of Medicinal Chemistry and Molecular 
Pharmocology at Purdue University.  The 3D structures of all active resveratrol 
analogues were generated using MacroModel and optimized in aqueous solution on the 
basis of the AMBER* force field.  The most potent resveratrol analogue identified for 
each of the four targets was used as the template for alignment for the other bioactive 
analogues in that set.  The software Symposar, developed by Lill and colleagues, was 
used to align the ligands in each of the four data sets.5  Symposar does this by first 
aligning the query molecule in 2D space on the template based on substructure similarity, 
followed by alignment in 3D space based on similarity of physiochemical fields.  In this 
way, Symposar is capable of yielding a superposition of the molecules in configurations 
relative to each other that would be expected in their bioactive conformations.  The 
software Raptor, also developed by Lill and colleagues, was then used to run the 3D-
QSAR simulations based on the prepared data sets.6 
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The 3D-QSAR generated for QR2 is displayed in Figure 2.7.  The highest affinity 
ligand, 2.1v, was used as the template for alignment.  The test set was composed of 
ligands 2.1b, 2.1c, 2.1d, 2.1h, 2.1l, 2.1q, 2.1s, and 2.1w (Figure 2.7, A).  All other 
ligands with bioactivity toward QR2 were used in the training set.  The alignment 
produced by Symposar (Figure 2.7, B) was then used to generate a 3D-QSAR using 
Raptor, which is displayed both pictorially and graphically.  The regions in blue represent 
hydrogen-bond donor character; the regions in red represent hydrogen-bond acceptor 
character and the regions colored yellow represent hydrophobic character (Figure 2.7, C).  
A graph plotting the predicted versus experimental affinity is also displayed, where the 
data points colored green are the compounds in the training set and the data points 






Figure 2.7. 3-D QSAR for QR2; (A) Template ligand 2.1v was used for the alignment of 
the training set.  The test set molecules are shown. (B) Symposar alignment of molecules 
in training set. (C) Common 3D features of active site determined by Raptor model, 
where blue indicates hydrogen-bond donor character, red indicates hydrogen-bond 
acceptor character, and yellow indicates hydrophobic character. (D) Graph plotting the 
predicted vs. experimental affinity of the analogues, where the molecules in the training 




 Similar 3D-QSAR models were determined for COX1, COX2, and NF-κB.  
Unfortunately, none of the 3D-QSAR models were useful to explain the observed 
bioactivity of the resveratrol analogues toward their respective targets.  This was clear as 
the 3D-QSARs for each of the targets could not accurately predict the activity of the 




assumption that all of the analogues shared a common binding orientation was erroneous.  
Additionally, the construction of QSARS (1D- or 3D-) for compounds containing a 
stilbene skeleton is a particular challenge due to the inherent pseudo-symmetry of these 
types of molecules.   
   
2.5. Conclusions 
 The 1D- and 3D-QSAR models generated for the resveratrol analogues’ activity 
toward COX1, COX2, NF-κB, and QR2 were largely unsuccessful for the determination 
and prediction of the structural and electronic factors of the molecules that produced 
good enzymatic inhibition.  The poor QSARs generated from the data sets can be 
explained by three factors: first, the QSARs were constructed using only compounds that 
were identified as good inhibitors of their respective targets.  These compounds had a 
quite narrow range of IC50 values, from 0.17 to 103.8 µM.  Second, the QSARs were 
derived from a small, structurally similar set of compounds.  This greatly increases the 
possibility of chance correlations within each of the models.  Third, because the nature of 
the stilbene skeleton of resveratrol, the symmetry of the compounds was an 
uncontrollable variable when aligning them for the construction of QSAR models.  There 
was no way to determine how the compounds truly aligned in the active site of each of 
the targets, if indeed they did align in a common binding pose at all.        
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DESIGN, SYNTHESIS, AND EVALUATION OF SUBSTITUTED RESVERATROL 





3.1. Design of QR2 Inhibitors 
The overall goal of the research reported herein was the synthesis and 
identification of novel analogues of resveratrol to serve as leads for future 
chemopreventative agents.  We embarked on the present work with the aim of identifying 
new resveratrol analogues that displayed either increased selectivity or potency toward 
QR2.  Our objectives were two-fold in this research.  First, we desired to find analogues 
of resveratrol that lacked the lacked the 3- and 4’-hydroxyl groups of resveratrol, 
therefore negating the biological deactivation of resveratrol by its metabolism in vivo.  
Second, we wished to further investigate exactly what structural features of resveratrol 
were pertinent for potent inhibition of QR2.  We set out to accomplish this through the 
synthesis and testing of two different sets of resveratrol analogues.  One set in which the 
3,5,4’-substitution pattern of resveratrol was held constant and only the central alkene 
was functionalized, and a second set in which the central alkene was replaced completely 




3.1.1. First Generation Influences 
Of the 78 first generation resveratrol analogues tested for inhibition of QR2, 24 
were found to actively inhibit the enzyme.  Of those, ten had IC50 values lower than 
resveratrol (Chapter 2, Table 2.1).  Six of those ten lack the 3- and 4’-hydroxyl 
substituents required for metabolic sulfation and glucuronation (2.1h, 2.1i, 2.1j, 2.1l, 
2.1r, and 2.1v).  Interestingly, two of the more potent analogues (2.1i and 2.1l) have 
naphthyl substituents, which may allow for a greater pi-stacking interaction with the 
isoalloxazine ring of the active site FAD cofactor. 
The most potent inhibitor of the series, compound 2.1v, has both a highly 
electron-deficient central alkene and aryl ring as a consequence of two trifluoromethyl 
substituents.  Interestingly, of the other six analogues in the 78-member first generation 
library that had trifluoromethyl alkene substituents,1 only one was active, compound 
2.1u, which has two electron-rich aryl rings.  Examination of the other analogues with 
trifluoromethyl alkene substituents does not show a clear pattern for QR2 inhibition.  For 
instance, while compound 2.1u was found to be an active inhibitor of QR2, compound 
2.1ac did not show inhibition of QR2 (Figure 3.1).  These two compounds differ only in 
the position of the dimethylresorcinol ring relative to the trifluoromethyl alkene 
substituent.  Comparing the most potent analogue in the library, 2.1v, to compound 
2.1aa, the only difference is that the 4-methoxy substituent has migrated to the 3-
position.  However, this change is significant enough to effectively deactivate the most 
potent compound of the first generation library.  Additionally, the analogue 2.1y which 
has the exact aryl substitution pattern of resveratrol was not found to be active.  Thus, in 
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this case, substitution of the central olefin of resveratrol with a trifluoromethyl group 
resulted in the deactivation of the compound.    
 
 
       
Figure 3.1. First generation resveratrol analogues with trifluoromethyl alkene 




3.1.2. Design of Second Generation Resveratrol Analogue Library 
To investigate this complex interplay between the position of the alkene 
substituent and the substitution pattern on the aryl rings, we envisioned a second 
generation resveratrol analogue library composed of two sets of molecules; one set where 
the substitution pattern of the aryl rings was held constant and various electron-
withdrawing groups were placed at the central alkene, and a second set where the alkene 
substitution was held constant and various substitutions were made on the aryl rings.  We 
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set out to accomplish this through the synthesis of a set of olefin-substituted resveratrol 









3.2 Construction of Second Generation Library 
 
3.2.1. Construction of Olefin-Substituted Resveratrol Analogue Set 
To investigate the role of substitution at the central alkene of resveratrol, the 
ability of the QR2 active site to accommodate aryl ethers at the traditional 3,5,4’-
positions of resveratrol, and the conformational effect of E/Z-isomerism on QR2 
inhibition, a small set of 21 olefin-substituted resveratrol analogues was synthesized.  
This was accomplished through the formation of three key nitrile resveratrol analogues 
that were amenable to further synthetic transformations (Scheme 3.1, analogues 3.4a-
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3.4c).  The analogues 3.4a-3.4c were produced in gram quantities with high yields by the 
condensation of the appropriately substituted aldehyde (3.2a or 3.2b) with the 
appropriately substituted phenylacetonitrile (3.3c or 3.3d).2, 3  These starting materials 
were either commercially available or were arrived at through the simple chemistry 
shown in Scheme 3.1.  Compound 3.4a was produced by the condensation of aldehyde 
3.2a with phenylacetonitrile 3.3c under which conditions the phenol of 3.3c was 
liberated. 




Scheme 3.1.  Construction of starting materials 3.2a, 3.3c, and 3.3d and condensation 
reaction forming key nitrile analogues 3.4a-3.4c. 
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With the key nitriles in hand, the synthesis of the eighteen remaining olefin-
substituted structural analogues of resveratrol commenced.  Deprotection of 3.4b by 
treatment with boron tribromide (Scheme 3.2) yielded the (Z)-nitrile analogue 3.4d, 
which upon protection of the free phenols as tert-butyldimethylsilyl ethers and reduction 
of the nitrile, resulted in a mixture of the (E)- and (Z)-aldehydes 3.5.  Treatment of this 
mixture 3.5 with tetra-n-butylammonium fluoride resulted in the aldehyde 3.4e as a single 
E isomer, where the Z isomer was not detected.  Further reduction of the mixture 3.5 by 
treatment with diisobutylaluminum hydride and subsequent exposure to dilute 










 Reduction of both (Z)-nitriles 3.4b and 3.4c using diisobutylaluminum hydride 
gave rise to the (Z)-aldehyde analogues 3.4g and 3.4h.  Additional reduction of the 
aldehydes by treatment with sodium borohydride yielded mixtures of both the (Z)- and 
(E)-alcohols, which were easily separated by flash chromatography, yielding the four 
resveratrol analogues 3.4i, 3.4j, 3.4k, and 3.4l.  Oxidation of the aldehyde 3.4h by 
treatment with manganese dioxide and potassium cyanide in methanol resulted only in 









A Pinnick-type oxidation of the aldehyde 3.4h using sodium chlorite-hydrogen 
peroxide was employed to yield an inseparable mixture of the desired (Z)-carboxylic acid 
3.6 and the chlorinated byproduct 3.7, which was formed by reaction with hypochlorite 
generated in situ.5  Fischer esterification was used to resolve the mixture of 3.6 and 3.7, 
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resulting in the two esters (Z)- 3.4n and (Z)- 3.4o which could be separated by flash 
chromatography.  Finally, treatment of 3.4o with boron tribromide resulted in the 









A palladium-catalyzed hydration of the nitrile 3.4b was used to obtain the (Z)-
amide 3.4q, which - when treated with boron tribromide - produced the (Z)-amide 
analogue 3.4r in good yield (Scheme 3.5).6  Concomitant reduction of the nitrile and the 
olefin was achieved by exposure of 3.4b to sodium borohydride and cobalt chloride 
hexahydrate, resulting in the amine analogue 3.4s.7  An oxidative Hofmann 
rearrangement of 3.4q was effected using (diacetoxyiodo)benzene, which resulted in the 
(Z)-methyl carbamate 3.4t.  Treatment of the carbamate with boron tribromide resulted in 











3.2.2. Construction of Benzanilide Resveratrol Analogue Set 
Former Lipton research group member Dr. SooSung Kang carried out the 
synthesis of a set of 26 substituted benzanilide resveratrol analogues.  The synthesis of 
these analogues was accomplished using standard amide bond forming techniques by 
reaction of the appropriately activated benzoic acid derivative with a substituted aniline.  
These analogues were designed to investigate the effect of complete substitution of the 
central alkene of resveratrol.  The effect of methylation of the amide and phenols, as well 
as the position of the resorcinol ring relative to the amide nitrogen was investigated by 
benzanilide analogues 3.8a-3.8e.  The complete second generation resveratrol analogue 




Figure 3.3.  Complete second generation resveratrol analogue library; (Top) Olefin-
substituted resveratrol analogues, (Bottom) Benzanilide resveratrol analogues.   
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3.3. Results of Second Generation Resveratrol Analogue Library 
 
3.3.1. Biological Evaluation 
 The ability of the second generation resveratrol analogues to inhibit QR2 was 
determined by Dr. Katherine Jensen and Prof. Andrew Mesecar of the Department of 
Biological Sciences at Purdue University.  Briefly, the enzymatic activity of QR2 at 
steady-state was determined using an assay where NMeH (N-
methyldihydronicotinamide) was used as a co-substrate and MTT ((3-(4,5-
Dimethylthiazol-2-yl)-2,5-dipenyltetrazolium bromide)) was used as the “quinone” 
substrate, and the activity of QR2 was followed by monitoring the increase in formazan 
product at 612 nm.8, 9  The resveratrol analogues were screened for activity at 100 μM 
and IC50 values were determined for compounds that showed greater than 50% inhibition 
of QR2 at this concentration.  The ability of the second-generation analogues to inhibit 



















Table 3.1. Inhibition of QR2 by olefin-substituted and benzanilide resveratrol analogues. 
 
Structure L.M.a R1 R2 R3 IC50 (μM) 
	
Res 4-OH H 3,5-(OH)2 6.9 ± 0.4 
3.4b 4-OMe CN 3,5-(OMe)2 31.6 ± 4.3 
3.4d 4-OH CN 3,5-(OH)2 5.9 ± 0.3 
3.4f 4-OH CH2OH 3,5-(OH)2 5.1 ± 0.3 
3.4g 4-OMe CHO 3,5-(OMe)2 24.2 ± 1.3 
3.4r 4-OH CONH2 3,5-(OH)2 9.3 ± 1.9 
	
3.4e H CHO H 25.5 ± 3.5 
3.4k Me CH2OH Me 27.5 ± 4.9 
	
3.8a - - - 27.6 ± 4.6 
	
3.8d - - - 16.8 ± 1.3 




 Nine of the forty-seven second generation resveratrol analogues showed 
inhibition of QR2 over 50% at 100 μM and subsequently the IC50 values of those 
compounds were determined.  Of those nine compounds, two compounds (3.4d and 3.4f) 
inhibited QR2 with IC50 values comparable to that of resveratrol, while the remaining 
seven compounds were slightly weaker inhibitors of QR2 than resveratrol (6.9 ± 0.4 μM).  
Of the remaining compounds, ten showed weak inhibition of QR2 (between 20-50% at 
100 μM); 3.4i, 3.4p, 3.4q, 3.4s, 3.4t, 3.8c, 3.8i, 3.8m, 3.8t, and 3.8z.  The remaining 
twenty-nine analogues showed minimal inhibition of QR2 (<20% at 100 μM).   
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Six of the analogues found to inhibit QR2 strongly had free phenolic hydroxyl 
groups, while the remaining three had phenolic methyl ethers (3.4b, 3.4g, and 3.4k).  
From the second generation library’s IC50 data, inhibitory activity of the analogues 
appears to decrease as steric bulk associated with the aryl rings increases.  An example of 
this is the series 3.4a-3.4d.  The nitrile analogue 3.4d with free phenolic hydroxyls was 
found to inhibit QR2 with an IC50 of 5.9 ± 0.3 μM and 88.8% maximal inhibition.  The 
nitrile analogue 3.4b, which differs from 3.4d only in that the phenolic hydroxyl groups 
have been substituted for methyl ethers, was found to inhibit QR2 with a six-fold increase 
in IC50 value of 31.6 ± 4.3 μM and 57.4% inhibition.  Extending this trend further, the 
nitrile analogues 3.4a and 3.4c, where the phenolic methyl ethers of 3.4d have been 
replaced by more sterically bulky isopropyl ethers, do not show inhibition of QR2 above 
20% at 100 μM (Figure 3.4).  The same trend can be observed in the comparison of 
analogues 3.4f and 3.4i.  This trend may be a result of the sterically bulky aryl ethers 
reducing the ability of the analogue to bind in the QR2 active site in the same orientation 
as resveratrol, thus reducing the ability of the molecule to form stabilizing hydrogen 










The trend illustrated in Figure 3.4 appears only to be consistent with the 
analogues of the second generation library and may heavily depend on the nature of the 
alkene substituent.  For example, comparison of resveratrol to the first generation 
analogue 2.1f shows only a modest increase in IC50 as a result of complete substitution of 
hydroxy for methoxy substituents (IC50 = 11.5 ± 3.2 μM for resveratrol vs. IC50 = 14.6 ± 
4.3 μM for 2.1a).  In contrast, comparison of first generation analogues 2.1m and 2.1q 
shows that substitution of the methoxy substituents for hydroxy substituents has the 
opposite effect in this case, actually improving IC50 value (IC50 = 39.0 ± 17.2 μM for 
2.1m vs. IC50 = 20.1 ± 0.1 for 2.1q).  Possibly the methyl-substituted central olefins of 
2.1m and 2.1q dictate an alternate binding conformation of the analogues in the QR2 
active site, and that binding in this alternative conformation is assisted by the sterically 
bulky (and hydrophobic) aryl ethers.  
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Two of the analogues, 3.4e and 3.4k, found to inhibit QR2 above 50% were of the 
E configuration, more closely resembling cis-resveratrol.  This is significant as the trans-
geometry is known to be the more bioactive form of the compound.  An interesting trend 
among the allylic alcohol analogue series 3.4f, 3.4i, and 3.4k can be inferred from the 
IC50 data.  The compound 3.4f, which is of the Z configuration, was found to be the most 
potent inhibitor in our second-generation library, having an IC50 of 5.1 ± 0.3 μM and 
87.4% inhibition at 100 μM.  Replacing the free phenolic hydroxyls of 3.4f with methyl 
ethers, as in compound 3.4i, drastically reduces the inhibitory potency of the analogue, 
lowering its inhibition at 100 µM from 87.4% to 27.7%, a finding consistent with the 
observation that steric bulk associated with the aryl rings has a detrimental effect on 
inhibition.  However, comparing analogue 3.4i to 3.4k, where the single difference 
between the compounds is their geometry (3.4i is of the Z configuration while 3.4k is of 
the E configuration), reveals that this trend can be negated by configuration.  Thus, 
isomerization of 3.4i to 3.4k increases inhibition of QR2 to 57.2% (Figure 3.5). To the 
best of our knowledge, this is the first report of a cis-resveratrol analogue having greater 





Figure 3.5. Effect of configuration on inhibition of QR2. 
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 Of the twenty-six benzanilide resveratrol analogues, two were found to inhibit 
QR2, 3.8a and 3.8d.  Interestingly, these two analogues have the same aryl substitution 
pattern as resveratrol and have secondary amide cores.  None of the benzanilide 
analogues with the tertiary, methyl amide core showed inhibition of QR2 above 20%.   
Comparison of the IC50s of 3.8a and 3.8d shows that the position of the amide nitrogen 
relative to the resorcinol ring has an observable effect on inhibition of QR2.  When the 
amide nitrogen in bound directly to the resorcinol ring, the IC50 is decreased by 
approximately 40% (16.8 ± 1.3 μM for 3.8d compared to 27.6 ± 4.6 μM for 3.8a).  
Additionally, only phenolic hydroxyls appear to be tolerated in the benzanilide 
resveratrol analogue set, and even then, only at the traditional 3,5,4’-positons of 
resveratrol.  This is illustrated by the comparison of 3.8a to 3.8t, where the 3-hydroxyl 
has been moved to the 4-position; this 2.7Å difference in the position the hydroxyl group 
is enough to decrease the inhibition of QR2 from 59.7% average inhibition for 3.8a to 
49.9% average inhibition for 3.8t.  Substituting the phenols of the resorcinol ring of 3.8a 
for methyl ethers, as in benzanilide analogue 3.8c, reduces inhibition of QR2 from 59.7% 
average inhibition to 43.2% average inhibition.  Comparing 3.8a to 3.8f and 3.8d to 3.8k 
shows that the replacement of the 4’-hydroxyl group with a 4’-dimethylamino group 
eliminates inhibition of QR2.  This is of consequence as previous reports have shown that 
the replacement of the 4’-hydroxyl group of resveratrol with a 4’-amino group can 
increase QR2 inhibition.9, 10   
 Of the eight second generation, naphthyl-substituted benzanilide analogues, only 
one was found to moderately inhibit QR2, analogue 3.8z (30.5% average inhibition at 
100 μM).  The first generation analogue 2.1l differs only from 3.8z in that it has a central 
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alkene instead of an amide; however, this difference results in 2.1l being a potent 
inhibitor of QR2, having an IC50 of 5.5 μM.  The naphthyl-substituted analogue 2.1i was 
the second most active inhibitor of the first generation library, having an IC50 of 0.7 μM.  
In comparison, the second generation benzanilide analogue 3.8p showed no inhibition of 
QR2 at 100 μM. 
 
3.3.2. Structural Evaluation of Second Generation Resveratrol Analogue Inhibitors 
To illuminate the structural factors beneath the trends seen in the inhibitory data 
of the second generation analogues, a series of X-ray crystal structures was determined 
for six of the nine most potent compounds.  One of the goals behind the acquisition of the 
structural data was to better understand why the E configured analogue 3.4k was a more 
potent inhibitor of QR2 than its corresponding Z isomer 3.4i.  Therefore, complete X-ray 
crystallographic data sets of inhibitors 3.4d, 3.4f, 3.4k, 3.4r, 3.8a, and 3.8d in complex 
with QR2 were collected in collaboration with Dr. Katherine Jensen and Prof. Andrew 
Mesecar and the structure of each complex was subsequently determined.   
All structures were determined to 1.40-1.63Å resolution (Figure 3.6).  The 
resveratrol analogues are shown in green, colored according to atom type, and shown in 
ball and stick representation.  Water molecules are shown as red spheres, with hydrogen 
bonds shown as grey dashes with distances (Å) labeled.  The FAD cofactor is shown in 
grey lines and colored according to atom type.  Electron density omit maps (Fo – Fc) are 
shown in grey mesh and contoured to 3.0 σ around the ligand only.  The binding 
orientation of each resveratrol analogue was the same in both active sites of the QR2 




Figure 3.6. X-ray crystal structures of (A) 3.4d, (B) 3.4f, (C) 3.4k, (D) 3.4r, (E) 3.8a, and 












Examination of the X-ray crystal structures of the Z configured analogues 3.4d, 
3.4f, 3.4r, 3.8a, and 3.8d in complex with QR2 confirms that they bind in almost 
identical conformations, placing their resorcinol and 4’-substituted aryl rings in the same 
chemical space within the active site, taking advantage of the same stabilizing 
interactions (Figure 3.6).  All of the alkene substituents are positioned toward the solvent-
exposed side of the active site and all of these analogues bind in the same conformation 
as resveratrol, utilizing the same hydrogen bonds to the same ordered active site water 
molecules and amino acids in the QR2 active site.  This finding may explain the trend 
among the second generation library where increasing steric bulk associated with the aryl 
rings decreases the inhibitory ability of the molecule.  Substitution of the aryl hydroxyl 
substituents for more sterically bulky alkyl aryl ethers may change this preferred binding 
orientation within the QR2 active site, thus disfavoring the utilization of the ordered 
hydrogen bonding network by the compound.  In support of this hypothesis, strong 
electron density of analogue 3.4b was not observed in the QR2 active site, suggesting that 
the inhibitor was present only at partial occupancy.   
This hypothesis is also supported by our observations regarding the series 3.4f, 
3.4i, and 3.4k (Figure 3.5).  The most active analogue of our second generation library, 
3.4f, is of the Z configuration and has free hydroxyl substituents at the traditional 3,5,4’-
positions of resveratrol, which easily participate in the well-characterized hydrogen-
bonding network within the QR2 active site.  In contrast, the analogue 3.4i, which is only 
different from 3.4f in that it has methyl aryl ethers in the 3,5,4’-positions, did not show 
great enough inhibition of QR2 to determine and IC50, serving as further evidence that 
increasing the size of the 3,5,4’-substituents is not easily accommodated by the QR2 
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active site.  The E configured isomer of 3.4i, the analogue 3.4k, was found not only to be 
a potent inhibitor of QR2, but also to inhibit QR2 in a completely novel binding 
orientation.  This orientation is entirely distinct from the binding orientations of the Z 
configured analogues, where only the dimethylresorcinol ring of 3.4k occupies the same 
molecular space as the other (Z)-conformation analogues (Figure 3.6, C).  The 
dimethylresorcinol ring of 3.4k is positioned parallel to the isoalloxazine ring of the FAD 
cofactor, possibly participating in a favorable pi-stacking interaction (Figure 3.7, A).  In 
this novel binding orientation 3.4k does not utilize the same stabilizing hydrogen bonding 
interactions as the other compounds, instead only forming two hydrogen bonds from the 
3- and 4’-methoxy oxygen atoms to a single water molecule which is further anchored 
through a hydrogen bonding interaction to Asn161.    The opposite end of the active site 
is not occupied by the molecule – instead, there are two new water molecules present, 
one of which occupies the same molecular space and participates in the same hydrogen 
bonding network as the 4’-hydroxyl of the Z configured resveratrol analogues.  
Combining the novel structure of 3.4k in the QR2 active site, and the partial electron 
density observed for 3.4b in the QR2 active site, we hypothesize that, for the QR2 active 
site to accommodate sterically bulky aryl substituents, the molecules must rotate 90° 
from their preferred binding orientation to allow for the stacking of at least one aryl ring 
on the isoalloxazine ring.  Whether this rotation is possible depends on the nature of the 
aryl substituents and the orientation of the active site water molecules. 
The two most active benzanilide analogues, 3.8a and 3.8b (Figure 3.6, E & F), are 
oriented within the QR2 active site to position all three of their hydroxyl substituents in 
the same chemical space as those of resveratrol.  They participate in identical hydrogen 
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bonding networks and utilize the same residues as resveratrol for stabilization.  The 
carbonyl groups of the benzanilide cores of each analogue are positioned to interact with 
the solvent exposed side of the active site and participate in a hydrogen bonding network 


















Figure 3.7. (A) Crystal structure of inhibitor 3.4k bound in the QR2 active site; where 
QR2 is shown in grey surface representation, and 3.4k and the FAD cofactor are shown 
in green and grey, respectively and all are colored according to atom type. (B) 
Superposition of X-ray structures of 3.8a (orange ball and stick) and 3.8d (green ball and 
stick) in complex with QR2, where active site waters are shown as non-bonding spheres, 














 Two generations of resveratrol analogues were designed, synthesized, and tested 
for the inhibition of QR2.  This was carried out to explore the types of modifications that 
could be implemented to increase the selectivity and potency of resveratrol toward QR2, 
and in an attempt to discover analogues of resveratrol that lacked the 3- and 4’-hydroxyl 
substituents required for metabolic deactivation.  The first generation of analogues was 
designed to investigate the effect of various substitutions at the both the central alkene 
and aryl rings of resveratrol.  Twenty-four of the seventy-eight first generation analogues 
were found to inhibit QR2 with ten being more potent inhibitors than resveratrol.  Five of 
the ten most active first generation analogues lacked the metabolically sensitive 3- and 
4’-hydroxyl substituents.  Based on the results of the first generation, a second generation 
of analogues was designed to investigate specifically the role of substitution at the central 
olefin of resveratrol.  A total library of forty-seven resveratrol analogues was synthesized 
and nine compounds from this second generation library were found to inhibit QR2.  Two 
of the second generation analogues had comparable activity to resveratrol while the 
remaining seven analogues were slightly less potent.  Because of the unique nature of 
these nine compounds, X-ray crystal structures of six of the active analogues were 
determined.  From these X-ray crystallographic studies, were learned that the Z 
configured resveratrol analogues share a common binding conformation, utilizing the 
same hydrogen bonding network within the QR2 active site as resveratrol.  Ultimately, 
these studies resulted in the identification of a novel binding orientation of our analogue 
3.4k, which is the first example of an E configured resveratrol analogue bound in the 
QR2 active site.  
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DE NOVO DESIGN, SYNTHESIS, AND EVALUATION OF SUBSTITUTED 
PHENOTHIAZINES AS INHIBITORS OF THE CLASS-II HMG-COENZYME A 





4.1 Introduction: Antiobiotic-Resistant Bacteria 
Penicillin was discovered in 1928 by the Scottish biologist Sir Alexander Fleming 
upon returning to his untidy laboratory after an extended vacation at his country house.  
As he sorted through a stack of Petri dishes, he noticed one that had been contaminated 
with a blue-green mold and that colonies of Staphylococcus aureus near the mold were 
being dissolved.  Interested, Fleming grew pure cultures of the mold and identified it to 
be from the Penicillium genus; he found that the mold produced a substance capable of 
killing various disease-causing bacteria.  He named the substance penicillin and 
published his work in the British Journal of Experimental Pathology in 1929, but was 
never able to isolate the compound in large quantity.1  In 1940, the researchers Howard 
Walter Florey and Ernst Boris Chain of the Radcliffe Infirmary in Oxford determined 
how to isolate and concentrate penicillin.  After several clinical trials, their team 
developed methods for mass production and distribution of the antibiotic in 1945.  The 
discovery and implementation of penicillin in the twentieth century by Florey, Chain, and 
Fleming revolutionized modern medicine, and in 1945 the three shared the Nobel Prize in 
Medicine for their work.  
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4.1.1 Current Demand for New Antibacterials 
Bacteria are constantly evolving in ways to negate the impact of environmental 
stresses, including antimicrobials.  As a result, antibiotic resistance has become a 
phenomenal problem in the twenty-first century as drug-resistant organisms have 
acquired resistance to many or all of the antimicrobials on the market.  In 2002, the U.S. 
Centers for Disease Control and Prevention (CDC) estimated no less than 90,000 U.S. 
deaths due to bacterial infections – more than half of which were caused by bacteria 
resistant to one or more generally used antibiotic.  In October of 2007, the CDC reported 
at least 100,000 serious bacterial infections a year in the U.S. due to methicillin-resistant 
Staphylococcus aureus (MRSA), with close to 19,000 related fatalities – a number higher 
than the HIV/AIDS U.S. death toll that same year.2  As a consequence, there is a 
continuous need for new antibacterials as the inevitable rise of bacterial resistance will 
undo the usefulness of currently used antibiotics.3  To compound the problem, two 
factors have served as a disincentive for the development of novel antimicrobials.  First, 
the nature of antibiotics dictates that they are used only for a short period of time, days to 
weeks, whereas other drugs used to treat chronic illnesses like depression or high 
cholesterol can be taken for years or even decades.4  Second, the use of newly approved 
antibiotics is often limited to the treatment of individuals with cases of serious bacterial 
infections.  This is done in an attempt to prolong the effective lifetime of the new drug by 
limiting its exposure to bacteria.  Thus, only the most severe cases of all those who could 
potentially benefit from the new antibiotic are able to use it.5  Furthermore, a drug that 
may take over a decade to develop could no longer be clinically useful in just a couple of 
years as a result of antibacterial resistance.  The combination of these factors has resulted 
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in the decline of antibiotic discovery and development while antibiotic resistance is 
increasing.  
This discovery disincentive has resulted in identification of only four new classes 
of antibiotics since the 1960s, four classes that have not made a major contribution to 
antibiotic therapy as a whole.  In addition, with the exception of the carbapenems in 
1985, all of the antibiotics between the 1960s and 2000 approved for clinical use have 
been synthetic derivatives of previously used scaffolds.  As an example, four scaffolds 
are responsible for 73% of new antibacterials between 1981 and 2005, the 
cephalosporins, penicillins, quinolones, and macrolides.6  This has led to a forty-year 
innovation gap in the drug pipeline (Figure 4.1).      








The late 1980s witnessed the start of an exodus of the pharmaceutical companies 
from antibiotic development.  Originally, fifteen major pharmaceutical companies were 
involved in antibiotic discovery programs.  Today, of those fifteen, eight companies have 
fully abandoned their discovery programs while two more have significantly reduced 
their research efforts.  Only five companies with antibiotic discovery programs remain, 
GlaxoSmithKline, Novartis, AstraZeneca, Merck, and Pfizer.2  Accordingly, almost all 
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new antibiotics, and those currently in the pipeline for Gram-positive bacteria, are 
second- or higher-generation drugs.  The combination of all of these factors has led to a 
desperate need for the development of novel antibacterials and synthetic scaffolds.      
 
4.1.2. Methicillin-Resistant Staphylococcus Aureus (MRSA) 
 Discovered in the 1880s, Staphylococcus aureus is a Gram-positive Firmicutes 
bacterium that colonizes the skin and mucosal surfaces in the nose and human respiratory 
tract of up to 30% of the population.  Though it is not always pathogenic, when it moves 
beyond its commensal locations, it may cause a variety of infections including boils, 
necrotizing pneumonia, post-operative wound infections, joint infections, and 
endocarditis.2, 7  Before the discovery and use of penicillin in the early 1940s, S. aureus 
infections were fatal in approximately 80% of cases.7   
In Gram-positive bacteria, penicillin and other β-lactam antibiotics function by 
inhibiting the transpeptidase activity of penicillin-binding proteins (PBPs), which are a 
class serine acyltransferases that cross-link the peptidoglycan that forms the bacterial cell 
wall.  The β-lactam antibiotics bind to the PBP’s catalytic cleft, forming a covalent 
association with an active site serine.  This covalent β-lactam-enzyme complex is stable 
and only hydrolyzed at a very slow rate, thus reducing the amount of peptidoglycan 
cross-linking that can occur.8  Ultimately, these antibiotics cause a disruption in the 
synthesis of the peptidoglycan layer and consequently bacterial death.  By 1942, the first 
strains of penicillin-resistant S. aureus were discovered in hospitals.  This resistance 
arose as a consequence of the bacteria acquiring a plasmid that encoded for penicillinase, 
a β-lactamase enzyme first described by Abraham and Chain in 1940 that deactivates 
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penicillin and other β-lactams by hydrolysis of the lactam.9  In the past half-century, close 
to 80% of all S. aureus isolates found have been penicillin-resistant. 
 To counteract the growing resistance of S. aureus to penicillin in the 1950s, the 
pharmaceutical industry developed a variety of semisynthetic penicillin variants designed 
to be resistant to hydrolysis by penicillinase.  As a result, methicillin was developed and 
introduced in 1959 (Figure 4.2).  By 1961, European hospitals had identified the first S. 
aureus strains that were resistant to methicillin.10  S. aureus resistance to methicillin is a 
result of the presence of the mecA gene, which encodes for the 78 k-Da penicillin-binding 
protein 2a (PBP2a).  The β-lactam antibiotics are not able to bind to PBP2a; therefore, 
they cannot disrupt the synthesis of the peptidoglycan layer and bacterial cell wall 
synthesis is maintained.7  Thus, MRSA was born and continues today to be a major cause 








4.1.3. Vancomycin-Resistant Enterococcus (VRE) 
 Enterococci are Gram-positive Firmicutes bacteria.  Dozens of Enterococcus 
species are known; however, there are two common commensal types of enterococci that 
reside in human intestines, E. faecalis and E. faecium.  These two species are also 
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responsible for the majority of human infections, where E. faecalis accounts for 80-90% 
of clinical isolates and E. faecium accounts for 5-15%, while the remaining other 
Enterococcus species account for less than 5%.11   
Beginning in the late 1970s, enterococci began to be identified as a major player 
in nosocomial infections.  Enterococci are intrinsically resistant to several antimicrobials 
including moderate concentrations of β-lactams, low concentrations of aminoglycosides, 
clindamycin, cephalosporins, fluoroquinolones, sulphonamides, and trimethoprim-
sulfamethoxazole.12  Enterococci also have an amazing ability to acquire resistance to all 
currently available antibiotics, either through mutation or by exchange of plasmids and 
transposons.13  Accordingly, enterococci have acquired resistance to high concentrations 
of β-lactams, high concentrations of aminoglycosides, glycopeptides, tetracycline, 
erythromycin, fluoroquinolones, rifampin, chloramphenicol, fusidic acid, and 
nitrofurantoin.       
Until recently, vancomycin was the only drug that could be reliably used to treat 
bacterial infections caused by multi-drug resistant enterococci.  Vancomycin is a tricyclic 
glycopeptide antibiotic that was discovered in 1953 when it was isolated from the 
actinomycete Amycolatopsis orientalis and is often used as the “antibiotic of last resort.”  
Vancomycin exerts its bactericidal effect by binding to peptides containing D-alanyl-D-
alanine, the substrate of peptidoglycan synthetase, thus disrupting peptidoglycan 
polymerization.12   It has been in use for over 30 years, and until recently, vancomycin-
resistance was relatively rare. 
The first strains of vancomycin-resistant Enterococcus (VRE) were isolated in 
England and France in 1986 and, after only one year, VRE was isolated in the U.S.14  
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Since then, five phenotypes of vancomycin resistance have been described in enterococci: 
VanA-VanE.11  VanA and VanB are the most clinically important of the phenotypes, and 
both are frequently found in E. faecalis and E. faecium.  The VanA phenotype shows 
high resistance to vancomycin and the semisynthetic glycopeptide antibiotic teicoplanin.  
Exposure of the VanA phenotype to antimicrobial agents triggers the synthesis of 
multiple proteins that work together to prevent the binding of vancomycin to its peptide 
substrates, thus conferring resistance.  The VanB phenotype enterococci show resistance 
to vancomycin but not teicoplanin.12  Between the years 1989 and 1993, the National 
Nosocomial Infections Surveillance System (NNIS) reported an increase from 0.3 to 
7.9% of enterococcal isolates containing VRE from intensive care units (ICUs).  By 
2000, of the 2575 enterococcal isolates tested from ICUs, the percentage containing VRE 
had risen to 26.3%.15          
   
4.2. Targeting MRSA and VRE 
 The overall aim of this research is the development of novel antibacterial 
compounds, compounds having previously unused scaffolds and that function through 
new modes of action, for the treatment of MRSA, VRE, and other pathogenic Gram-
positive bacteria.  The Class II 3-hydroxy-3-methylglutaryl coenzyme A reductase (II-
HMGR) enzyme was selected as the target for the development of novel antibacterials.  
The high druggability of II-HMGR makes it an appealing target; it is essential for the 
survival of Gram-positive cocci, it is highly conserved among staphylococcal, 
streptococcal, and enterococcal pathogens, it is distinct from the Class I HMGR of 
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humans, absent in a large quantity of other commensal bacteria, and harbors an active site 
region amenable to small molecule binding. 
 
4.2.1. 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (HMGR) 
 The HMGR enzyme catalyzes the first committed step in the mevalonate 
pathway, which is the biological pathway used by humans, other eukaryotes, archaea, and 
Gram-positive cocci for the biosynthesis of isopentenyl diphosphate (isopentenyl 
pyrophosphate).  Isopentenyl diphosphate (IPP) is an essential precursor for the synthesis 
of isoprenoids.  In bacteria, IPP is used in the construction of undecaprenol, a lipid carrier 
that is crucially involved in cell wall biosynthesis.  Other products of IPP include the 
menaquinones and ubiquinones which are involved in electron transport.16  Two 
pathways for the synthesis of IPP have been identified.  The mevalonate pathway is the 
more common of the two, while the glyceraldehyde 3-phosphate/pyruvate (GAP) 
pathway is less common and is employed by Gram-negative bacteria.17 
 The mevalonate pathway was described by Joseph Goldstein and Micheal Brown 
in 1970 when it was first identified in eukaryotic cells.18  This pathway ultimately results 
in the production of IPP from the linking of three acetyl coenzyme A (acetyl-CoA) units.  
First, the enzyme acetyl-CoA transferase joins two acetyl-CoA units.  The addition of a 
third acetyl-CoA unit is then catalyzed by HMG-CoA synthase, forming 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA).  A series of biological reactions involving the 
reduction of HMG-CoA to mevalonate, phosphorylation, decarboxylation, and 












 HMG-CoA reductase is the best characterized enzyme in the mevalonate 
pathway.  It is a four-electron oxidoreductase that catalyzes the reductive deacylation of 
(S)-HMG-CoA to (R)-mevalonate, a reaction that occurs in three parts, where the first 
and third part are reductive.  There are four conserved catalytic residues that are crucial 
for HMGR function as determined by site-directed mutagenesis: a histidine,19, 20 
aspartate,21 glutamate, and lysine.22  The role of the histidine is the protonation of the 
departing CoA thiolate, which reduces the ability of the sulfur to attack the bound 
mevaldehyde intermediate, an event that would subsequently hinder the overall reaction.  
The other residues, the catalytic lysine, aspartate, and glutamate, function through a 
hydrogen bond network that interacts with the carbonyl group of HMG-CoA and 





























































    
 




 The difference between the two classes of HMGRs (Class I for humans and 
eukaryotes, Class II for prokaryotes) resides in the placement of the active site lysine, 
which is only conserved within the two classes and is present on different structural 
elements.17  The eukaryotic I-HMGRs contain a highly conserved C-terminal catalytic 
domain and a weakly conserved, membrane-bound N-terminal domain that is made of 
two to eight transmembrane helices.  Unlike the I-HMGRs, II-HMGRs do not contain a 
membrane-bound N-terminal domain.  Both I- and II-HMGRs form obligate dimers that 
associate into a tetramer in the human form and a dimer or hexamer in the bacterial form, 
where the overall fold of both classes of HMGR are similar and have the active site 
located at the dimer interface.  The catalytic domains of both I- and II-HMGRs are 
analogous, where the positions and orientations of the key catalytic residues are 
conserved between Class I- and II-HMGRs. The catalytic area of the I-HMGR is 
composed of three domains: a helical N-terminal domain (N-domain), a larger central 
domain (L-domain), and a small domain (S-domain) that resides within the L-domain.  
The II-HMGRs contain all of the domains of the I-HMGRs in addition to a fourth 
domain, the C-terminal helical domain.  This C-terminal domain is known as the ‘flap 
domain’ and is only ordered upon binding of the substrate and cofactor.  When the 
substrate and cofactor bind to HMGR, a helical domain (a single helix in Class I and 
three helices in Class II HMGRs) folds over the active site.  In the Class I HMGRs, this 
single helix delivers the critical lysine to the active site, a feature known as the ‘cis-loop’.  
In contrast, in the Class II HMGRs, this critical catalytic lysine is always present in the 
active site, residing on a well-defined helix.23 
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 These differences in the structures and catalytic sites of I- and II-HMGRs create a 
therapeutic window for targeting II-HMGR.  An example of this are the well known 
statin drugs, used to treat high cholesterol in humans through the inhibition I-HMGR.  
Lovastatin inhibits hamster I-HMGR with a Ki of 5 nM.  Against the II-HMGRs of S. 
aureus, E. faecalis, and P. mevalonii, Lovastatin has Ki’s of 320, 500, and 530 µM, 
respectively.24 
 
4.3. Previous Work 
 The Stauffacher Research Group of the Department of Biological Sciences at 
Purdue University produced and purified the II-HMGR enzyme from E. faecalis to be 
used as a target for an initial high throughput screen to identify inhibitors for II-HMGR.25  
The E. faecalis II-HMGR enzyme was chosen as the target for the screen as it was the 
most stable and easily purified enzyme of the pathogens of interest.  The purified enzyme 
was sent to the Southern Research Institute (SRI) in Birmingham, AL where a high 
throughput screen of 305,000 compounds was performed to identify II-HMGR inhibitors.  
Inhibitor ability was determined using an assay that monitored the reverse reaction of II-
HMGR by following the conversion of NADP to NADPH at 340 nm (Equation 4.1). 
 
Mevalonate + 2NADP+ + CoASH      HMG-CoA + 2NADPH + 2H+ 
 
Equation 4.1. Reverse reaction of II-HMGR (non-physiological direction). 
  
 
 This high throughput screen of 305,000 commercially available compounds 
resulted in the identification of 27 small molecules that inhibited II-HMGR in the non-
physiological direction with IC50 values less than 250 µM.  These 27 small molecules 
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were re-assayed at Purdue against II-HMGR from E. faecalis and P. mevalonii where 
seven of the compounds were found to inhibit II-HMGR in the non-physiological 
direction with IC50 values less than 250 µM.  Structural studies were then undertaken for 
these seven compounds, where only one of the seven identified inhibitors was found to 
show electron density when soaked into P. mevalonii II-HMGR crystals, resulting in the 
identification of the compound 5-(N-(4-butylphenyl)sulfamoyl)-2-hydroxybenzoic acid 
(N-bsha).  Subsequently, the X-ray crystal structure of the N-bsha-E. faecalis II-HMGR 
complex was determined and N-bsha was found to competitively inhibit E. faecalis II-
HMGR with and IC50 of 50 µM in the physiological direction and 5 µM in the non-












 The X-ray crystal structure of the N-bsha-E. faecalis II-HMGR complex shows 
that N-bsha binds in the active site of II-HMGR, utilizing the same chemical space as 
mevalonate (Figure 4.6, A&B).  N-bsha forms several direct and water-mediated 
stabilizing hydrogen-bonds from each of its heteroatoms to key residues within the II-
HMGR active site, including two of the residues that are functional in the catalytic 
mechanism, Asn213 and Glu86.  The orientation of N-bsha within the II-HMGR active 
site is such that the butylphenyl group of N-bsha is in a position to effectively block the 
closing of the C-terminal flap domain, inhibiting catalysis.  Comparison of the N-bsha-E. 
faecalis II-HMGR complex and a complex of E. faecalis II-HMGR bound with an HMG-
CoA analogue shows that the carboxylate groups of each compound are aligned in the 
active site, allowing for the hydrogen-bonding interaction of each carboxylate with 
Arg257.  Furthermore, the phenol ring of N-bsha shares the same chemical space as the 
hydroxymethylglutamate of HMG-CoA and the sulfonamide of N-bsha imitates the 
amide of HMG-CoA resulting in very little reorganization of the II-HMGR active site 
upon binding of N-bsha.       
         
   







Figure 4.6. (A) X-ray crystal structure of N-bsha bound in E. faecalis II-HMGR active 
site showing key hydrogen-bonding network, where N-bsha is shown in blue and colored 
by atom type, waters are shown as red spheres, and the critical active site residues are 
shown as sticks and colored by atom type. (B) Superposition of E. faecalis II-HMGR 
(light yellow) and P. mevalonii II-HMGR (light pink, PDB: 1QAY), where mevalonate is 



















4.4 De Novo Design of II-HMGR Inhibitors 
 
 Using the structural features elucidated by the X-ray crystal structure of the 
inhibited E. faecalis II-HMGR active site, we set out to discover novel inhibitors of II-
HMGR through a strategy of de novo design and in silico screening.   
 
4.4.1. Tandem Design Approach: e-LEA3D and AutoDock Vina (ADV) 
 A tandem design approach was utilized for the design of novel II-HMGR 
inhibitors.  The initial de novo design was performed using the e-LEA3D web server and 
the results of the de novo design were evaluated in silico using the docking program 
AutoDock Vina (ADV).  The e-LEA3D web server is a program that utilizes a fragment-
based approach for the generation of original drug candidates.26  This fragment-based 
approach employs a genetic algorithm that optimizes a combination of chemical 
fragments by evolving a population of molecules over several generations.  A scoring 
function that incorporates various user-defined molecular properties and the protein-
ligand docking score calculated by the program PLANTS is used to assess the fitness of 
each candidate within a population.27  Only the most fit combinations are used in the next 
generation. 
 The binding site from the X-ray crystal structure of P. mevalonii II-HMGR 
complexed with HMG-CoA (PDB: 1R31) was used to define the region for fragment-
based design.  The P. mevalonii II-HMGR was used as the enzyme structure uploaded to 
the e-LEA3D web server for fragment-based design, as the X-ray crystal structure of E. 
faecalis II-HMGR in complex with N-bsha was not yet published.  Residues K267 and 
T264 of P. mevalonii II-HMGR were chosen to define the binding region around which 
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ligand design was based.  The K267 residue was chosen due to its critical function in the 
II-HMGR mechanism (vide supra) and the T264 residue was chosen as a result of its 
prime location within the interior of the II-HMGR active site.  The P. mevalonii II-
HMGR residues K267 and T264 correspond to the E. faecalis II-HMGR residues K263 
and T260.  Fifteen generations of twenty candidates each were produced by e-LEA3D, 
where the binding site radius was limited to 15 Å around the specified amino acid and the 
molecular weight of the candidates produced was limited so as not to exceed 469 Da.   
The results produced by e-LEA3D were assessed using ADV, a program for the 
molecular docking and virtual screening of compounds in silico.28, 29  The output of ADV 
was evaluated in three ways.  First, the predicted orientation of the candidate relative to 
the II-HMGR active site was examined.  The defined search space for ADV, the space in 
the II-HMGR enzyme available for ADV to dock the candidate, was defined to 
encompass an entire half of the II-HMGR enzyme.  Because II-HMGR is a homodimer, 
each side is essentially identical and the enzyme has two identical active sites.  Therefore, 
by defining the search space as half of the II-HMGR homodimer, ADV was essentially 
allowed to dock the candidate anywhere on II-HMGR.  Here, the binding orientation is 
used to refer to the placement of the docked candidate relative into the II-HMGR active 
site.  Nine binding orientations were produced for each candidate, and candidates that had 
better binding orientations were candidates that were oriented in or near the II-HMGR 
active site as predicted by ADV.  Second, ADV uses a scoring function that is tuned to 
recognize promising conformations of the candidate molecule in the II-HMGR enzyme, 
and ADV uses this scoring function to predict the binding affinity of the candidate.  This 
output, produced in kcal/mol, is different for each predicted binding conformation and 
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orientation of a given candidate.  Candidates with better scores have lower binding 
affinities.  Third, the binding conformation is used here to refer to the conformation of 
the molecule when docked in the enzyme.     
The results of the initial e-LEA3D de novo design were evaluated by ADV for 
two reasons; first, ADV was used as a means to “double-check” the results of e-LEA3D 
and second, it provided a method to validate that the candidates produced by e-LEA3D 
for P. mevalonii II-HMGR would also be active against E. faecalis II-HMGR.  To 
determine these two things, the predicted orientation, binding conformation, and binding 
affinity produced by ADV were all taken into consideration.  The candidates from the 
initial e-LEA3D design that had the best binding affinities and most promising 
orientations predicted by ADV were then carried forward and subjected to further 
modifications, this time using the functionalization feature of e-LEA3D to decorate the 
molecules at user-specified positions that were identified by the analysis of the 
candidate’s predicted binding orientations produced by ADV. 
 The functionalization results produced by e-LEA3D from the second design step 
were then evaluated with ADV.  Again, ADV was used to assess the predicted 
orientation, binding conformation, and binding affinity of the functionalized candidates.  
The candidates with the best predicted binding affinities and most selective predicted 
binding orientations were then subjected to further user-specified functionalization.  
These user-specified modifications were made to confer further selectivity to the 
candidate, and the success of the various functionalizations was determined by ADV.  
Three candidate scaffolds were arrived at through this design approach: a phenothiazine 
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scaffold, a quinoline scaffold, and an indole scaffold.  A pictorial representation of this 





Figure 4.7. (Left) Pictorial representation of tandem e-LEA3D/ADV design approach, 
(Top Right) Other scaffolds arrived at through tandem design approach, (Bottom Right) 
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Tandem e-LEA3D/ADV Design Approach
	 92
4.4.2. Validation of ADV Results 
 To test the validity of the docking results produced by ADV for the candidate 
inhibitors, ADV was used to predict the binding conformation of the known II-HMGR 
inhibitor N-bsha in E. faecalis II-HMGR.  Starting from the unbound structures of the II-
HMGR enzyme and N-bsha, where the rotatable bonds, torsion angles, and position of N-
bsha had been randomized prior to docking, ADV was able to correctly predict the actual 
binding conformation of N-bsha to within a small margin of difference.  Thus, the scoring 
function utilized by ADV correctly identified the true binding conformation of N-bsha 
actually determined by the X-ray crystal structure, recognizing this binding pose as an 
energy minimum.  The predicted binding conformation overlaid with the actual crystal 
structure of N-bsha are shown in Figure 4.8, A. 
 The predicted binding affinity produced by ADV for the top scored binding pose 
of N-bsha (Figure 4.8) was -7.0 kcal/mol.  Using Equation 4.2, this predicted binding 
affinity (ΔG) can be used to predict the dissociation constant (Ki) for N-bsha and E. 
faecalis II-HMGR to be roughly 8 µM.  Though the actual Ki for N-bsha and E. faecalis 
II-HMGR has not been determined, the Ki for N-bsha and S. aureus II-HMGR has been 
determined by the Stauffacher group to be 71 µM in the non-physiological direction, 
roughly an order of magnitude higher than that predicted.  The predicted binding affinity 
produced by ADV for the top binding pose of the designed phenothiazine 4.40 was -10.1 
kcal/mol, which corresponds to a predicted Ki of roughly 43 nM (Figure 4.8, B & C). 
 
Ki = e^(ΔG/kBT) where kBT[300K] = 0.596165 kcal/mol 
 




Figure 4.8. (A) Validation of ADV exercise, predicted and actual binding conformation 
of N-bsha in E. faecalis II-HMGR, where the blue N-bsha molecule is the actual binding 
conformation determined by X-ray crystal structure and the white N-bsha molecule is the 
predicted binding conformation produced by ADV. (B) Designed phenothiazine 
compound 4.40. (C) Overlay of predicted fourth binding mode of 4.40 superimposed on 










4.5. Construction of Substituted Phenothiazine Library 
Based on our de novo design and in silico screening work, we set out to 
synthesize a small library of substituted phenothiazines for the inhibition of II-HMGR.  
The phenothiazines synthesized were derivatives of the general structure shown in Figure 
4.7, and were selected for synthesis based on their docking score, synthetic accessibility, 
and availability of starting materials.  To construct the phenothiazine library, we 
envisioned the formation of three phenothiazine cores amenable to functionalization, 4.1, 

































4.5.1. Attempted Synthesis of Phenothiazine Cores 
 
4.5.1.1. Smiles Rearrangement 
 We first set out to accomplish the synthesis of the phenothiazine cores by a 
Smiles rearrangement, the mechanism of which is shown in Scheme 4.2.30-33  Envisioning 
that reaction of the o-nitro bromide 4.4 with the o-amino thiophenol 4.5 would result in 
the phenothiazine in one synthetic step, we set out to synthesize these molecules.  The 
two reactants 4.4 and 4.5 were obtained by derivatization of the same commercially 
available starting material.  The o-nitro bromide 4.4 was formed by the nitration of 4-
bromoacetophenone using potassium nitrate in sulfuric acid and the o-amino thiophenol 
4.5 was obtained by treatment of 4.4 with sodium sulfide followed by reduction of the 
nitro group with stannous chloride.  With the two desired reactants in hand, we attempted 
to affect the Smiles rearrangement using the established procedure, by treatment with 
potassium hydroxide in refluxing ethanol.  To our dismay, this reaction did not produce 
the desired phenothiazine, and the only product isolated from the reaction mixture was 
the sulfide 4.6 (Scheme 4.2, bottom).  Presumably, this reaction did not proceed to the 
phenothiazine because the aryl ring containing the nitro moiety was not sufficiently 
electron deficient.  Though the sulfide obtained was not the desired compound, we were 
curious as to whether this derivative could inhibit II-HMGR.  Analysis of 4.6 using ADV 
produced a predicted binding affinity of -7.4 kcal/mol for the best scored binding pose, 





Scheme 4.2.  (Top) Mechanism of Smiles rearrangement.  (Bottom) Synthesis of reactants 
and first attempt at production of phenothiazine core via Smiles rearrangement.   
 
 
 We then turned our attention to a slightly modified synthetic route to the 
phenothiazine, still employing the similar reactants.32  Treatment of the commercially 
available o-aminothiophenol and 4.4 with sodium acetate in refluxing ethanol produced 
the desired sulfide 4.7, which was predicted by ADV to have a binding affinity of -6.6 
kcal/mol.  The amine was then formylated, increasing its acidity, and treated with 
potassium hydroxide in a refluxing mixture of acetone and ethanol.  This reaction 


























(ADV G -7.4 kcal/mol)
4.4 + 4.5
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products including the byproduct 4.9 which arose as a result of the di-substitution of o-
aminothiophenol.  Again, ADV was used to predict the ability of the synthesized 
compounds to inhibit II-HMGR and, to our surprise, the byproduct 4.9 had a predicted 
binding affinity of  -8.4 kcal/mol for its top scored binding pose.  An analogue of 4.9 was 
then synthesized by reduction of the carbonyls using sodium borohydride, resulting in the 
desired compound 4.10 (Scheme 4.3).  Though the modified Smiles rearrangement 
resulted in the desired phenothiazine core, it could not be optimized to give reliable 
results in higher yields and was therefore not a suitable synthetic route.  
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4.5.1.2. CuI-Catalyzed Cascade C-S and C-N Bond Formation 
 Turning toward a new synthetic route, we sought to employ a copper-catalyzed 
cascade C-S and C-N bond forming reaction.34  The starting materials for this reaction 
were again synthesized from the same commercially available 4-bromoacetophenone.  
Reduction of the nitro moiety of 4.4 with stannous chloride followed by diazotization and 
substitution using potassium iodide resulted in the o-dihalide 4.11.  Reaction of 4.11 with 
the commercially available o-aminothiophenol following the reported ligand-free 
protocol of Dai,34 with freshly recrystallized Cu(I)I and potassium carbonate in 
dimethylsulfoxide at 120 °C for 48 hours under an inert atmostphere, did not yield the 
desired phenothiazine.  Instead the bis-sulfide 4.12 was obtained in 89% yield.  This 
result was rationalized as a consequence of the two very labile carbon-halogen bonds.  
Thinking that reducing the lability of these bonds would promote the desired 
intramolecular cascade reaction over the two intermolecular S-C couplings, the reaction 
was carried out again using the two commercially available substrates, o-
bromochlorobenzene and o-aminothiophenol.  Unfortuately, this attempt was not met 
with success; instead, the reaction stopped after formation of the sulfide 4.13, and C-N 
bond formation did not take place, indicating that the C-Cl bond was not labile enough to 
promote the intramolecular coupling.  In a final attempt at this ligand-free protocol, the 
commercially available o-dibromobenzene was reacted with o-aminothiophenol.  Here, 
the two C-Br bonds proved too labile and the intermolecular reaction was again favored, 
producing the bis-sulfide 4.14.  All of the byproducts produced from these coupling 
attempts were analyzed using ADV and their predicted binding affinities are shown in 








 After our many failures at employing the ligand-free CuI-catalyzed route toward 
the phenothiazine, we attempted the use of L-proline as a ligand to promote the 
reaction.35  However, subjecting the commercially available o-dibromide and o-
aminothiophenol to the conditions shown in Scheme 4.5 using L-proline as a ligand did 
not result in the desired phenothiazine in pure form.  Instead, the sulfide 4.15 was 
obtained in 50% yield along with a complex mixture of products that appeared to contain 
the phenothiazine, but from which it could not purified.  Finally, re-subjecting the sulfide 
4.15 to the coupling conditions produced phenothiazine by NMR analysis of the crude 
	 100
reaction mixture; however, because of the long reaction times and inconsistency of the 




    
 




4.5.2. The Cadogan Reaction: Synthesis of First Phenothiazine Set  
 After the various, detailed failures in our synthetic efforts towards the 
phenothiazines cores, we envisioned effecting the formation of the phenothiazine through 
a new route - the formation of an electrophilic nitrogen (Scheme 4.6).  We had learned 
through our previous failures that the sulfide was easy to access, and therefore we 
thought to create a sulfide starting material that bore a nitrogen-containing functionality 
that could eventually react as an electrophile in an aromatic substitution reaction, forming 
the phenothiazine.  A literature search of such reaction types resulted in the discovery of 
the Cadogan reaction.   
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The Cadogan reaction was first reported in 1966 and is an underutilized method 
for the synthesis of phenothiazines, as most phenothiazines are currently synthesized by 
various coupling reactions.36, 37  These reactions employ metal catalysts, various ligands, 
are extremely sensitive to air and moisture, have long reactions times, and often times 
have variable results (vide supra).  In contrast, the Cadogan reaction uses easily 
accessible starting materials and inexpensive reagents, is only mildly air sensitive, and 
consistently results in the desired phenothiazine product in moderate to good yields 
depending on the substitution pattern of the starting materials.   
The Cadogan reaction employs the reductive cyclization of an aromatic nitro 
compound using triethylphosphite to generate a nitrene in situ; the mechanism of this 
rearrangement is shown in Scheme 4.7.  First, attack of triethylphosphite on the nitro 
group followed by elimination of triethyl phosphate produces the nitroso compound [A].  
Attack of a second molecule of triethylphosphite on the nitroso moiety followed by 
alpha-elimination produces the nitrene intermediate [B].  Electrophilic aromatic 
substitution at the ipso-carbon of the sulfide then gives the cyclic intermediate [C], which 














































             
 
Scheme 4.7. Mechanism of Cadogan reaction. 
       
 
 
 We set out to produce the Cadogan cyclization in two ways from the same sulfide 
(4.16).  First, we sought to generate the reactive nitrene via treatment of 4.16 with 
triethylphosphite.  Second, we explored thermal decomposition of the corresponding 
azide to the nitrene.  With this synthetic plan in hand, the sulfide 4.16 was synthesized by 
the reaction of 4.4 and commercially available 4-methoxythiophenol in quantitative yield.  
Our first attempt at the Cadogan reaction utilized the original synthetic procedure, where 
the starting material was refluxed in triethylphosphite.  However, this resulted in a 
complex reaction mixture that appeared to contain the desired phenothiazine as well as 
several ethylated byproducts.  A variant of Cadogan’s original procedure was then 
employed, where mesitylene was used as the reaction solvent and the sulfide 4.16 was 
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treated with six equivalents of triethylphosphite under reflux conditions.  To our delight, 
the desired phenothiazine 4.1 was obtained in good yield.  Concurrently, we were 
working towards accessing the same phenothiazine by means of thermally decomposing 
an azide.  Treatment of 4.16 with stannous chloride resulted in the desired amine 4.17 in 
moderate yield, which upon diazotization, formation of the azide, and refluxing of the 













 With the first desired phenothiazine core in hand, the synthesis of the library 
commenced.  Two different routes toward the same “one-armed” phenothiazine were 
undertaken simultaneously to expedite the process.  The first route entailed the protection 
of the secondary amine of 4.1 with a tert-butyl carbamate, yielding 4.18. Aldol 
condensation of 4.18 with 4-chlorobenzaldehyde resulted in the intermediate 4.19, which 
upon treatment with 4 N HCl/dioxane gave the desired functionalized phenothiazine 4.20 
(Route A, Scheme 4.9).  Meanwhile, starting from sulfide 4.17, aldol condensation with 
4-chlorobenzaldehyde yielded the functionalized sulfide 4.21.  Reduction of the nitro 
group with stannous chloride followed by diazotization and treatment with sodium azide 
resulted in formation of the azide, which was subsequently thermally decomposed to the 
nitrene to affect the Cadogan reaction and yield the same “one-armed” phenothiazine 
4.20 (Route B, Scheme 4.9).  
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Scheme 4.9. Two successful routes toward the same “one-armed” phenothiazine 4.20. 
 
 
 Of the two available routes toward the synthesis of the functionalized 
phenothiazines, Route A (Scheme 4.9) was chosen for the construction of the remaining 
phenothiazine library members as it required fewer synthetic steps and gave the products 
in higher overall yields.  A second “one-armed” phenothiazine was synthesized with the 
4.1 core structure, using a modified Route A.  Treatment of 4.1 with boron tribromide 
resulted in the free phenolic phenothiazine 4.22 in quantitative yield.  Treatment of 4.21 
with di-tert-butyl dicarbonate gave the di-protected product 4.23, which upon Aldol 
condensation with 4-dimethylaminobenzaldehyde resulted in the “one-armed” 
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phenothiazine product 4.24 where the phenol was liberated under those reaction 










 With the two phenothiazine analogues 4.20 and 4.24 from the 4.1 phenothiazine 
core in hand, we set out to synthesize a set of analogues arrived at from the phenothiazine 
core 4.2.  The sulfide 4.26 was obtained in 75% yield from the reaction of 4.4 and 
commercially available thiophenol.  Subsequent, Cadogan cyclization of sulfide 4.26 
resulted in the phenothiazine core 4.2 in 75% yield, a slightly lower yield than that 
obtained for phenothiazine core 4.1.  This result was not entirely unexpected as the 
absence of the methoxy group of 4.1 dictates a less electron rich aryl ring of 4.2.  
Protection of the amine of 4.2 as a tert-butyl carbamate resulted in 4.27, which was 
followed by aldol condensation with 4-chlorobenzaldehyde to give library member 4.28.  
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Deprotection of the amine subsequently produced phenothiazine 4.29 (Scheme 4.11, top).  
Another series of “one-armed” phenothiazines was accomplished by the condensation of 
4.27 with 2,4-dimethoxybenzaldehyde, yielding 4.30 in 50% yield.  Deprotection of the 





Scheme 4.11. (Top) Synthesis of phenothiazines 4.2, 4.26-4.28. (Bottom) Synthesis of 





4.5.3. Biological Evaluation of First Phenothiazine Set 
At this point, six desired “one-armed” phenothiazines had been synthesized: 4.20, 
4.24, 4.28, 4.29, 4.30, and 4.31.  These phenothiazines had predicted binding affinities 
between -8.4 and -9.3 kcal/mol by ADV.  In addition, another seventeen molecules 
including twelve byproducts and intermediates and five phenothiazine cores had been 
synthesized that had been screened in silico for E. faecalis II-HMGR binding using ADV.  
These other compounds 4.1, 4.6-4.10, 4.12, 4.13, 4.14-4.18, 4.21, 4.22, 4.26, and 4.27 
had predicted binding affinities between -6.6 and -8.9 kcal/mol by ADV; therefore, these 
compounds were submitted with the six phenothiazines to be assayed for inhibition of II-
HMGR.    
 The twenty-three compounds were assayed for II-HMGR inhibition by Dr. Calvin 
Steussy of the Stauffacher Research Group of the Department of Biological Sciences at 
Purdue University.  Briefly, enzymatic inhibition of E. faecalis II-HMGR was determined 
spectroscopically, where the disappearance of NADPH was monitored at 340 nm, in the 
physiological direction where HMG-CoA was converted to mevalonate.  To our delight, 
all six of the “one-armed” phenothiazines were found to decrease E. faecalis II-HMGR 
activity by at least twenty percent.  Compound 4.24 was found to decrease E. faecalis II-
HMGR activity sufficiently enough for an IC50 value to be determined.  None of the 
byproducts or intermediates tested were found to be inhibitors of E. faecalis II-HMGR.  





Table 4.1. Inhibition of E. faecalis II-HMGR by first phenothiazine set. 
 






4.18 -7.3 24.9 ± 5.9 n/d 






4.24 -9.3 83.3 ± 1.4 130 
	
4.28 -9.3 19.0 ± 5.6 n/d 
	
4.29 -8.8 35.9 ± 11.5 n/d 
	
4.30 -8.8 39.2 ± 9.0 n/d 
	
4.31 -8.4 31.9 ± 4.0 n/d 
aL.M. = library member, n/d = not determined. 
	 111
  Compound 4.24 was found to inhibit E. faecalis II-HMGR in the physiological 
direction with an IC50 of 130 µM.  Interestingly, compound 4.24 also had the best 
predicted binding affinity of the compounds screened by ADV, -9.3 kcal/mol.  The 
predicted binding conformation produced by ADV for compound 4.24 is shown in Figure 
4.9.  The aldol fragment of 4.24 occupies the same chemical space within the II-HMGR 
active site as N-bsha while the phenothiazine core fragment occupies space not utilized 
by N-bsha.  The tert-butyl carbamate moiety of 4.24 extends out toward the solvent 
exposed side of the active site.  Attempts at obtaining an X-ray crystal structure of 4.24 




Figure 4.9. Predicted binding conformation of 4.24 (IC50 = 130 µM) produced by ADV, 
where 4.24 is shown in white and colored by atom type, N-bsha shown in blue and 
colored by atom type, the E. faecalis II-HMGR enzyme is shown in light orange and the 
residues involved in catalysis or hydrogen bonding interaction to N-bsha are shown as 











 The initial inhibition results of the designed phenothiazines were very promising.  
The strength of our tandem de novo design and in silico screening approach can be fully 
appreciated by a comparison to the high-throughput screening method.  When inhibitors 
of E. faecalis II-HMGR were initially sought, a commercial library of 305,000 
compounds was screened for II-HMGR inhibition.  From that library of 305,000 
compounds, one compound was found as a lead inhibitor, N-bsha; a success rate of 
0.0003%.  In contrast, from the six designed phenothiazines that were assayed for II-
HMGR inhibition, the compound 4.24 arose as a lead inhibitor; a 16.7% success rate. 
 
4.5.4. Synthesis of Second Phenothiazine Set 
 Based on the results of the first set of phenothiazine compounds submitted for 
testing, we set out to synthesize two variants of 4.24 while attempts at obtaining 
structural data for 4.24 complexed with II-HMGR were underway.  In order to elucidate 
what aspects of 4.24 were important for II-HMGR inhibition, we synthesized two 
analogues: 4.32 and 4.33.  Starting from 4.18, aldol condensation with 4-
dimethylaminobenzaldehyde yielded the variant 4.32, where the importance of the free 
phenol of 4.24 on inhibition of II-HMGR could be investigated.  Deprotection of the 
amine of 4.32 using boron tribromide resulted in the analogue 4.33, where the effect of 
the free amine could be examined.  Subjecting 4.32 to boron tribromide for longer 
reaction times resulted in the analogue 4.34; unfortunately, no amount of purification was 









 We then turned our attention to the synthesis of the phenothiazine core 4.3.  
Starting from the commercially available 4-mercaptobenzoic acid, Fischer esterification 
yielded the ester 4.35 in quantitative yield.  The sulfide 4.36 was formed in lower yield 
than that seen for the previous sulfides, presumably as a consequence of the electron-
withdrawing ester.  The Cadogan reaction was attempted directly from the sulfide 
intermediate 4.36; however, the desired phenothiazine was not obtained and the reaction 
only resulted in a complex mixture.  We rationalized this again as a consequence of the 
electron-withdrawing ester and thought to get around this problem by reduction of the 
ester to the alcohol.  Thus, the ester was subjected to saponification conditions and the 
acid was obtained in quantitative yield.  We then sought to take advantage of the known 
increased rate of reduction of an acid over a ketone by borane-dimethylsulfide complex, 
and therefore subjected the acid form of 4.36 to those conditions.  To our dismay, our 
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molecule had the opposite reactivity, and the ketone was reduced in the presence of the 
acid, seemingly as a result of the electron-withdrawing nitro group.  We were left with no 
choice but to reduce both the ketone and ester to the corresponding alcohols, a reaction 
that was also accomplished by treatment with borane-dimethylsulfide complex in 
refluxing tetrahydrofuran, yielding 4.37.  With 4.37 in hand, we tried to obtain the 
phenothiazine core 4.3 directly through the Cadogan reaction, but the free alcohols were 
not tolerated and a complex reaction mixture obtained.  Silyl ether protection of the 
alcohols was carried out by treatment of 4.37 with tert-butyldimethylsilyl chloride, which 
resulted in the protected compound 4.38.  Fortunately, when 4.38 was subjected to the 
conditions of the Cadogan reaction, the desired phenothiazine 4.39 was formed, albeit in 
lower yield than the 4.1 and 4.2 phenothiazine cores.  Finally, deprotection of the 
alcohols was accomplished by treatment with tetrabutylammonium fluoride yielding the 
phenothiazine core 4.3 (Scheme 4.13, top).  The functionalized phenothiazines 4.40 and 
4.41 were then obtained by coupling of the appropriate benzoic acid with 4.3 using EDC 





Scheme 4.13. (Top) Synthetic route toward phenothiazine core 4.3. (Bottom) Synthesis of 








4.5.5. Biological Evaluation of Second Phenothiazine Set 
The four phenothiazines 4.32, 4.33, 4.40, and 4.41 were submitted to Dr. Calvin 
Steussy for determination of II-HMGR inhibition using the same conditions as described 
previously.  The sulfide 4.36 was also assayed for E. faecalis II-HMGR inhibition.  
Gratifyingly, all of the phenothiazines were found to decrease E. faecalis II-HMGR 
activity, though none as potently as 4.24.  This data is summarized in Table 4.2.       
 
Table 4.2. Inhibition of E. faecalis II-HMGR by second phenothiazine set. 
 






4.32 -9.4 26.9 ± 2.8 n/d 
4.33 -8.6 19.2 ± 4.7 n/d 
4.40 -10.1 11.6 ± 5.1 n/d	
	
4.41 -9.2 9.2 ± 6.1 n/d	




 A comparison of phenothiazines 4.24, 4.32, and 4.33 prove that both the tert-butyl 
carbamate and free phenol are required for good inhibition of E. faecalis II-HMGR.  
Whether all the compounds bind to E. faecalis II-HMGR in similar conformations and 
whether the free phenol of 4.24 and the phenyl methyl ethers of 4.32 and 4.33 occupy the 
same molecular space in the enzyme is a mystery.  Interestingly, the “two-armed” 
phenothiazine 4.40, which had the best binding affinity predicted by ADV, did not show 
potent inhibition of E. faecalis II-HMGR, possibly as a consequence of the absence of a 
free hydroxyl able to make stabilizing hydrogen bonds within the enzymatic binding 
cavity.   
















 With the overall goal of discovering novel small molecule inhibitors of the II-
HMGR enzyme, a de novo design strategy was used that incorporated a tandem 
computational approach consisting of two programs: the e-LEA3D web server and the 
docking program ADV.  From this tandem design approach, we identified three 
molecular scaffolds with the potential for II-HMGR inhibition.  Based on the results of 
our de novo design and in silico screening strategy, we set out to synthesize a set of 
phenothiazine compounds.   
 Two sets of compounds were successfully synthesized that combined contained 
nine “one-armed” phenothiazines, one “two-armed” phenothiazine, five phenothiazine 
cores, and thirteen sulfides that were either intermediates or byproducts that ADV scored 
highly.  The enzymatic inhibition of E. faecalis II-HMGR by each set of phenothiazine 
compounds was determined.  At 100 mM concentration, all ten of the designed 
phenothiazines were found to decrease E. faecalis II-HMGR activity, between 10 and 
83%.  This work resulted in the successful identification of the novel compound 4.24, 
which was found to inhibit E. faecalis II-HMGR with an IC50 of 130 µM in the 
physiological direction.  Attempts at obtaining an X-ray crystal structure of 4.24 
complexed with E. faecalis II-HMGR are currently underway.  This work represents a 






4.7. Future Directions 
 In the future, the X-ray crystal structure of 4.24 in complex with E. faecalis II-
HMGR will be determined. Based on that structural information, 4.24 will be modified 
accordingly in an attempt to confer more selectivity and potency to the molecule.  
Additionally, sets of compounds derived from the quinoline and indole scaffolds may be 
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Appendix A: Experimental Procedures 
 All reagents (chemicals) were purchased from Sigma or Acros and used without 
further purification.  Solvents were purified by passage through a solvent column 
composed of activated alumina and a supported copper redox catalyst.  Infrared spectra 
were obtained using a ThermoNicolet Nexus 470 FT-IR spectrometer with OMNIC 
software package.  Mass spectral analyses were performed using a Waters Micromass ZQ 
with ESI-MS injection port utilizing MassLynx V4.1 software package.  Analytical thin-
layer chromatography was performed on Sorbent Technologies Glass Backed Silica Gel 
HL TLC Plates w/UV254.  Flash chromatography was performed with Sorbent 
Technologies 200-400 mesh silica gel.  1H NMR spectra were obtained at 300, 400, 500, 
or 800 MHz and 13C NMR spectra were obtained at 75, 100, 125, or 200 MHz, using 
Varian Inova30, Bruker ARX400, Bruker Avance DRX500, or Bruker AV-III-800 
spectrometers, respectively.  E/Z isomerism was determined by Nuclear Overhauser 
Effect experiments.  All compounds were purified by flash chromatography to >90% 












3,5-diisopropoxybenzaldehyde (3.2a).   
A mixture of 3,5-dihydroxybenzoic acid (1.00 g, 6.49 mmol), potassium 
carbonate (4.04 g, 29.2 mmol) and isopropyl bromide (3.65 mL, 38.93 mmol) in 12 mL 
dimethylformamide was heated to reflux for 4 days.  After cooling to room temperature, 
6 mL water and 6 mL 2M hydrochloric acid were added to dissolve the carbonate and 
acidify the reaction mixture.  The aqueous layer was extracted with ethyl acetate (3 x 20 
mL) and the combined organic layers were dried over magnesium sulfate, filtered and 
concentrated to yield 3,5-diisopropoxybenzoic acid as a clear oil that was used without 
further purification.   
 A 0.54 M solution of DIBAL-H in dichloromethane (4.66 mL, 2.52 mmol) was 
added to a solution of 3,5-diisopropoxybenzoic acid (282 mg, 1.01 mmol) in toluene (5 
mL) at -78 °C.  The reaction mixture was allowed to stir for 45 minutes at that 
temperature before quenching with 5% aqueous hydrochloric acid (1 mL).  After 
warming to room temperature, the reaction mixture was diluted with water and the 
aqueous  layer was extracted with ethyl acetate (3 x 5 mL), the combined organic layers 
were dried over magnesium sulfate, filtered and concentrated to yield a mixture of 3,5-
diisopropoxybenzaldehyde and (3,5-diisopropoxyphenyl)methanol in 97% combined 
yield.  3,5-Diisopropoxybenzaldehyde: 1H-NMR (400 MHz, CDCl3) δ (ppm): 9.77 (1H, 
s), 6.86 (2H, d, J = 2.31), 6.57 (1H, t, J = 2.31), 4.48 (2H, m, J = 6.15), 1.24 (6H, d, J = 
125 
 




2-(4-Methoxyphenyl)acetonitrile (3.3d).   
Triphenyl phosphine (1.14 g, 4.34  mmol) was added portion-wise to a solution of 
(4-methoxyphenyl)methanol (300 mg, 2.17 mmol) and carbon tetrabromide (1.22 g, 3.69 
mmol) in anhydrous dichloromethane (7.2 mL) at 0 °C.  The reaction mixture was stirred 
at that temperature for 20 minutes then concentrated to yield a viscous oil which was 
dissolved in 10 mL of 50% hexanes 50% ethyl acetate.  The precipitate was filtered off 
and the filtrate concentrated.  The residue was taken up in dimethylformamide (7.2 mL) 
and potassium cyanide (0.99 g, 15.2 mmol) was added.  The reaction mixture was 
allowed to stir for 90 minutes before quenching with saturated aqueous sodium 
bicarbonate (10 mL).  The aqueous layer was extracted with ethyl acetate (3 x 10 mL) 
and the combined organic layers were washed with brine, dried over magnesium sulfate, 
filtered and concentrated.  The crude product was purified by flash chromatography using 
20% ethyl acetate 80% hexanes to yield the pure product 3 in 45% yield.  1H-NMR (300 
MHz, CDCl3) δ (ppm): 7.19 (2H, d, J = 8.38), 6.86 (2H, d, J = 8.38), 3.74 (3H, s), 3.61 
(2H, s).  13C NMR (75 MHz, CDCl3) δ (ppm): 159.15, 129.01, 121.89, 118.42, 114.35, 




General Procedure for Aldol Condensation (3.4a-3.4c). 
Aqueous 40% potassium hydroxide (0.23 mL/mmol nitrile) was diluted with 
absolute ethanol (0.46 mL/mmol nitrile) and added at room temperature to a solution of 
the appropriate aldehyde (1.1 equivalents) and nitrile (1.0 equivalent) in absolute ethanol 
(0.35 mL/mmol nitrile).  The reaction was then allowed to stir at room temperature for 
12-24 hours before concentrating.  The resulting yellow residue was taken up in water 
and ethyl acetate and dilute hydrochloric acid was added to neutralize the aqueous layer.  
The aqueous layer was then extracted with ethyl acetate and the combined organic layers 
were washed with brine, dried over magnesium sulfate, filtered and concentrated to yield 
the crude product.  Purification by flash chromatography yielded the pure nitrile products 
in 80-95% yield.   
 
 
(Z)-3-(3,5-diisopropoxyphenyl)-2-(4-hydroxyphenyl)acrylonitrile (3.4a).  
 General procedure for Aldol condensation was used in combination with 3.2a 
and 2-(4-((tert-butyldimethylsilyl)oxy)phenyl)acetonitrile (28%).  1H-NMR (300 MHz, 
CDCl3) δ (ppm): 7.56 (2H, d, J = 8.71), 7.31 (1H, s), 6.98 (2H, d, J = 2.15), 6.90 (2H, d, J 
= 8.71), 6.50 (1H, t, J = 2.15), 5.06 (1H, s), 4.58 (2H, m, J = 6.05), 1.36 (12H, d, J = 





(Z)-3-(3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)acrylonitrile (3.4b).   
General procedure for Aldol condensation was used in combination with 3,5-
dimethoxybenzaldehyde and 3.3d (95%).  1H-NMR (300 MHz, CDCl3) δ (ppm): 7.61 
(2H, d, J = 8.91), 7.34 (1H, s), 7.04 (2H, d, J = 2.13), 6.96 (2H, d, J = 8.91), 6.53 (1H, t, 
2.13), 3.85 (9H, s).  13C NMR (75 MHz, CDCl3) δ (ppm): 160.73, 160.32, 139.83, 
135.47, 127.16, 126.59, 118.11, 114.27, 111.14, 106.71, 102.65, 55.28.  ESIMS(+) m/z 
318 (M + Na).   
 
 
(Z)-3-(3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)acrylonitrile (3.4c).   
General procedure for Aldol condensation was used in combination with 3.2a and 
3.3d (92%).  1H-NMR (300 MHz, CDCl3) δ (ppm): 7.56 (2H, d, J = 8.83), 7.32 (1H, s), 
7.01 (2H, d, J = 1.86), 6.94 (2H, d, J = 8.83), 6.51 (1H, t, 1.86), 4.58 (2H, m, J = 6.04), 
3.81 (3H, s), 1.37 (12H, d, J = 6.04).  13C NMR (75 MHz, CDCl3) δ (ppm): 160.31, 
159.15, 140.24, 135.45, 127.19, 126.79, 118.08, 114.30, 110.98, 108.30, 108.24, 106.13, 





(Z)-3-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)acrylonitrile (3.4d).   
A 1.0 M solution of boron tribromide in dichloromethane (2.34 mL, 2.34 mmol) 
was added slowly to a solution of 3.4b (138 mg, 0.46 mmol) in dichloromethane (2.3 
mL) at -78 °C under nitrogen atmosphere.  The reaction was allowed to stir at room 
temperature for four hours before cooling to -78 °C and quenching with an aqueous 
solution of saturated sodium bicarbonate (2 mL).  The reaction mixture was warmed to 
room temperature and the aqueous layer was extracted with ethyl acetate (3 x 2 mL).  The 
combined organic layers were washed with saturated sodium bicarbonate (3 x 5 mL), 
water (1 x 5 mL), and brine (1 x 5 mL) before being dried over magnesium sulfate, 
filtered, and concentrated.  The pure product was obtained in 80% yield after purification 
by flash chromatography using 50% ethyl acetate 50% hexanes.  1H-NMR (400 MHz, 
CD3OD) δ (ppm): 7.52 (2H, d, J = 8.70), 7.42 (1H, s), 6.85 (2H, d, J = 8.70), 6.82 (2H, d, 
J = 2.02), 6.33 (1H, t, J = 2.02).  13C NMR (100 MHz, CD3OD) δ (ppm): 159.85, 141.34, 
137.32, 128.35, 127.07, 119.17, 116.86, 111.91, 108.56, 105.58.  IR vmax 3216 (OH), 






(E)-3-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)acrylaldehyde (3.4e).   
A 1.0 M solution of tetrabutylammonium fluoride solution in THF (0.15 mL, 0.15 
mmol) was added to a solution of 3.5 (29 mg, 0.05 mmol) in THF (0.25 mL) at 0 °C.  The 
reaction was allowed to stir overnight before quenching with saturated ammonium 
chloride.  The aqueous layer was extracted with ethyl acetate ( 3 x 3 mL) and the 
combined organic layers were washed with brine, dried over magnesium sulfate, filtered 
and concentrated.  The pure product 4e was obtained in 15% yield after flash 
chromatography using 50% ethyl acetate 50% hexanes.  1H-NMR (400 MHz, 
CD3OD:CDCl3 50:50) δ (ppm): 9.44 (1H, s), 7.03 (1H, s), 6.81 (2H, d, J = 8.59), 6.63 
(2H, d, J = 8.59), 6.07 (2H, s).  13C NMR (100 MHz, CD3OD) δ (ppm): 195.25, 157.48, 
157.33, 151.12, 140.98, 135.65, 130.39, 123.78, 115.27, 109.10, 104.54.  ESIMS(+) m/z 





Tert-Butyldimethylsilyl chloride (202 mg, 1.34 mmol) and imidazole (228 mg, 
3.35 mmol) were added to a stirred solution of 3.4d (94 mg, 0.37 mmol) in 
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dimethylformamide (2 mL) at 0 °C.  The reaction mixture was warmed to room 
temperature.  After stirring overnight, the reaction mixture was diluted with water and 
extracted with ethyl acetate (3 x 5 mL).  The combined organic layers were then washed 
with brine, dried over magnesium sulfate, filtered and concentrated to yield the protected 
nitrile in 52% yield after flash chromatography using 5% ethyl acetate 95% hexanes. 
 A 0.54 M solution of DIBAL-H in hexanes (0.31 mmol, 0.57 mL) was added 
slowly to the protected nitrile (155 mg, 0.26 mmol) in toluene (1.3 mL) at 0 °C under 
nitrogen atmosphere.  After 40 minutes the reaction was quenched by addition of 
methanol (0.32 mL) and water (0.31 mL), warmed to room temperature and stirred for an 
additional 3 hours.  The reaction mixture was diluted with water and the aqueous phase 
was extracted with ethyl acetate ( 3 x 5 mL).  The combined organic layers were washed 
with brine, dried over magnesium sulfate, filtered and concentrated.  Flash 
chromatography using 5% ethyl acetate 95% hexanes yielded the pure aldehyde product 
3.5 in 80% yield.  (Z)-5: 1H-NMR (300 MHz, CDCl3) δ (ppm): 9.71 (1H, s), 7.20 (1H, s), 
7.05 (2H, d, J = 8.41), 6.85 (2H, s, J =8.41), 6.39 (2H, d, J = 2.18), 6.29 (1H, t, J = 2.18), 
1.00 (12H, s), 0.92 (18H, s), 0.23 (6H, s), 0.08 (9H, s).  (E)-3.5: 1H-NMR (300 MHz, 
CDCl3) δ (ppm): 10.10 (1H, 1), 7.70 (1H, s), 7.39 (2H, d, J = 8.38), 6.94 (2H, d, J = 
8.38), 6.50 (2H, d, J = 2.07), 6.41 (1H, t, J =2.07), 1.00 (12H, s), 0.92 (18H, s), 0.23 (6H, 
s), 0.08 (9H, s).  13C NMR (75 MHz, CDCl3) δ (ppm): 192.46, 156.47, 145.57, 140.63, 









(Z)-5-(3-hydroxy-2-(4-hydroxyphenyl)prop-1-en-1-yl)benzene-1,3-diol (3.4f).   
 A 0.54 M solution of DIBAL-H in hexanes (0.7 mmol, 0.12 mL) was added 
slowly to 3.5 (40 mg, 0.07 mmol) in toluene (.4 mL) at -78 °C under nitrogen 
atmosphere.  The reaction was allowed to warm to room temperature and stirred for 4 
hours.  The reaction was quenched by addition of methanol (0.12 mL) and 0.1 N HCl 
(0.12 mL) at -78 °C.  The reaction mixture was diluted with water and the aqueous phase 
was extracted with ethyl acetate ( 3 x 5 mL).  The combined organic layers were washed 
with brine, dried over magnesium sulfate, filtered and concentrated.  Flash 
chromatography using 5% ethyl acetate 95% hexanes yielded the pure protected alcohol 
in 55% yield.   
 The protected alcohol (15 mg, 0.04 mmol) was dissolved in methanol (0.5 mL) 
and a catalytic amount of hydrochloric acid was added.  The reaction was allowed to stir 
until all of the starting material had disappeared from TLC.  The reaction mixture was 
then concentrated.  The residue was taken up in ethyl acetate and water, and the aqueous 
phase was extracted with ethyl acetate (3 x).  The combined organic layers were washed 
with brine, dried over magnesium sulfate, filtered and concentrated.  The product 4f was 
obtained in 35% yield after purification by flash chromatography using 70% ethyl acetate 
30% hexanes.  1H-NMR (400 MHz, CD3OD) δ (ppm): 7.43 (2H, d, J = 8.64), 6.78 (2H, d, 
J = 8.64), 6.73 (1H, s), 6.37 (2H, d, J = 2.13), 6.19 (1H, t, J = 2.13), 4.59 (2H, s). 13C 
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NMR (100 MHz, CD3OD) δ (ppm): 159.33, 158.05, 141.01, 140.74, 133.78, 130.22, 
128.76, 116.09, 109.11, 108.50, 102.42, 101.57, 84.02, 60.22. 
 
General Procedure for Nitrile Reduction (3.4g, 3.4h).  
 A 0.54 M solution of DIBAL-H in hexanes (2.0 equivalents) was added slowly to 
a solution of the appropriate nitrile (1.0 equivalent) in toluene (0.2 M) at -78 °C.  The 
reaction mixture was stirred at that temperature for four hours before quenching with 
water and ethyl acetate.  The organic layer was washed (3x) with dilute hydrochloric 
acid.  The combined aqueous layers were extracted with ethyl acetate (3x) and the 
combined organic layers were washed with brine, dried over magnesium sulfate, filtered 




(Z)-3-(3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)acrylaldehyde (3.4g).   
General procedure for nitrile reduction was used starting from 3.4b (67%).  1H-
NMR (400 MHz, CDCl3) δ (ppm): 9.75 (1H, s), 7.28 (1H, s), 7.15 (2H, d, J = 8.71), 6.96 
(2H, d, J = 8.71), 6.41 (3H, s), 3.83 (3H, s), 3.59 (6H, s).  13C NMR (100 MHz, CDCl3) δ 
(ppm): 194.16, 160.36, 159.56, 149.81, 141.68, 135.80, 130.70, 125.30, 114.23, 108.37, 





(Z)-3-(3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)acrylaldehyde (3.4h).  
General procedure for nitrile reduction was used starting from 3.4c (80%).  1H-
NMR (300 MHz, CDCl3) δ (ppm): 10.13 (1H, s), 7.73 (1H, s), 7.37 (2H, d, J = 8.77), 
6.94 (2H, d, J = 8.77), 6.49 (3H), 4.54 (2H, m, J = 6.04), 3.84 (3H, s), 1.35 (12H, d, J = 
6.04).  13C NMR (75 MHz, CDCl3) δ (ppm): 192.58, 159.69, 158.88, 145.96, 140.65, 
135.82, 129.89, 128.43, 113.72, 109.81, 104.68, 70.07, 55.22, 21.94. 
 
General Procedure for Aldehyde Reduction (3.4i-3.4l).  
Sodium borohydride (1.2 equivalents) was added portion-wise to a stirred solution 
of the appropriate aldehyde (1.0 equivalent) in methanol (0.2 M) at 0 °C.  The reaction 
mixture was concentrated under reduced pressure after 30 min.  The residue was 
dissolved in CH2Cl2 and extracted with H2O, and the aqueous layer was washed with 
CH2Cl2 (3x).  The combined organic layers were washed with H2O (3x) and brine, dried 
over MgSO4, filtered and concentrated.  Purification by flash chromatography afforded 






(Z)-3-(3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)prop-2-en-1-ol (3.4i).   
General procedure for aldehyde reduction as used from 3.4g (13%).  1H-NMR 
(300 MHz, CDCl3) δ (ppm): 7.53 (2H, d, J = 8.82), 6.94 (2H, d, J = 8.82), 6.85 (1H, s), 
6.57 (2H, d, J = 2.16), 6.42 (1H, t, J = 2.16), 4.70 (2H, s), 3.84 (3H, s), 3.82 (6H, s).  13C 
NMR (100 MHz, CDCl3) δ (ppm): 160.63, 159.32, 139.94, 139.00, 132.70, 129.62, 
127.68, 114.01, 106.80, 99.44, 60.39, 55.29. 
 
 
(Z)-3-(3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)prop-2-en-1-ol (3.4j).   
General procedure for aldehyde reduction was used from 3.4h (27%).  1H-NMR 
(400 MHz, CDCl3) δ (ppm): 7.52 (2H, d, J = 8.71), 6.93 (2H, d, J = 8.71), 6.82 (1H, s), 
6.53 (2H, d, J = 2.16), 6.39 (1H, t, J = 2.16), 4.70 (2H, s), 4.54 (2H, m, J = 6.07), 3.84 
(3H, s), 1.34 (12H, d, J = 6.07).  13C NMR (100 MHz, CDCl3) δ (ppm): 159.25, 158.92, 






(E)-3-(3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)prop-2-en-1-ol (3.4k).   
General procedure for aldehyde reduction was used from 3.4g (35%).  1H-NMR 
(300 MHz, CDCl3) δ (ppm): 7.17 (2H, d, J = 8.77), 6.88 (2H, d, J = 8.77), 6.59 (1H, s), 
6.24 (1H, t, J = 2.23), 6.20 (2H, d, J = 2.23), 4.43 (2H, s), 3.80 (3H, s), 3.56 (6H, s).  13C 
NMR (75 MHz, CDCl3) δ (ppm): 160.05, 158.97, 141.52, 138.37, 130.47, 129.86, 
126.01, 114.09, 106.98, 99.50, 68.36, 55.17, 54.88. 
 
 
(E)-3-(3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)prop-2-en-1-ol (3.4l).   
General procedure for aldehyde reduction was used from 3.4h (44%).  1H-NMR 
(300 MHz, CDCl3) δ (ppm): 7.17 (2H, d, J = 8.63), 6.88 (2H, d, J = 8.63), 6.56 (1H, s), 
6.21 (1H, t, J = 2.02), 6.16 (2H, d, J = 2.02), 4.41 (2H, s), 4.19 (2H, m, J = 6.05), 1.17 





(E)-methyl 3-(3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)acrylate (3.4m).   
To a stirred solution of 3.4h (64 mg, 0.18 mmol) in methanol (1.8 mL) was added 
potassium cyanide (59 mg, 0.91 mmol) and manganese dioxide (317 mg, 3.65 mmol).  
After six days, the reaction mixture was diluted with dichloromethane and filtered 
through a celite pad.  The combined organic layers were washed with brine, dried over 
magnesium sulfate, filtered and concentrated.  Flash chromatography using 10% ethyl 
acetate 90% hexanes afforded the pure product in 17% yield.  1H-NMR (300 MHz, 
CDCl3) δ (ppm): 7.72 (1H, s), 7.16 (2H, d, J = 8.70), 6.92 (2H, d, J = 8.70), 6.29 (1H, t, J 
= 2.22), 6.20 (2H, d, J = 2.22), 4.16 (2H, m, J = 6.06), 3.81 (3H, s), 3.79 (3H, s), 1.17 
(12H, d, J = 6.06). 
 
 
(Z)-methyl 3-(3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)acrylate (3.4n).   
See procedure for 3.4o (34%).  1H-NMR (400 MHz, CDCl3) δ (ppm): 7.37 (2H, d, 
8.86), 6.91 (2H, d, J = 8.86), 6.85 (1H, s), 6.49 (2H, d, J = 2.11), 6.38 (1H, t, J = 2.11), 
4.50 (2H, m, J = 6.07), 3.83 (3H, s), 3.80 (3H, s), 1.33 (12H, d, J = 6.07).  13C NMR (100 
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MHz, CDCl3) δ (ppm):  170.24, 159.71, 159.02, 137.48, 134.37, 129.44, 129.23, 127.52, 
114.06, 107.71, 104.14, 69.92, 55.26, 52.17, 22.03, 21.90. 
 
 
(Z)-methyl 3-(2-chloro-3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)acrylate (3.4o).   
Sodium chlorite (66 mg, 0.73 mmol) in water (0.73 mL) was added drop-wise to a 
mixture of 3.4h (185 mg, 0.52 mmol) in acetonitrile (0.54 mL), monosodium phosphate 
(108 mg, 0.78 mmol) in water (0.25 mL) and 30% hydrogen peroxide (0.07 mL) at 0 °C.  
The reaction was then allowed to stir for 48 hours at room temperature before addition of 
a saturated solution of sodium thiosulfate.  The aqueous phase was then extracted with 
ethyl acetate (3 x 5 mL).  The combined organic layers were washed with brine, dried 
over magnesium sulfate, filtered and concentrated to afford an inseparable  mixture of 
(Z)-3-(3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)acrylic acid and (Z)-3-(2-chloro-
3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)acrylic acid in 81-88% yield. 
 The above mixture of acids was dissolved in methanol (2.33 mL) and a catalytic 
amount of concentrated sulfuric acid was added.  The reaction mixture was then refluxed 
for 48 hours, cooled to room temperature and concentrated.  The residue was taken up in 
ethyl acetate and water, and the aqueous layer was extracted with ethyl acetate (3 x 8 
mL).  The combined organic layers were washed with brine, dried over magnesium 
sulfate, filtered and concentrated to yield a mixture of 3.4o and 3.4n, which were 
separated by flash chromatography using 49% petroleum ether, 49% toluene, 1% t-
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butanol to yield 3.4o in 34% yield and 3.4n in 14% yield.  1H-NMR (400 MHz, CDCl3) δ 
(ppm): 7.42 (2H, d, J = 8.84), 7.15 (1H, s), 6.92 (2H, d, J = 8.84), 6.55 (1H, d, J = 2.63), 
6.47 (1H, d, J = 2.63), 4.51 (1H, m, J = 6.03), 4.46 (1H, m, J = 6.05), 3.83 (3H, s), 3.71 
(3H, s), 1.39 (6H, d, J = 6.05), 1.33 (6H, d, J = 6.03).  13C NMR (100 MHz, CDCl3) δ 
(ppm): 169.70, 159.88, 156.63, 154.38, 136.10, 135.85, 128.97, 127.97, 127.73, 115.50, 
114.03, 106.95, 104.71, 71.99, 70.39, 55.27, 52.04, 21.97.  ESIMS m/z 441 (M + Na).  IR 
vmax 1726 (CO) cm-1.    
 
 
(Z)-methyl 3-(2-chloro-3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)acrylate (3.4p).   
A 1.0 M solution of boron tribromide in dichloromethane ((0.60 mL, 0.60 mmol) 
was added slowly to a solution of 3.4o (50 mg, 0.12 mmol) in dry dicholormethane (0.60 
mL) at -78 °C.  The reaction was gradually allowed to warm to room temperature.  After 
six hours the reaction mixture was cooled to -78 °C and quenched with saturated sodium 
bicarbonate.  The aqueous layer was extracted with ethyl acetate (3 x 5 mL) and the 
combined organic layers were washed with brine, dried over magnesium sulfate, filtered 
and concentrated.  The pure product was obtained in 10% yield after flash 
chromatography using 50% ethyl acetate 50% hexanes.  1H-NMR (400 MHz, CD3OD) δ 
(ppm): 7.80 (1H, s), 6.94 (2H, d, J = 8.67), 6.69 (2H, d, J = 8.67), 6.26 (1H, d, J = 2.70), 
5.84 (1H, d, J = 2.70).  13C NMR (100 MHz, CD3OD) δ (ppm):   170.02, 158.35, 157.17, 




(Z)-3-(3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)acrylamide (3.4q).  
A mixture of 3.4b (45 mg, 0.15 mmol), acetaldoxime (0.02 mL, 0.30 mmol), 
palladium acetate (3 mg, 0.02 mmol), and triphenylphosphine (8 mg, 0.03 mmol) in 
aqueous ethanol (0.5 mL, 1:4 water:ethanol) was heated to reflux for three hours under 
nitrogen atmosphere.  The reaction mixture was diluted with ethanol, filtered through a 
celite pad, washed with dichloromethane, and the combined organic layers were 
concentrated.  The pure product was obtained in 92% yield after purification by flash 
chromatography using 40% ethyl acetate 60% hexanes.  1H-NMR (300 MHz, CDCl3) δ 
(ppm): 7.34 (2H, d, J = 8.91), 6..79 (2H, d, J = 8.91), 6.70 (1H, s), 6.57 (2H, d, J = 2.06), 
6.28 (1H, t, J = 2.06), 3.86 (2H, s), 3.71 (3H, s), 3.66 (6H, s).  13C NMR (100 MHz, 
CDCl3) δ (ppm): 173.13, 160.51, 159.62, 137.32, 137.24, 129.21, 127.30, 126.65, 113.92, 
106.17, 100.24, 55.05.    
 
 
(Z)-3-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)acrylamide (3.4r).  
A 1.0 M solution of boron tribromide in dichloromethane ((0.94 mL, 0.94 mmol) 
was added slowly to a solution of 3.4q (50 mg, 0.13 mmol) in dry dicholormethane (0.60 
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mL) at -78 °C.  The reaction was gradually allowed to warm to room temperature.  After 
four hours the reaction mixture was cooled to -78 °C and quenched with saturated sodium 
bicarbonate.  The aqueous layer was extracted with ethyl acetate (3 x 5 mL) and the 
combined organic layers were washed with brine, dried over magnesium sulfate, filtered 
and concentrated.  The pure product was obtained in quantitative yield after flash 
chromatography using 60% ethyl acetate 40% hexanes.  1H-NMR (400 MHz, CD3OD) δ 
(ppm): 7.38(2H, d, J = 8.66), 6.79 (2H, d, J = 8.66), 6.70 (1H, s), 6.52 (2H, s), 6.19 (1H, 
s).  13C NMR (100 MHz, CD3OD) δ (ppm): 175.86, 159.43, 158.82, 139.17, 138.47, 
130.03, 128.45, 126.91, 116.43, 108.12, 103.31.    
 
 
3-(3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)propan-1-amine (3.4s).   
To a mixture of 3.4b (20 mg, 0.07 mmol) cobalt chloride hexahydrate (32 mg, 
0.14 mmol)  in anhydrous methanol (0.5 mL) was added sodium borohydride (26 mg, 
0.68 mmol) portionwise.  After stirring overnight a second portion of sodium borohydride 
was added.  After one hour, an aqueous solution of 3N HCl was added to the reaction 
mixture until it because clear in appearance.  The aqueous layer was then extracted with 
ether (3 x) to remove any remaining nitrile.  The aqueous layer was then made alkaline 
using ammonium hydroxide (pH = 10) and extracted with ethyl acetate (3 x 5 mL).  The 
combined organic layers were washed with brine, dried over magnesium sulfate, filtered 
and concentrated.  The pure product was obtained in 64% yield after purification by flash 
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chromatography using 5% methanol 95% dichloromethane.  1H-NMR (400 MHz, CDCl3) 
δ (ppm): 7.09 (2H, d, J = 8.57), 6.84 (2H, d, J = 8.57), 6.26 (1H, t, J = 2.17), 6.21 (2H, d, 
J = 2.17), 3.78 (3H, s), 3.71 (6H, s), 2.96-2.81 (5H, m).  13C NMR (100 MHz, CDCl3) δ 
(ppm): 160.42, 158.22, 142.46, 134.57, 128.82, 113.89, 107.01, 97.93, 55.11, 49.88, 
46.82, 41.15.  
 
 
(Z)-methyl (2-(3,5-dimethoxyphenyl)-1-(4-methoxyphenyl)vinyl)carbamate (3.4t).   
Potassium hydroxide (14 mg, 0.26 mmol) was added to 3.4q (32 mg, 0.10 mmol) 
in anhydrous methanol (1.25 mL) at room temperature under nitrogen atmosphere.  Once 
a clear reaction mixture was obtained, (diacetoxyiodo)benzene (33 mg, 0.10 mmol) was 
added in one portion.  The reaction mixture was concentrated after three hours and the 
crude residue as taken up in water and dichloromethane.  The aqueous phase was 
extracted with dichloromethane (3 x 5 mL) and the combined organic layers were washed 
with brine, dried over magnesium sulfate, filtered and concentrated.  The pure product 
was obtained in 86% yield after purification by flash chromatography using 30% ethyl 
acetate 70% hexanes.  1H-NMR (400 MHz, CDCl3) δ (ppm): 7.44 (2H, d, J = 8.80), 6.91 
(2H, d, J = 8.80), 6.58 (2H, d, J = 2.20), 6.37 (1H, t, J = 2.20), 6.20 (1H, s), 3.83 (3H, s), 
3.78 (6H, s), 3.67 (3H, s).  13C NMR (100 MHz, CDCl3) δ (ppm): 160.84, 159.85, 154.67, 




2-(3,5-dimethoxyphenyl)-1-(4-methoxyphenyl)ethanimine (3.4u).   
A 1.0M solution of boron tribromide in dichloromethane (0.66 mL, 0.66 mmol) 
was added slowly to a solution of 3.4t (30 mg, 0.09 mmol) in dichloromethane (0.5 mL) 
at -78 °C under nitrogen atmosphere.  The reaction was allowed to stir at room 
temperature for four hours before cooling to -78 °C and quenching with an aqueous 
solution of saturated sodium bicarbonate (2 mL).  The reaction mixture was warmed to 
room temperature and the aqueous layer was extracted with ethyl acetate (3 x 2 mL).  The 
combined organic layers were washed with saturated sodium bicarbonate (3 x 5 mL), 
water (1 x 5 mL), and brine (1 x 5 mL) before being dried over magnesium sulfate, 
filtered, and concentrated.  The pure product was obtained in 77% yield after purification 
by flash chromatography using 30% ethyl acetate 70% hexanes.  1H-NMR (400 MHz, 
CDCl3) δ (ppm): 7.99 (2H, d, J = 8.97), 6.92 (2H, d, J = 8.97), 6.43 (2H, d, J = 2.26), 6.34 
(1H, t, J = 2.26), 4.15 (2H, s), 3.85 (3H, s), 3.76 (6H, s).  13C NMR (100 MHz, CDCl3) δ 
(ppm): 195.94, 163.45, 160.83, 137.07, 130.90, 129.50, 113.70, 107.32, 98.76, 55.37, 








To a solution of 4.16 (1.0 eq.) in mesitylene (0.5 M) under N2 atmosphere at 
ambient temperature was added triethylphosphite (6.0 eq.) slowly.  The reaction mixture 
was then refluxed for 5 hours.  After cooling to ambient temperature, the reaction mixture 
was diluted with toluene and concentrated as much as possible.  Under no circumstance 
was the phenothiazine product dissolved in a chlorinated solvent.  The crude residue was 
purified directly by flash chromatography using 20% ethyl acetate 80% hexanes and the 
pure product was isolated as an orangish brown flaky solid in 87% yield.  1H-NMR (800 
MHz, d6-DMSO) δ (ppm): 8.56 (1H (NH), s), 7.32 (1H, dd, J = 1.82, 7.98), 7.17 (1H, J = 
1.82), 7.03 (1H, d, J = 7.98), 6.62 (2H, m), 6.58 (1H, d, J = 2.40), 3.67 (3H, s), 2.48 (3H, 
s).  13C NMR (75 MHz, d6-DMSO:CD3OD 3:1) δ (ppm): 196.69, 154.83, 142.56, 136.02, 
134.51, 125.81, 122.66, 121.41, 116.41, 114.93, 113.08, 112.26, 111.44, 54.94, 25.83.  
ESIMS(+) m/z 272 (M + H), 294 (M + Na).  IR vmax 3342.68 (NH), 1666.04 (CO) cm-1. 
     
 
1-(10H-phenothiazin-2-yl)ethanone (4.2). 
 The procedure for compound 4.1 was followed starting from the sulfide 4.26.  The 
desired phenothiazine product was isolated in 42% yield after purification.  1H-NMR 
(400 MHz, CD3OD) δ (ppm): 7.35 (1H, dd, J = 1.79, 8.01), 7.16 (1H, d, J = 1.79), 6.94 
144 
 





 The protected phenothiazine 4.39 (1.0 eq.) in anhydrous THF (0.2 M) was added 
a 1.0 M solution of TBAF in THF dropwise (4.0 eq.), with vigorous stirring.  The 
reaction mixture turned light brown and was allowed to stir at ambient temperature for 3 
hours before it was diluted with water and extracted with ethyl acetate (3X).  The 
combined organic layers were washed with brine, dried over magnesium sulfate, and 
concentrated.  The crude product was used without further purification.  1H-NMR (800 
MHz, d6-DMSO) δ (ppm): 8.52 (1H (NH), s), 6.92 (1H, dd, J = 1.42, 8.03), 6.86 (1H, s), 
6.84 (1H, d, J = 7.91), 6.74 (1H, d, J = 1.42), 6.70 (1H, dd, J = 1.48, 7.91), 6.64 (1H, d, J 




 A solution of commercially available 4-bromoacetophenone (1.0 eq) in sulfuric 
acid (4 ml/mmol of 4-bromoacetophenone) was cooled to 0 °C and potassium nitrate (1.1 
eq.) was added portionwise at that temperature.  After 6 hrs, the reaction was SLOWLY 
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poured onto a mixture of ice and water and the pure product crashed out as a white solid.  
After vacuum filtration the desired compound 4.4 was isolated in 92% yield.  1H-NMR 
(300 MHz, CDCl3) δ (ppm): 8.33 (1H, d, J = 2.00), 7.97 (1H, dd, J = 2.00, 8.34), 7.85 
(1H, d, J = 8.34), 2.63 (3H, s).  13C-NMR (75 MHz, CDCl3) δ (ppm): 194.69, 149.84, 




 To a solution of 4.4 (1.0 eq.) in DMF (0.4 M) was added sodium sulfide 
nonahydrate (2.0 eq.).  The reaction was allowed to stir overnight before diluting with 
water and acidifying with 1 N HCl to pH 1-2.  At this point, the sulfide product 
precipitated and was collected by vacuum filtration as an organish yellow solid in 75% 
yield.  The sulfide was then dissolved in anhydrous methanol (0.2 M) and stannous 
chloride dihydrate (5.0 eq.) was added.  The reaction mixture was refluxed until starting 
material disappeared from TLC.  After cooling to room temperature, the reaction mixture 
was rotovapped onto a small amount of silica gel and used directly on the flash 
chromatography column for purification with 50% ethyl acetate 50% hexanes, giving the 
product in 53% yield.  1H-NMR (300 MHz, CDCl3) δ (ppm): 7.25 (2H, m), 7.12 (1H, d, J 






 To a stirred suspension of 4.5 (1.0 eq.) and sodium hydroxide (1.0 eq.) in absolute 
ethanol (0.5 M) was added an alcoholic solution of 4.4 (1.0 eq.).  The reaction mixture 
was refluxed for four hours before it was concentrated.  The crude residue was diluted 
with water and extracted with ethyl acetate (3X).  The combined organic layers were 
washed with brine, dried over magnesium sulfate, and concentrated.  The crude resiude 
was purified by flash chromatography using a gradient column from 20%-40% ethyl 
acetate 80%-60% hexanes to give the product in 43% yield.  1H-NMR (400 MHz, CDCl3) 
δ (ppm): 8.82 (1H, d, J = 1.78), 7.72 (1H, dd, J = 1.78, 8.53), 7.55 (1H, d, J = 7.95), 7.42 
(1H, d, J = 1.45), 7.36 (1H, dd, J = 1.68, 7.95), 6.90 (1H, d, J = 8.53), 4.44 (2H, s), 2.62 
(3H, s), 2.61 (3H, s).  13C-NMR (100 MHz, CDCl3) δ (ppm): 197.67, 194.91, 149.29, 
144.97, 141.86, 140.60, 137.84, 134.26, 132.28, 127.57, 126.13, 118.70, 116.41, 114.66, 




 Commercially available 2-aminobenzenethiol (1.0 eq.) was dissolved in absolute 
ethanol (0.5 M) containing sodium acetate (1.0 eq.) in a round bottom flash that had been 
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flame dried under N2 atmosphere. A solution of 4.4 (1.0 eq.) in absolute ethanol (1 M) 
was then added and the reaction mixture was refluxed under N2 atmosphere for 6 hours.  
After cooling to ambient temperature, the reaction mixture was diluted with 
dichloromethane and concentrated to an orange residue.  The residue was taken up in 
water and extracted with ethyl acetate (3X).  The combined organic extracts were washed 
with brine, dried over magnesium sulfate, and concentrated.  The product was purified by 
flash chromatography using 20% ethyl acetate and 80% hexanes, giving the product in 
66% yield.  1H-NMR (300 MHz, CDCl3) δ (ppm): 8.44 (1H, d, J = 1.90), 7.89 (1H, dd, J 
= 1.90, 8.53), 7.40 (1H, dd, J = 1.46, 7.67), 7.34 (1H, m), 6.93 (1H, d, J = 8.53), 6.85 
(1H, dd, J = 0.91, 8.21), 6.81 (1H, dd, J = 1.18, 7.53), 2.59 (3H, s).  13C-NMR (75 MHz, 
CDCl3) δ (ppm): 195.13, 149.26, 144.75, 143.29, 137.46, 133.81, 132.68, 132.15, 127.61, 





 Compound 4.6 (1.0 eq.) was refluxed in 88% formic acid for five hours before it 
was cooled to room temperature and poured onto ice.  The yellow precipitate was 
collected by vacuum filtration and dissolved in acetone (0.6 M).  The solution was heated 
to reflux and an alcoholic solution of potassium hydroxide (0.4 eq.) was added.  The 
reaction was heated for 30 minutes and another aliquot of potassium hydroxide was 
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added.  The reaction mixture was then refluxed for 12 hours before it was cooled to room 
temperature and poured onto ice.  After the ice melted, the aqueous layer was extracted 
with ethyl acetate (3X).  The combined organic extracts were washed with brine, dried 
over magnesium sulfate, and concentrated.  The reaction mixture yielded a variety of 
products, two of which were purified by flash chromatography using a gradient of 100% 
dichloromethane ramped to 3% methanol 97% dichloromethane.  1H-NMR (300 MHz, 
CDCl3) δ (ppm): 9.80 (1H, s), 8.78 (1H, d, J = 2.07), 7.93 (1H, dd, J = 1.89, 9.02), 7.65 
(1H, dd, J = 1.27, 7.83), 7.32 (1H, m), 7.22 (1H, m), 6.92 (1H, d, J = 9.02), 2.59 (3H, s).  
ESIMS(+) m/z 242 (M + H), 264 (M + Na), 280 (M + K).  IR vmax 3480.25 (NH), 3375.31 




 This product was isolated from the reaction mixture described for compound 4.8 
in 5% yield.  1H-NMR (300 MHz, CDCl3) δ (ppm): 9.82 (1H (NH), s), 8.75 (1H, d, J = 
1.82), 8.69 (1H, d, J = 2.03), 7.99 (1H, dd, J = 2.00, 9.01), 7.87 (1H, dd, J = 1.91, 8.50), 
7.81 (1H, d, J = 7.48), 7.64 (2H, m), 7.41 (1H, m), 7.29 (1H, d, J = 9.01), 6.92 (1H, d, J = 
8.50), 2.59 (3H, s), 2.56 (3H, s).  13C-NMR (75 MHz, CDCl3) δ (ppm): 194.79, 194.54, 
145.00, 143.80, 142.31, 140.86, 138.21, 134.55, 134.38, 132.89, 132.25, 128.13, 127.81, 
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127.32, 126.17, 124.43, 115.51, 26.42, 26.02.  ESIMS(+) m/z 452 (M + H), 474 (M + 
Na), 490 (M + K).  IR vmax 3288.83 (NH) cm-1. 




 Compound 4.9 (1.0 eq.) was dissolved in anhydrous methanol (0.2 M) and sodium 
borohydride (4.0 eq.) was added portionwise.  The reaction mixture was allowed to stir 
for one hour before it was concentrated.  The crude residue was taken up in dilute 
hydrochloric acid and extracted with dichloromethane (3X).  The combined organic 
layers were washed with brine, dried over magnesium sulfate, and concentrated.  The 
pure product was obtained in quantitative yield after purification by flash 
chromatography using 40% ethyl acetate 60% hexanes.  1H-NMR (300 MHz, CDCl3) δ 
(ppm): 9.28 (1H (NH), s), 8.09 (1H, t, J = 2.04), 8.02 (1H, m), 7.79 (1H, m), 7.52 (2H, 
m), 7.38 (1H, m), 7.30 (1H, dd, J = 2.06, 6.71), 7.16 (1H, d, J = 8.80), 6.86 (1H, d, J = 
8.32), 4.83 (2H, m), 1.47 (3H, d, J = 6.45), 1.43 (3H, d, J = 6.47).  13C-NMR (75 MHz, 
CDCl3) δ (ppm): 145.89, 144.59, 141.40, 139.96, 137.60, 136.24, 134.57, 133.01, 132.89, 
131.23, 130.65, 128.41, 125.86, 125.37, 124.13, 123.20, 122.66, 116.38, 68.96, 68.55, 





 Compound 4.4 (1.0 eq.) was dissolved in anhydrous methanol (0.2 M) and 
stannous chloride dihydrate (5.0 eq.) was added.  The reaction mixture was refluxed 
under N2 atmosphere for two hours before it was cooled to room temperature and poured 
onto ice.  The pH was adjusted to 7-8 using sodium bicarbonate and the aqueous layer 
was extracted with ethyl acetate (3X).  The combined organic layers were washed with 
brine, dried over magnesium sulfate, and concentrated.  The crude amine was then 
dissolved in 6 N HCl (1 M) and sodium nitrite (1.1 eq.) was then added slowly at 0 °C 
and the reaction was stirred at that temperature for 15 minutes.  A solution of potassium 
iodide (3.5 eq.) in water (1 M) was then slowly added to the reaction mixture and it was 
stirred overnight.  The reaction mixture was extracted with ether (3X) and the combined 
organic layers were washed with brine, 2 N NaOH, saturated Na2S2O3, water, and brine.  
The organic layer was dried over magnesium sulfate and concentrated to give the pure 
product in 93% yield.  1H-NMR (300 MHz, CDCl3) δ (ppm): 8.34 (1H, d, J = 1.98), 7.71 







NH2 H2N  
1-(3,4-bis((2-aminophenyl)thio)phenyl)ethanone (4.12). 
 Copper iodide (0.3 eq.) and potassium carbonate (5.0 eq.) were weighed into a 
seal tube flask that was subsequently flushed with argon.  To the flask were added 2-
aminothiophenol (1.1 eq.), 4.11 (1.0 eq.), and dimethylsulfoxide (0.2 M).  The reaction 
vessel was then heated to 120 °C for 48 hours.  After cooled to room temperature, the 
reaction mixture was diluted with ethyl acetate and washed with water.  The aqueous 
layer was extracted with ethyl acetate (3X) and the combined organic layers were washed 
with brine, dried over magnesium sulfate, and concentrated.  Flash chromatography using 
20% ethyl acetate and 80% hexanes of the crude residue resulted in 4.12 in 89% yield.  
1H-NMR (300 MHz, CDCl3) δ (ppm): 7.47 (4H, m), 7.26 (2H, m), 6.77 (5H, m), 4.30 
(4H (NH), s), 2.34 (3H, s).  13C-NMR (75 MHz, CDCl3) δ (ppm): 196.80, 149.07, 148.69, 
142.46, 137.44, 136.66, 134.52, 133.99, 131.81, 131.29, 127.87, 126.06, 125.51, 118.88, 
115.53, 113.65, 112.17, 26.25.  ESIMS(+) m/z 367 (M + H), 389 (M + Na).  IR vmax 
3464.58 (NH), 3427.24 (NH), 1673.82 (CO) cm-1. 







 A three-neck round bottom flask was flame dried under argon gas, evacuated, and 
backfilled with argon.  Copper iodide (0.3 eq.) and potassium carbonate (5.0 eq.) and 
dimethylsulfoxide (0.2 M) were then added.  The reaction vessel was evacuated and 
backfilled with argon.  The commercially available starting materials 2-aminothiophenol 
(1.1 eq.) and 2-chlorobromobenzne (1.0 eq) were then added.  The reaction vessel was 
then heated to 120 °C for 48 hours.  After cooled to room temperature, the reaction 
mixture was diluted with ethyl acetate and washed with water.  The aqueous layer was 
extracted with ethyl acetate (3X) and the combined organic layers were washed with 
brine, dried over magnesium sulfate, and concentrated.  Flash chromatography using 20% 
ethyl acetate 80% hexanes resulted in the product in 22% yield.  1H-NMR (300 MHz, 
CDCl3) δ (ppm): 7.47 (1H, dd, J = 1.53, 7.65), 7.32 (2H, m), 7.06 (2H, m), 6.81 (2H, m), 
6.65 (1H, m).  13C-NMR (75 MHz, CDCl3) δ (ppm): 149.15, 137.84, 135.90, 131.67, 
130.85, 129.41, 127.07, 126.07, 125.91, 118.86, 115.33, 112.33.  IR vmax 3460.47 (NH), 
3364.73 (NH) cm-1. 









 Followed procedure for 4.13 with 2-aminothiophenol and 1,2-dibromobenzene.  
The product was isolated in 57% yield after flash chromatography with 10% ethyl acetate 
90% hexanes.  1H-NMR (300 MHz, CDCl3) δ (ppm): 7.48 (2H, dd, J = 1.55, 8.00), 7.26 
(2H, ddd, J = 1.55, 9.34), 7.00 (2H, m), 6.88 (2H, m), 6.79 (4H, m), 4.27 (4H (NH), s).  
13C-NMR (75 MHz, CDCl3) δ (ppm): 148.71, 136.94, 134.87, 130.98, 127.52, 126.35, 




A three-neck round bottom flask was flame dried under argon gas, evacuated, and 
backfilled with argon.  Copper iodide (0.3 eq.) and potassium carbonate (5.0 eq.) and 2-
methoxyethanol (0.2 M) were then added.  The reaction vessel was evacuated and 
backfilled with argon.  The commercially available starting materials 2-aminothiophenol 
(1.1 eq.) and 1,2-dibromobenzne (1.0 eq) were then added.  The reaction vessel was then 
heated to 110 °C for 48 hours.  After cooled to room temperature, the reaction mixture 
was diluted with ethyl acetate and washed with water.  The aqueous layer was extracted 
with ethyl acetate (3X) and the combined organic layers were washed with brine, dried 
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over magnesium sulfate, and concentrated.  Flash chromatography using 20% ethyl 
acetate 80% hexanes resulted in the product in 50% yield.  1H-NMR (300 MHz, CDCl3) δ 
(ppm): 7.54 (1H, dd, J = 1.35, 7.87), 7.48 (1H, dd, J = 1.52, 7.61), 7.31 (1H, m), 7.11 
(1H, td, J = 1.35, 7.65), 6.98 (1H, td, J = 1.60, 7.61), 6.82 (2H, m), 6.64 (1H, dd, J = 1.60, 
7.93), 4.26 (2H (NH), s).  13C-NMR (75 MHz, CDCl3) δ (ppm): 149.12, 137.82, 132.71, 
131.75, 127.71, 126.15, 120.58, 118.91, 115.40, 112.91.  IR vmax 3320.58 (NH) cm-1.  







 A solution of 4-methoxythiophenol (1.05 eq.), 4.4 (1.0 eq.), and sodium 
hydroxide (1.0 eq.) was heated in DMF (0.4 M) at 60 °C for 12 hours.  The reaction was 
cooled to room temperature, and poured into saturated aqueous lithium chloride.  The 
aqueous layer was then extracted with ethyl acetate (3X).  The combined organic layers 
were washed with saturated aqueous lithium chloride (5X), dried over magnesium 
sulfate, and concentrated.  The crude residue was purified by flash chromatography using 
15% ethyl acetate 85% hexanes, to give the product in quantitative yield.  1H-NMR (300 
MHz, CDCl3) δ (ppm): 8.70 (1H, d, J = 1.95), 7.83 (1H, dd, J = 1.95, 8.59), 7.44 (2H, d, J 
= 8.79), 6.99 (2H, d, J = 8.79), 6.97 (1H, d, J = 8.59), 3.85 (3H, s), 2.57 (3H, s).  13C-
NMR (75 MHz, CDCl3) δ (ppm): 195.04, 161.40, 146.58, 143.87, 137.43, 133.34, 









 A solution of 4.16 (1.0 eq.) and stannous chloride dihydrate (5.0 eq.) in anhydrous 
methanol was refluxed for 6 hours.  It was cooled to room temperature and poured onto 
ice.  The pH was adjusted to 7-8 using sodium bicarbonate and the aqueous layer was 
extracted with ethyl acetate (3X).  The combined organic layers were washed with brine, 
dried over magnesium sulfate, and concentrated.  The desired amine was purified by flash 
chromatography using 40% ethyl acetate 60% hexanes and obtained in 64% yield.  1H-
NMR (300 MHz, CDCl3) δ (ppm): 7.31 (1H, m), 7.24 (4H, m), 6.85 (2H, d, J = 6.85), 
3.79 (3H, s), 2.54 (3H, s).  13C-NMR (75 MHz, CDCl3) δ (ppm): 197.77, 159.17, 146.15, 
137.41, 133.29, 132.10, 124.95, 124.00, 118.63, 114.97, 114.24, 55.27, 26.57.  IR vmax 







tert-butyl 2-acetyl-7-methoxy-10H-phenothiazine-10-carboxylate (4.18). 
 A solution of 4.1 (1.0 eq.), di-tert-butyl dicarbonate (6.0 eq.), and DMAP (1.0 eq.) 
was refluxed in acetonitrile (0.2 M) for 8 hours.  After cooling to room temperature, the 
reaction mixture was poured into water and extracted with ethyl acetate (3X).  The 
combined organic layers were washed with brine, dried over magnesium sulfate, and 
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concentrated.  The pure product was obtained in 95% yield after flash chromatography 
using 5% ethyl acetate 95% hexanes.  1H-NMR (300 MHz, CD3OD) δ (ppm): 8.08 (1H, 
d, J = 1.72), 7.80 (1H, dd, J =1.82, 8.20), 7.46 (1H, d, J = 8.20), 7.41 (1H, d, J = 8.77), 
6.90 (2H, dt, J = 2.72, 8.77), 3.79 (3H, s), 2.60 (3H, s), 1.47 (9H, s).  13C-NMR (100 
MHz, CDCl3) δ (ppm): 196.66, 157.59, 152.32, 138.96, 138.07, 135.54, 131.78, 130.81, 
127.82, 127.14, 126.98, 125.48, 113.23, 111.59, 82.24, 55.52, 28.05, 26.52.  IR vmax 
3425.46 (NH), 3351.24 (NH), 1673.32 (CO) cm-1.         








 To a solution of 4.18 (1.0 eq.) and 4-chlorobenzaldehyde (1.0 eq.) in absolute 
ethanol (0.4 M) was added a solution of potassium hydroxide (1.0 eq.) in ethanol (0.4 m).  
The reaction was allowed to stir for 24 hours before water was added.  The aqueous layer 
was extracted with ethyl acetate (3X).  The combined organic layers were washed with 
brine, dried over magnesium sulfate, and concentrated.  The crude residue was used 
without further purification.  1H-NMR (300 MHz, CDCl3) δ (ppm): 8.15 (1H, s), 7.72 







 To a solution of 4.19 (1.0 eq.) in dichloromethane (10 ml/mmol) was added a 4N 
solution of hydrochloric acid in dioxane (20 eq.).  The reaction was stirred at room 
temperature for 12 hours.  The reaction was diluted with ethyl acetate and washed with 1 
N sodium hydroxide (3X), water (2X), brine (2X), dried over magnesium sulfate, and 
concentrated.  The crude residue was purified by flash chromatography using 20% ethyl 
acetate 80% hexanes to afford the pure product in 89% yield.  1H-NMR (800 MHz, d6-
DMSO) δ (ppm): 8.60 (1H (NH), s), 7.91 (2H, d, J = 8.49), 7.82 (1H, d, J = 15.63), 7.70 
(1H, d, J = 15.63), 7.61 (1H, dd, J = 1.81, 8.04), 7.54 (2H, d, J = 8.49), 7.28 (1H, d, J = 
1.81), 7.10 (1H, d, J = 8.04), 6.62 (3H, m), 3.67 (3H, s).  13C-NMR (200 MHz, d6-
DMSO) δ (ppm): 188.47, 155.31, 143.30, 142.74, 137.26, 135.54, 134.98, 134.16, 
130.98, 129.46, 126.62, 123.59, 123.13, 122.63, 116.78, 115.75, 114.01, 113.12, 112.15, 
















 To a stirred solution of sulfide 4.16 (1.0 eq.) and 4-chlorobenzaldehyde (1.0 eq.) 
in absolute methanol (1.3 M) was added a solution of a solution of sodium hydroxide (1.3 
eq.) in absolute methanol (1.3 M) dropwise.  The resulting mixture was stirred at room 
temperature for 12 hours, water was added and the aqueous layer was extracted with 
ethyl acetate (3X).  The combined organic layers were washed with brine, dried over 
magnesium sulfate, and concentrated.  The crude product was purified by flash 
chromatography giving the desired sulfide in 26% yield.  1H-NMR (400 MHz, CDCl3) δ 
(ppm): 8.86 (1H, d, J = 1.84), 7.97 (1H, dd, J = 1.84, 8.61), 7.80 (1H, d, J = 15.59), 7.58 
(2H, d, J = 8.49), 7.51 (2H, d, J = 8.73), 7.46 (1H, d, J = 15.59), 7.40 (2H, d, J = 8.49), 
7.04 (2H, d, J = 8.73), 6.96 (1H, d, J = 8.60), 3.89 (3H, s).  13C-NMR (100 MHz, CDCl3) 
δ (ppm): 186.71, 161.48, 146.68, 144.48, 144.04, 137.53, 136.90, 134.29, 132.84, 132.21, 
129.71, 129.28, 128.20, 125.72, 120.70, 120.04, 115.89, 55.42.  IR vmax 1588.61 (CO) 








 To a solution of 4.18 (1.0 eq.) in anhydrous dichloromethane (0.2 M) under N2 
atmosphere at -78 °C was added a solution of 1.0 M boron tribromide in dichloromethane 
(2.5 eq.) dropwise. The reaction mixture was allowed to stir for 6 hours.  The reaction 
mixture was cooled back to -78 °C and quenched with saturated sodium  bicarbonate and 
methanol.  The aqueous layer was extracted with ethyl acetate (3X).  The combined 
organic layers were washed with saturated sodium bicarbonate (4X) and brine (3X).  The 
combined organic layers were then dried over magnesium sulfate and concentrated.  The 
crude residue was purified by flash chromatography using 30% ethyl acetate 70% 
hexanes, giving the pure product in quantitative yield.  1H-NMR (400 MHz, CDCl3) δ 
(ppm): 8.41 (1H, d, J = 1.80), 8.05 (1H, dd, J = 1.80, 8.35), 7.62 (1H, d, J = 9.91), 7.53 
(1H, d, J = 8.37), 6.95 (1H, dd, J = 2.05, 9.91), 6.77 (1H, d, J = 2.05), 2.68 (3H, s).  13C-
NMR (100 MHz, CDCl3) δ (ppm): 182.35, 147.95, 147.27, 139.70, 138.90, 136.50, 
135.50, 134.12, 133.95, 129.47, 128.85, 125.32, 120.91, 26.45.  IR vmax 1675.26 (CO) 










 To a solution of 4.22 (1.0 eq.) in anhydrous acetonitrile (0.2 M) was added di-tert-
butyl dicarbonate (6.0  eq.) and DMAP (1.0 eq.) and the reaction mixture was refluxed 
under N2 atmosphere for 24 hours.  The reaction mixture was allowed to cool to room 
temperature and poured into water.  The aqueous layer was extracted with ethyl acetate 
(3X).  The combined organic layers were washed with brine, dried over magnesium 
sulfate, and concentrated.  The crude residue was purified by flash chromatography using 
10% ethyl acetate 90% hexanes to afford the pure product in 16% yield.  1H-NMR (400 
MHz, CDCl3) δ (ppm): 8.04 (1H, d, J = 1.62), 7.74 (1H, dd, J = 1.62, 8.15), 7.51 (1H, d, J 
= 8.77), 7.39 (1H, d, J = 8.15), 7.19 ( 1H, d, J = 2.59), 7.10 (1H, dd, J = 2.59, 8.77), 2.61 
(3H, s), 1.55 (9H, s), 1.49 (2H, s).  13C-NMR (100 MHz, CDCl3) δ (ppm): 196.60, 
151.97, 151.35, 148.66, 138.54, 137.80, 135.73, 131.92, 127.67, 127.24, 126.97, 125.69, 










 To a solution of 4.23 (1.0 eq.) and 4-dimethylaminobenzaldehyde (1.0 eq.) in 
absolute ethanol (1.3 M) was added a solution of sodium hydroxide (1.3 eq.) in ethanol 
(1.3 M).  The resulting mixture was stirred at room temperature for 24 hours, water was 
added and the aqueous layer was extracted with ethyl acetate (3X).  The combined 
organic layers were washed with brine, dried over magnesium sulfate, and concentrated.  
The crude product was purified by flash chromatography giving the desired 
phenothiazine 4.24 in 27% yield and compound 4.25 in 22% yield.  1H-NMR (800 MHz, 
CDCl3) δ (ppm): 8.15 (1H, d, J = 1.57), 7.85 (1H, d, J = 15.41), 7.82 (1H, dd, J = 1.70, 
8.09), 7.58 (2H, d, J = 8.85), 7.44 (1H, d, J = 8.09), 8.71 (1H, d, J = 8.71), 7.33 (1H, d, J 
= 15.41), 6.82 (1H, d, J = 2.71), 6.76 (1H, dd, J = 2.72, 8.71), 6.73 (2H, d, J = 8.85), 3.09 
(6H, s), 1.53 (9H, s).  13C-NMR (200 MHz, CDCl3) δ (ppm): 189.28, 153.95, 152.73, 
152.19, 146.39, 139.04, 137.64, 137.02, 132.39, 130.98, 130.59, 128.04, 127.18, 125.75, 
122.60, 116.34, 114.50, 113.69, 111.86, 82.45, 40.15, 28.22.  IR vmax 3316.24 (OH), 






tert-butyl 2-acetyl-7-hydroxy-10H-phenothiazine-10-carboxylate (4.25). 
 See procedure for 4.24.  1H-NMR (800 MHz, CDCl3) δ (ppm): 8.10 (1H, d, J = 
1.69), 7.77 (1H, dd, J = 1.81, 8.15), 7.43 (1H, d, J = 8.15), 7.39 (1H, d, J = 8.71), 6.81 




 A solution of thiophenol (1.05 eq.), 4.4 (1.0 eq.), and sodium hydroxide (1.0 eq.) 
was heated in DMF (0.4 M) at 60 °C for 12 hours.  The reaction was cooled to room 
temperature, and poured into saturated aqueous lithium chloride.  The aqueous layer was 
then extracted with ethyl acetate (3X).  The combined organic layers were washed with 
saturated aqueous lithium chloride (5X), dried over magnesium sulfate, and concentrated.  
The crude residue was purified by flash chromatography using 10% ethyl acetate 90% 
hexanes, to give the product in 75% yield.  1H-NMR (400 MHz, CDCl3) δ (ppm): 8.76 
(1H, d, J = 1.85), 7.87 (1H, dd, J = 1.85, 8.59), 7.58 (2H, m), 7.52 (3H, m), 6.91 (1H, d, J 
= 8.59).  13C-NMR (100 MHz, CDCl3) δ (ppm): 195.00, 145.57, 144.25, 135.84, 133.62, 





tert-butyl 2-acetyl-10H-phenothiazine-10-carboxylate (4.27). 
A solution of 4.2 (1.0 eq.), di-tert-butyl dicarbonate (6.0 eq.), and DMAP (1.0 eq.) was 
refluxed in acetonitrile (0.2 M) for 8 hours.  After cooling to room temperature, the 
reaction mixture was poured into water and extracted with ethyl acetate (3X).  The 
combined organic layers were washed with brine, dried over magnesium sulfate, and 
concentrated.  The pure product was obtained in 95% yield after flash chromatography 
using 5% ethyl acetate 95% hexanes.  1H-NMR (400 MHz, CDCl3) δ (ppm): 8.10 (1H, d, 
J = 1.70), 7.73 (1H, dd, J = 1.70, 8.18), 7.54 (1H, d, J = 8.10), 7.39 (1H, d, J = 8.18), 7.31 
(2H, m), 7.16 (1H, td, J = 1.03, 7.60), 2.59 (3H, s), 1.49 (9H, s).  13C-NMR (100 MHz, 
CDCl3) δ (ppm): 196.65, 152.07, 138.61, 138.36, 138.04, 135.57, 130.69, 127.32, 127.24, 









 To a solution of 4.27 (1.0 eq.) and 4-chlorobenzaldehyde (1.0 eq.) in absolute 
methanol (0.4 M) was added a solution of sodium hydroxide (1.0 eq.) in methanol (0.4 
m).  The reaction was allowed to stir for 24 hours before water was added.  The aqueous 
layer was extracted with ethyl acetate (3X).  The combined organic layers were washed 
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with brine, dried over magnesium sulfate, and concentrated.  The crude residue was 
purified by flash chromatography to give the pure product 4.28 in 18% yield.  1H-NMR 
(800 MHz, CDCl3) δ (ppm): 8.20 (1H, s), 8.10 (1H, d, J = 8.10), 7.82 (1H, d, J = 15.67), 
7.62 (2H, d, J = 8.33), 8.08 (1H, d, J = 8.10), 7.50 (1H, d, J = 15.67), 4.49 (1H, d, J = 
7.76), 7.44 (2H, d, J = 8.33), 7.38 (1H, d, J = 7.76), 7.34 (1H, m), 7.22 (1H, m), 1.53 (9H, 
s).  13C-NMR (200 MHz, CDCl3) δ (ppm): 188.86, 152.25, 143.72, 138.81, 138.40, 
138.17, 136.58, 136.53, 133.36, 130.81, 129.67, 129.31, 127.46, 127.36, 127.04, 126.42, 








To a solution of 4.28 (1.0 eq.) in dichloromethane (10 ml/mmol) was added a 4N 
solution of hydrochloric acid in dioxane (20 eq.).  The reaction was stirred at room 
temperature for 12 hours.  The reaction was diluted with ethyl acetate and washed with 1 
N sodium hydroxide (3X), water (2X), brine (2X), dried over magnesium sulfate, and 
concentrated.  The crude residue was purified by flash chromatography using 20% ethyl 
acetate 80% hexanes to afford the pure product in 27% yield.  1H-NMR (800 MHz, d6-
DMSO) δ (ppm): 8.80 (1H, s), 7.92 (2H, d, J = 8.41), 7.83 (1H, d, J = 15.61), 7.71 (1H, d, 
J = 15.61), 7.65 (1H, dd, J = 1.47, 8.05), 7.54 (2H, d, J = 8.41), 7.31 (1H, d, J = 1.47), 
7.10 (1H, d, J = 8.05), 7.02 (1H, m), 6.93 (1H, m), 6.78 (1H, m), 6.67 (1H, d, J = 7.92).  
1H-NMR (200 MHz, d6-DMSO) δ (ppm): 188.39, 142.77, 142.65, 141.58, 137.24, 
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135.55, 135.02, 134.17, 130.99, 129.46, 128.51, 126.77, 126.62, 124.27, 123.11, 122.61, 





 To a solution of 4.27 (1.0 eq.) and 2,5-dimethoxybenzaldehyde (1.0 eq.) in 
absolute methanol (0.4 M) was added a solution of sodium hydroxide (1.0 eq.) in 
methanol (0.4 m).  The reaction was allowed to stir for 24 hours before water was added.  
The aqueous layer was extracted with ethyl acetate (3X).  The combined organic layers 
were washed with brine, dried over magnesium sulfate, and concentrated.  The crude 
residue was purified by flash chromatography to give the pure product 4.30 in 50% yield. 
1H-NMR (400 MHz, CDCl3) δ (ppm): 8.17 (1H, d, J = 1.64), 8.10 (1H, d, J = 15.81), 7.81 
(1H, dd, J = 1.64, 8.16), 7.58 (2H, m), 7.44 (1H, d, J = 8.16), 7.35 (1H, m), 7.31 (1H, m), 
7.18 (2H, m), 6.95 (1H, dd, J = 3.00, 9.00), 6.88 (1H, d, J = 9.00), 3.88 (3H, s), 3.82 (3H, 
s), 1.51 (9H, s).  13C-NMR (100 MHz, CDCl3) δ (ppm): 189.42, 153.43, 153.35, 152.13, 
140.40, 138.67, 138.12, 137.74, 136.91, 130.83, 127.31, 127.21, 126.88, 126.24, 125.88, 
124.37, 122.59, 117.25, 113.82, 112.41, 82.42, 56.03, 55.77, 28.07.  IR vmax 1710.23 







To a solution of 4.30 (1.0 eq.) in dichloromethane (10 ml/mmol) was added a 4N solution 
of hydrochloric acid in dioxane (20 eq.).  The reaction was stirred at room temperature 
for 12 hours.  The reaction was diluted with ethyl acetate and washed with 1 N sodium 
hydroxide (3X), water (2X), brine (2X), dried over magnesium sulfate, and concentrated.  
The crude residue was purified by flash chromatography using 20% ethyl acetate 80% 
hexanes to afford the pure product in 89% yield.  1H-NMR (800 MHz, d6-DMSO) δ 
(ppm): 8.80 (1H, s), 7.99 (1H, d, J = 15.71), 7.78 (1H, d, J = 15.71), 7.62 (1H, dd, J = 
1.79, 8.02), 7.51 (1H, d, J = 2.60), 7.31 (1H, d, J = 1.79), 7.09 ( 1H, d, J = 7.96), 7.06 
(2H, m), 7.02 (1H, td, J = 1.39, 7.84), 6.93 (1H, dd, J = 1.21 7.64), 6.78 (1H, td, J = 1.21, 
7.64), 6.68 (dd, J = 1.09, 7.96), 3.86 (3H, s), 3.80 (3H, s).  13C-NMR (200 MHz, d6-
DMSO) δ (ppm): 188.56, 153.74, 153.21, 142.63, 141.63, 138.59, 137.48, 128.49, 
126.76, 126.60, 123.98, 123.96, 123.03, 122.59, 122.34, 118.61, 115.70, 115.08, 113.54, 
113.39, 113.12, 56.64, 56.19.  IR vmax 3332.24 (NH), 1646.26 (CO) cm-1.              








To a solution of 4.18 (1.0 eq.) and 4-dimethylaminobenzaldehyde (1.0 eq.) in 
absolute ethanol (1.3 M) was added a solution of sodium hydroxide (1.3 eq.) in ethanol 
(1.3 M).  The resulting mixture was stirred at room temperature for 24 hours, water was 
added and the aqueous layer was extracted with ethyl acetate (3X).  The combined 
organic layers were washed with brine, dried over magnesium sulfate, and concentrated.  
The crude product was purified by flash chromatography giving the desired 
phenothiazine 4.32 in 27% yield.  1H-NMR (400 MHz, CDCl3) δ (ppm): 8.14 (1H, s), 
7.81 (2H, m), 7.55 (2H, 8.25), 7.43 (2H, m), 7.31 (1H, J = 15.40), 6.84 (2H, m), 6.68 
(2H, d, J = 8.26), 3.78 (3H, s), 3.03 (6H, s), 1.50 (9H, s).  1H-NMR (100 MHz, CDCl3) δ 
(ppm): 188.94, 157.55, 152.44, 152.02, 146.09, 138.93, 137.54, 136.81, 132.08, 131.02, 
130.44, 127.84, 127.03, 125.60, 122.46, 116.20, 113.18, 111.73, 111.62, 82.17, 55.56, 











 A 1.0 M solution of boron tribromide in dicholomethane (6.0 eq.) was added to a 
solution of 4.32 (1.0 eq.) in dichloromethane (0.2 M) under N2 atmosphere at -78 °C.  
The reaction was allowed to stir at that temperature for 3 hours before quenching with 
saturated sodium bicarbonate and methanol.  The aqueous layer was extracted with ethyl 
acetate (3X) and the combined organic layers were washed with saturated sodium 
bicarbonate (4X) and brine (1X), dried over magnesium sulfate, and concentrated.  The 
pure product was obtained after flash chromatography using 50% ethyl acetate 50% 
hexanes in 53% yield.  1H-NMR (800 MHz, d6-DMSO) δ (ppm): 8.57 (1H, s), 7.68 (2H, 
d, J = 8.85), 7.66 (1H, d, J = 15.33), 7.53 (1H, dd, J = 1.69, 8.01), 7.49 (1H, d, J = 15.33), 
7.28 (1H, d, J = 1.69), 7.06 (1H, d, J = 8.01), 6.75 (2H, d, J = 8.85), 6.62 (3H, m), 3.67 
(3H, s), 3.02 (6H, s).  13C-NMR (200 MHz, d6-DMSO) δ (ppm): 188.01, 155.27, 152.47, 
145.43, 143.21, 138.20, 135.18, 134.92, 131.16, 126.50, 122.42, 122.10, 116.95, 116.30, 
115.70, 113.95, 113.19, 112.24, 112.15, 55.90.  IR vmax 3331.26 (NH), 1726.18 (CO) cm-







one (4.34).  
A 1.0 M solution of boron tribromide in dicholomethane (6.0 eq.) was added to a 
solution of 4.32 (1.0 eq.) in dichloromethane (0.2 M) under N2 atmosphere at -78 °C.  
The reaction was allowed to stir at that temperature for 6 hours before quenching with 
saturated sodium bicarbonate and methanol.  The aqueous layer was extracted with ethyl 
acetate (3X) and the combined organic layers were washed with saturated sodium 
bicarbonate (4X) and brine (1X), dried over magnesium sulfate, and concentrated.  The 
pure product was obtained after flash chromatography using 50% ethyl acetate 50% 
hexanes in 71% yield.  1H-NMR (800 MHz, d6-DMSO) δ (ppm): 9.07 (1H (NH), s), 8.46 
(1H (OH), s), 7.66 (3H, m), 7.49 (2H, m), 7.28 (1H, s), 7.04 (1H, d, J = 7.88), 6.74 (2H, 
d, J = 8.62), 6.54 (1H, d, J = 8.46), 6.47 (1H, dd, J = 2.19, 8.46), 6.40 (1H, d, J = 1.99), 
3.01 (6H, s).  13C-NMR (200 MHz, d6-DMSO) δ (ppm): 188.05, 153.17, 152.45, 145.37, 
143.51, 138.13, 133.75, 131.13, 126.45, 122.52, 122.46, 121.82, 116.63, 116.33, 115.85, 







methyl 4-mercaptobenzoate (4.35). 
 4-mercaptobenzoic acid (1.0 M) was dissolved in anhydrous methanol (0.2 M) 
and a catalytic amount of sulfuric acid was added.  The reaction mixture was then 
refluxed for 6 hours.  After cooling to room temperature, the methanol was evaporated 
and the residue was taken up in water and ethyl acetate.  The aqueous layer was extracted 
with ethyl acetate (3X) and the combined organic layers were washed with brine, dried 
over magnesium sulfate, and concentrated to yield the product in quantitative yield and 
sufficient purity for subsequent reactions.  1H-NMR (300 MHz, CDCl3) δ (ppm): 7.88 
(2H, d, J = 8.22), 7.27 (2H, d, J =8.22), 3.89 (3H, s).  13C-NMR (75 MHz, CDCl3) δ 
(ppm): 166.34, 138.14, 130.02, 127.91, 126.91, 52.03.   
 
 
methyl 4-((4-acetyl-2-nitrophenyl)thio)benzoate (4.36). 
A solution of thiophenol (1.05 eq.), 4.4 (1.0 eq.), and sodium hydroxide (1.0 eq.) was 
heated in DMF (0.4 M) at 60 °C for 12 hours.  The reaction was cooled to room 
temperature, and poured into saturated aqueous lithium chloride.  The aqueous layer was 
then extracted with ethyl acetate (3X).  The combined organic layers were washed with 
saturated aqueous lithium chloride (5X), dried over magnesium sulfate, and concentrated.  
The crude residue was purified by flash chromatography using 10% ethyl acetate 90% 
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hexanes, to give the product in 56% yield.  1H-NMR (400 MHz, CDCl3) δ (ppm): 8.74 
(1H, d, J = 1.54), 8.13 (2H, d, J = 8.11), 7.87 (1H, dd, J = 1.54, 8.55), 7.64 (2H, d, J = 
8.11), 6.93 (1H, d, J = 8.55), 3.94 (3H, s), 2.59 (3H, s).  13C-NMR (100 MHz, CDCl3) δ 
(ppm): 194.83, 165.95, 144.75, 143.79, 135.74, 135.33, 134.12, 131.97, 131.12, 128.56, 




 To a solution of 4.36 (1.0 eq.) in THF (0.2 M) at room temperature under N2 
atmosphere was added a 10.0 M solution of borane dimethylsulfide complex in THF (3.6 
eq.) dropwise.  The mixture was heated to reflux for three hours before it was cooled to 
room temperature and the solvent was evaporated.  The residue was taken up in water and 
extracted with ethyl acetate (3X).  The combined organic layers were washed with brine, 
dried over magnesium sulfate, and concentrated.  The crude residue was purified by flash 
chromatography using 50% ethyl acetate 50% hexanes.  1H-NMR (400 MHz, CDCl3) δ 
(ppm): 8.23 (1H, d, J = 1.63), 7.56 (2H, d, J = 8.09), 7.47 (2H, d, J = 8.09), 7.35 (1H, dd, 
J = 1.69, 8.48), 6.84 (1H, d, J = 8.48), 4.92 (1H, q, J = 6.43), 4.79 (2H, s), 1.48 (3H, d, J 







 To a solution of 4.37 (1.0 eq.) in DMF (0.2 M) was added TBSCl (4.0 eq.), 
imidazole (8.0 eq.), and DMAP (1.0 eq.).  The reaction mixture was allowed to stir at 
room temperature for 14 hours.  The reaction mixture was then poured into saturated 
lithium chloride (aq.) and the organic layer was extracted with ethyl acetate (3X).  The 
combined organic layers were then washed with saturated lithium chloride (aq., 5X), 
dried over magnesium sulfate, and concentrated.  The crude residue was purified by flash 
chromatography using 5% ethyl acetate 95% hexanes to give the pure product in 85% 
yield.  1H-NMR (300 MHz, CDCl3) δ (ppm): 8.20 (1H, d, J = 1.64), 7.55 (2H, d, J = 
8.16), 7.44 (2H, d, J = 8.16), 7.31 (1H, dd, J = 1.64, 8.49), 6.81 (1H, d, J = 8.49), 4.87 
(1H, q, J = 6.35), 4.82 (2H, s), 1.39 (3H, d, J = 6.35), 0.97 (9H, s), 0.90 (9H, s), 0.15 (6H, 
s), 0.07 (3H, s), -0.01 (3H, s).  13C-NMR (75 MHz, CDCl3) δ (ppm): 144.45, 143.49, 
137.46, 135.64, 130.21, 129.01, 127.99, 127.31, 122.14, 69.31, 64.36, 26.89, 25.96, 










To a solution of 4.38 (1.0 eq.) in mesitylene (0.5 M) under N2 atmosphere at 
ambient temperature was added triethylphosphite (6.0 eq.) slowly.  The reaction mixture 
was then refluxed for 5 hours.  After cooling to ambient temperature, the reaction mixture 
was diluted with toluene and concentrated as much as possible.  Under no circumstance 
was the phenothiazine product dissolved in a chlorinated solvent.  The crude residue was 
purified directly by flash chromatography using 10% ethyl acetate 90% hexanes and the 
pure product was isolated as an orangish brown flaky solid in 54% yield.  1H-NMR (800 
MHz, d6-DMSO) δ (ppm): 8.57 (1H, s), 6.92 (1H, dd, J = 1.86, 8.09), 6.85 (1H, d, J = 
8.45), 6.84 (1H, d, J = 1.86), 6.71 (2H, m), 6.66 (1H, d, J = 8.08), 4.75 (1H, q, J = 6.33), 
4.52 (2H, s), 6.33 (3H, d, J = 6.33), 0.89 (9H, s), 0.88 (9H, s), 0.06 (6H, s), 0.06 (3H, s), -











 To a stirred solution of 4-methyl-3-nitrobenzoic acid (8.0 eq.), DIEA (8.0 eq.), 
and DMAP (2.0 eq.) in DMF (0.4 M) was added EDC (3.0 eq.) at 0 °C.  After 30 
minutes, 4.39 (1.0 eq.) was added.  The reaction mixture was allowed to stir for 24 hours.  
The reaction mixture was then poured into saturated lithium chloride (aq.) and the 
organic layer was extracted with ethyl acetate (3X).  The combined organic layers were 
then washed with saturated lithium chloride (aq., 5X), dried over magnesium sulfate, and 
concentrated.  The crude residue was purified by flash chromatography using 15% ethyl 
acetate 85% hexanes to give the pure product in 34%.  1H-NMR (800 MHz, d6-DMSO) δ 
(ppm): 8.75 (1H, s), 8.47 (1H, d, J = 1.71), 8.43 (1H, d, J = 1.71), 8.18 (1H, dd, J = 1.75, 
7.95), 8.14 (1H, dd, J = 1.75, 7.98), 7.70 (1H, d, J = 8.07), 7.66 (1H, d, J = 8.03), 7.12 
(1H, dd, J = 1.86, 8.18), 7.06 (1H, d, J = 1.75), 6.93 (1H, d, J = 7.94), 6.88 (1H, dd, J = 
1.64, 8.02), 6.76 (1H, d, J = 1.64), 6.68 (1H, d, J = 8.18), 5.93 (1H, q, J = 6.54), 5.19 (2H, 
s), 2.61 (3H, s), 2.59 (3H, s), 1.59 (3H, d, J = 6.54).  13C-NMR (200 MHz, d6-DMSO) δ 
(ppm): 164.40, 163.71, 149.46, 149.39, 142.40, 142.29, 141.50, 138.85, 138.75, 134.13, 
134.10, 133.75, 129.55, 129.37, 129.27, 128.92, 127.30, 126.83, 125.39, 125.35, 120.04, 
116.77, 116.21, 114.79, 112.31, 73.40, 66.95, 22.33, 20.22.  IR vmax 3360.12 (NH), 




(8-(1-hydroxyethyl)-10H-phenothiazin-3-yl)methyl 3,4-dimethoxybenzoate (4.41). 
To a stirred solution of 3,4-dimethoxybenzoic acid (8.0 eq.), DIEA (8.0 eq.), and DMAP 
(2.0 eq.) in DMF (0.4 M) was added EDC (3.0 eq.) at 0 °C.  After 30 minutes, 4.39 (1.0 
eq.) was added.  The reaction mixture was allowed to stir for 24 hours.  The reaction 
mixture was then poured into saturated lithium chloride (aq.) and the organic layer was 
extracted with ethyl acetate (3X).  The combined organic layers were then washed with 
saturated lithium chloride (aq., 5X), dried over magnesium sulfate, and concentrated.  
The crude residue was purified by flash chromatography using 15% ethyl acetate 85% 
hexanes to give the pure product in 59%.  1H-NMR (800 MHz, d6-DMSO) δ (ppm): 8.67 
(1H, s), 7.60 (1H, dd, J = 2.01, 8.44), 7.44 (1H, d, J = 2.01), 7.09 (1H, dd, J = 1.89, 8.12), 
7.07 (1H, d, J = 8.44), 7.02 (1H, d, J = 1.89), 6.85 (1H, d, J = 7.82), 6.74 (1H d, J = 1.58), 
6.72 (1H, dd, J = 1.58, 8.04), 6.69 (1H, d, J = 8.12), 5.13 (3H, s), 4.57 (1H, m), 3.84 (3H, 
s), 3.81 (3H, s), 1.27 (3H, d, J = 6.45).  13C-NMR (200 MHz, d6-DMSO) δ (ppm): 
165.88, 153.50, 148.92, 147.80, 142.63, 142.04, 129.99, 128.54, 127.03, 126.25, 123.72, 
122.27, 119.59, 117.02, 114.70, 114.19, 112.12, 112.06, 111.61, 68.01, 66.03, 56.19, 
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Figure B.131. 200 MHz 13C NMR of compound 4.31 in d6-DMSO.  
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a b s t r a c t
Resveratrol (3,5,40-trihydroxylstilbene) has been proposed to elicit a variety of positive health effects
including protection against cancer and cardiovascular disease. The highest affinity target of resveratrol
identified so far is the oxidoreductase enzyme quinone reductase 2 (QR2), which is believed to function in
metabolic reduction and detoxification processes; however, evidence exists linking QR2 to the metabolic
activation of quinones, which can lead to cell toxicity. Therefore, inhibition of QR2 by resveratrol may
protect cells against reactive intermediates and eventually cancer. With the aim of identifying novel
inhibitors of QR2, we designed, synthesized, and tested two generations of resveratrol analogue libraries
for inhibition of QR2. In addition, X-ray crystal structures of six of the resveratrol analogues in the active
site of QR2 were determined. Several novel inhibitors of QR2 were successfully identified as well as a
compound that inhibits QR2 with a novel binding orientation.
 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Resveratrol (3,5,40-trihydroxystilbene, Fig. 1) is a naturally
occurring phytoalexin that was discovered in 1940, when it was
isolated from the roots of white hellebore.1–3 Resveratrol occurs
in nature as both the cis- and trans-isomers and it can be found
in a variety of dietary sources including peanuts, pistachios, and
berries.4,5 Of the more common dietary sources of resveratrol,
the skins and seeds of grapes are the most notable with red wine
being the most heavily consumed form.5,6
Interest in resveratrol increased dramatically in 1992, when it
was hypothesized to explain the cardioprotective effects of red
wine and the ‘French paradox,’ the observation of reduced inci-
dence of cardiovascular disease in regions of France where red
wine and saturated fats are consumed in greater quantities than
in the US.7,8 Since then, numerous studies have demonstrated the
ability of resveratrol to prevent or slow the progression of various
disease states including cancer and cardiovascular disease.9,10 Res-
veratrol has even been shown to increase the lifespans of several
organisms including yeast, worms, fruit flies and fish.11–13
A number of direct targets for resveratrol have been discovered
in vitro, including cyclooxygenase-1 (COX1), cyclooxygenase-2
(COX2), and the transcription factor NF-jB.14–16 The highest affin-
ity target of resveratrol identified to date is quinone reductase 2
(QR2), a FAD-dependent cytosolic enzyme that catalyzes the 1-,
2-, or 4-electron reduction of quinones and other compounds using
N-alkyl- and N-ribosylnicotinamides.17,18 QR2 is an oxidoreductase
thought to function in metabolic reduction and detoxification;
however, the true physiological role of QR2 is currently
unknown.19 Evidence exists that QR2 is capable of catalyzing the
metabolic activation of quinones and anti-tumor drugs, leading
to cell toxicity.20–22 Thus, in some cases, inhibition of QR2 by res-
veratrol may guard cells against these reactive species that induce
DNA damage, which may subsequently lead to cancer.23
Resveratrol has been found to bind tightly to the oxidized, FAD-
form of QR2 and it acts as a competitive inhibitor against N-meth-
yldihydronicotinamide (NMeH) with a Ki value of 88 ± 20 nM,
determined by steady-state kinetic studies, and a Kd value of
0968-0896/$ - see front matter  2013 Elsevier Ltd. All rights reserved.
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54 ± 0.6 nM, determined by isothermal titration calorimetry17,24
Additionally, plasma levels of resveratrol are able to reach concen-
trations of 500 nM, which suggests that significant inhibition of
QR2 by resveratrol in vivo may be achievable.24 Taken together,
these data suggest that the amount of resveratrol consumed from
dietary sources may be sufficient for effective inhibition of QR2.
However, circulating resveratrol is rapidly metabolized in the liver
and gut by sulfation and glucuronation to its 3- and 40-O-sulfate
and 3-O-glucuronide conjugates.24–27 These primary metabolites
of resveratrol have been shown to have far lower affinity for QR2.24
The present work was undertaken in an attempt to identify no-
vel analogues of resveratrol that could potently inhibit QR2 with
increased affinity and to serve as leads for the development of fu-
ture QR2 inhibitors as cancer chemopreventive or anticancer
drugs. To do this, we first tested a library of 78 previously synthe-
sized resveratrol analogues designed to investigate the effects of
different steric and electronic substituents on both the aryl rings
and central olefin resveratrol.28 Based on the inhibition of QR2
by the most active of these compounds, we set out to determine
what effect functionalization of the central olefin of resveratrol
with electron withdrawing substituents would have on inhibition
of QR2 by creating a series of olefin-substituted and benzanilide
resveratrol analogues. In addition, to circumvent inhibitory inacti-
vation of resveratrol by its rapid metabolism, identification of
effective resveratrol analogues that lacked the 3- and 40-hydroxyl
groups required for sulfation and glucuronation was of interest.
2. Results and discussion
2.1. Inhibition of QR2 by a first-generation resveratrol analogue
library
The first-generation library of resveratrol analogues was de-
signed to investigate the effects of substitution on each of the
two aryl rings and central alkene of resveratrol. Therefore, to ex-
plore the electronic and steric demands of each of the aryl rings,
electron-donating (OH, OMe, and NMe2) and electron-withdrawing
(F, CF3 and NO2) and naphthyl substitutents were selected. Four
substituents were chosen to determine the effect of sterics and
electronics on the central olefin (H, Me, Et, CF3). The synthesis of
this first generation library of 78 resveratrol analogues has been
previously reported.28 Twenty-four of the seventy-eight resvera-
trol analogues were found to effectively inhibit QR2. These results
are displayed in Table 1.
Of the 78 resveratrol analogues tested, twenty-four were found
to actively inhibit QR2. Of the twenty-four active analogues, ten
were more potent inhibitors of QR2 than resveratrol, five of which
lacked both the 3- and 40-hydroxyl substituents that undergo met-
abolic sulfation and glucuronation (1h, 1i, 1j, 1r, and 1v). Interest-
ingly, two of the analogues found to be more active inhibitors of
QR2 than resveratrol had a naphthyl substituted for an aryl ring
(1i and 1l), possibly allowing for a greater pi–stacking interaction
with the oxidized isoalloxazine ring of the FAD in the active site
of QR2. The most potent inhibitor of QR2 identified from the first
generation library was compound 1v, which has both a highly
electron-deficient aryl ring and central olefin as a result of the
trifluoromethyl substituents. Unfortunately, attempts at obtaining
an X-ray crystal structure of our most active compound 1v in the
active site of QR2 were unsuccessful; however, as a result we were
determined to further investigate the effect of substitution at the
central olefin. Therefore, we set out to synthesize a second-gener-
ation library comprised of analogues with electron-withdrawing
substituents on the central olefin as well as a set of resveratrol ana-
logues where the central olefin had been replaced by an amide.
2.2. Synthesis of olefin-substituted resveratrol analogues
To investigate the effect of substitution of both the central
olefin and the phenols, as well as the conformational effect of
E/Z-isomerism of resveratrol on its inhibition of QR2, a small li-
brary of 21 olefin-substituted resveratrol analogues was synthe-
sized. The synthesis of (Z)-cyano resveratrol analogues 4a, 4b,
and 4cwas accomplished by condensation of the appropriate alde-
hyde 2 with the appropriate 2-phenylacetonitrile 3, as shown in
Scheme 129,30 With these easily functionalized nitriles in hand,
the remaining eighteen resveratrol structural analogues could be
synthesized. Deprotection of 4b with boron tribromide yielded
(Z)-nitrile analogue 4d. Protection of the phenols of 4d as tert-
butyldimethylsilyl ethers followed by the reduction of the nitrile
using diisobuytlaluminum hydride yielded a mixture of (E)- and
(Z)-aldehydes 5. Treatment of 5with tetra-n-butylammonium fluo-
ride resulted in the isomerically pure (E)-acrylaldehyde 4e, where
the (Z)-isomer was not detected. Further reduction of 5 with dii-
sobutylaluminum followed by deprotection of the hydroxyls with
dilute hydrochloric acid in methanol yielded the isomerically pure
(Z)-alcohol 4f (Scheme 1).
Reduction of (Z)-nitriles 4b and 4c using diisobutylaluminum
hydride resulted in (Z)-aldehyde analogues 4g and 4h in moderate
to good yields. Further reduction of the aldehydes 4g and 4h with
sodium borohydride yielded mixtures of both (Z)- and (E)-alcohols,
which could be separated by flash chromatography to give the four
Figure 1. Trans- and cis-resveratrol.
Table 1
Inhibition of QR2 by first generation resveratrol analogue library
Analogue R1 R2 R3 IC50a (lM)
Resveratrol 4-OH H 3,5-(OH)2 11.5 ± 3.2
1a 4-OH H 3,4-(OH)2 6.0 ± 1.2
1b 4-OH H 3,5-(OMe)2 5.1 ± 1.2
1c 3,4-(OH)2 H 4-OMe 9.3 ± 3.7
1d 3,4-(OH)2 H 3-F 20.8 ± 8.6
1e 3,4-(OH)2 H 4-CF3 14.2 ± 4.3
1f 4-OMe H 3,5-(OMe)2 14.6 ± 4.3
1g 3,5-(OMe)2 H 3,4-(OMe)2 37.1 ± 6.8
1h 3,5-(OMe)2 H 4-F 4.6 ± 1.0
1i 3,5-(OMe)2 H 2-Naphthyl 0.73 ± 0.12
1j 3,4-(OMe)2 H 3-OMe 6.8 ± 1.2
1k 3,4-(OMe)2 H 4-NMe2 13.0 ± 3.5
1l 3,4-(OMe)2 H 2-Naphthyl 5.5 ± 1.3
1m 4-OH Me 3,5-(OH)2 39.0 ± 17.2
1n 4-OH Me 4-CF3 2.8 ± 1.2
1o 3,5-(OH)2 Me 4-OH 4.8 ± 1.2
1p 4-OMe Me 3,5-(OH)2 12.0 ± 8.4
1q 4-OMe Me 3,5-(OMe)2 20.1 ± 0.1
1r 4-OMe Me 3,4-(OMe)2 6.7 ± 3.0
1s 3,4-(OMe)2 Me 3,5-(OH)2 33.7 ± 32.4
1t 3,4-(OMe)2 Me 3,5-(OMe)2 9.9 ± 4.0
1u 3,5-(OMe)2 CF3 4-OMe 13.0 ± 3.1
1v 3-CF3 CF3 3,4-(OMe)2 0.18 ± 0.3
1w 3,5-(OH)2 Et 4-NMe2 10.9 ± 2.2
1x 3,4-(OMe)2 Et 3,5-(OMe)2 16.3 ± 7.0
a The lowest IC50 values are highlighted in bold.
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analogues 4i, 4j, 4k, and 4l. The (E)-methyl ester 4m was obtained
by oxidation of aldehyde 4h using manganese dioxide and potas-
sium cyanide in methanol (Scheme 2).31
A Pinnick-type oxidation of aldehyde 4h by sodium chlorite-
hydrogen peroxide yielded an inseparable mixture of the desired
(Z)-carboxylic acid 6 and chlorinated byproduct 7, formed by reac-
tion with hypochlorite generated in situ.32 Fischer esterification of
the acids 6 and 7 yielded the methyl esters (Z)-4n and (Z)-4o,
which could be separated by flash chromatography. Finally, depro-
tection of 4o using boron tribromide yielded the desired (Z)-ester
analogue 4p (Scheme 3).
Palladium-catalyzed hydration of nitrile 4b yielded the
(Z)-amide 4q, which upon treatment with boron tribromide gave
(Z)-amide analogue 4r in good yield, as shown in Scheme 4.33 Con-
comitant reduction of the nitrile and olefin of 4bwas accomplished
using sodium borohydride and cobalt chloride hexahydrate, result-
ing in amine analogue 4s.34 The (Z)-methyl carbamate 4t was ob-
tained in good yield by oxidative Hofmann rearrangement of 4q
Scheme 2. Synthesis of olefin-substituted resveratrol analogues 4g–4m.
Scheme 1. Synthesis of olefin-substituted resveratrol analogues.
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using (diacetoxyiodo)benzene. Treatment of the carbamate 4twith
boron tribromide deprotected the methyl carbamate, which upon
aqueous workup afforded the imine analogue 4u (Scheme 4).35
The structures of all olefin-substituted resveratrol analogues are
displayed in Figure 2.
2.3. Synthesis of benzanilides
A separate modification of the central alkene of resveratrol was
accomplished by replacing the alkene with an amide bond; conse-
quently, a small library of 26 substituted benzanilides (Fig. 2) was
synthesized using standard amide bond forming reactions. Con-
struction of the library was accomplished by reaction of the appro-
priately activated benzoic acid derivative with the corresponding
substituted aniline. In most cases, benzoyl chlorides were suitable
for the coupling reaction; however, when acid-sensitive substrates
were used, EDC activation was employed instead. N-methyl benza-
nilide derivatives were made by treatment of the appropriate ben-
zanilide with sodium hydride and methyl iodide. The imidate 8v
(Fig. 2) was obtained by treatment of TBS-protected 8rwith thionyl
chloride and methanol.
The relationship between resveratrol and its benzanilide ana-
logues’ bioactivity was directly compared using analogues 8a, 8b,
8c, 8d, and 8ewhere the methylation of the amide and the phenols,
and the position of the resorcinol ring relative to the nitrogen of
the amide were varied. An additional 21 benzanilide resveratrol
analogues were synthesized to probe the effect of different substi-
tutions on bioactivity (Fig. 2, top).
2.4. Inhibition of QR2 by olefin-substituted and benzanilide
resveratrol analogues
The ability of the second-generation analogues to inhibit QR2 is
outlined in Table 2. Of the forty-seven second generation resvera-
trol analogues that were synthesized, nine were found to inhibit
QR2. Two analogues, 4d and 4f, inhibited QR2 with IC50s compara-
ble to resveratrol, while the remaining seven were slightly weaker
inhibitors of QR2 as compared to resveratrol (6.9 ± 0.4 lM). Ten
analogues showed weak inhibition of QR2 (between 20% and 50%
at 100 lM) and twenty-nine of the forty-seven analogues showed
minimal inhibition of QR2 (<20% at 100 lM). This result could be a
consequence of substitution at the central olefin perturbing the
binding orientation of the analogue within the active site of QR2.
Each of the analogues that inhibited QR2 strongly had free hydro-
xyl groups, with the exception of analogues 4b, 4g, and 4k, which
had methyl ethers. In general, inhibitory activity decreased as
Scheme 4. Synthesis of olefin-substituted resveratrol analogues 4q, 4r, 4s, 4t, & 4u.
Scheme 3. Synthesis of olefin-substituted resveratrol analogues 4o, 4n, & 4p.
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steric bulk associated with the aryl rings increased. For example,
the nitrile analogue 4d was found to inhibit QR2 with an IC50 of
5.9 ± 0.3 lM and 88.8% inhibition, while the nitrile analogue 4b,
which differs from 4d only in that the hydroxyl groups have been
replaced with methyl ethers, was found to inhibit QR2 with a six-
fold increase in IC50 of 31.6 ± 4.3 lM and 57.4% inhibition. Further-
more, the nitrile analogues 4a and 4c, where the methyl ethers of
4b have been replaced with bulkier isopropyl ethers, did not show
inhibition of resveratrol over 20% at a concentration of 100 lM.
This result may be a consequence of the bulky ethers reducing
the ability of the molecule to form stabilizing hydrogen bonds to
ordered QR2 active site water molecules (vide infra). Previous re-
ports have demonstrated that methoxy groups and even acetates
at the 2-, 3-, 4-, and 5-positions of resveratrol can be accommo-
dated by the QR2 active site when the 40-position is substituted
with an amine.36,37
Two of the olefin-substituted resveratrol analogues found to in-
hibit QR2, 4e and 4k, were of the E geometry, which more closely
resembles cis-resveratrol. Interestingly, the (E)-alcohol 4k was
found to effectively inhibit QR2 with an IC50 of 27.5 ± 4.9 lM and
57.2% inhibition at 100 lM, whereas its (Z)-isomer 4i only had an
average inhibition of 27.7% at 100 lM. Furthermore, the analogue
4f, which only differs from 4i in that the methoxy substituents
have been replaced with hydroxyl groups, was found to be the
Figure 2. (Top) Benzanilide resveratrol analogue library, (bottom) olefin-substituted resveratrol analogue library.
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most potent inhibitor in our library, having an IC50 of 5.1 ± 0.3 lM
and 87.4% average inhibition at 100 lM of QR2. This supports our
observation that substitution of sterically bulky ethers for the hy-
droxyl groups of resveratrol decreases inhibitory ability of a given
compound; however, this data suggests that this trend may be ne-
gated when taking into consideration the effect of conformation.
To the best of our knowledge, this is the first report of an isomer-
ically pure (E)-resveratrol analogue inhibiting QR2 and having
greater inhibition of QR2 than its corresponding (Z)-conformation
(Fig. 3).
Two of the twenty-six benzanilide resveratrol analogues were
found to inhibit QR2, 8a and 8d. Examination of the IC50 data
shows that the position of the amide nitrogen relative to the resor-
cinol ring has a measurable effect on the ability of the benzanilide
analogue to inhibit QR2: when the nitrogen is directly bound to the
resorcinol ring the IC50 is decreased by roughly 40% (16.8 ± 1.3 lM
vs 27.6 ± 4.6 lM). Additionally, only hydroxyl substituents on the
aryl rings are tolerated for good inhibition of QR2 by the benzani-
lide analogues and even then, only at the same positions found in
resveratrol itself. Comparison of 8a, which has free hydroxyl
groups at the 3-, 5-, and 40-positions, to 8c, where the 3- and
5-hydroxyls are replaced by methyl ethers, shows the average per-
cent inhibition at 100 lM of QR2 decreases from 59.7% to 43.2%,
respectively. Additionally, moving one hydroxyl substituent from
the 3- to the 4-position on the resorcinol ring, as observed in the
comparison of 8a and 8t, decreases the analogue’s ability to inhibit
QR2 from 59.7% to 49.9% at 100 lM. Replacement of the 40-hydro-
xyl group by a 40-dimethylamino group eliminates inhibition of
QR2, which is seen in both the comparison of 8a to 8f and 8d to
8k. This is significant since previous reports have shown that
replacement of the hydroxyl group at the 40-position of resveratrol
by an amine can increase its inhibitory activity.36,37
Of the eight synthesized naphthyl-substituted benzanilide ana-
logues, only 8z showed weak inhibition of QR2 (30.5% average
inhibition at 100 lM). In contrast, the first generation analogue
1l, which differs from 8z only in that 8z has an amide in place of
the central alkene, was a potent inhibitor of QR2, having an IC50
of 5.5 lM. Interestingly, second generation benzanilide analogue
8p showed no inhibition of QR2 at 100 lM, while compound 1i
was the second most active analogue in the first generation library,
having an IC50 of 0.7 lM.
2.5. X-ray crystallographic analysis of QR2 in complex with
active olefin-substituted and benzanilide resveratrol analogues
To elucidate the structural factors underlying the inhibitory
trends observed in the kinetic data, and to answer questions such
as why does the (E)-geometry 4k analogue lead to a more potent
inhibitor of QR2 than its (Z)-isomer 4i, a series of X-ray crystal
structures were determined for the most potent olefin-substituted
and benzanilide QR2 inhibitors. Resveratrol binds in the in the ac-
tive site of QR2 fitting into a hydrophobic cleft that is approxi-
Figure 3. Effect of substitution and alkene geometry on QR2 inhibition.
Table 2
Inhibition of QR2 by olefin-substituted and benzanilide resveratrol analogues
Structure Analogue R1 R2 R3 IC50 (lM)
Resveratrol 4-OH H 3,5-(OH)2 6.9 ± 0.4
4b 4-OMe CN 3,5-(OMe)2 31.6 ± 4.3
4d 4-OH CN 3,5-(OH)2 5.9 ± 0.3
4f 4-OH CH2OH 3,5-(OH)2 5.1 ± 0.3
4g 4-OMe CHO 3,5-(OMe)2 24.2 ± 1.3
4r 4-OH CONH2 3,5-(OH)2 9.3 ± 1.9
4e H CHO H 25.5 ± 3.5
4k Me CH2OH Me 27.5 ± 4.9
8a — — — 27.6 ± 4.6
8d — — — 16.8 ± 1.3
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mately 17 Å long and 7 Å wide (Fig. 4A and B). Three sides of the
QR2 binding cavity are composed of hydrophobic amino acids,
while the fourth side is solvent exposed. The ends of the cavity
contain residues that are available for hydrogen bond formation.
The planar structure of resveratrol allows it to fit into the QR2
binding cleft in an orientation coplanar to the isoalloxazine ring
of the FAD cofactor.17 The narrow width of the QR2 binding site
dictates that it can only accommodate molecules such as resvera-
trol that can adopt essentially planar conformations. Additionally,
molecules that bind tightly to QR2 are generally planar and polyar-
omatic with the ability to stack with the isoalloxazine ring of FAD,
possibly utilizing a pi–stacking interaction with the isoalloxazine
for binding (Fig. 4A and B).38,39
Complete X-ray crystallographic data sets of QR2 in complex
with inhibitors 4d, 4f, 4k, 4r, 8a, and 8d were collected and the
structures for each complex were determined. The final data col-
lection and refinement statistics are summarized in Table 3. With
the exception of 4k, all of the olefin-substituted and benzanilide
resveratrol analogues bind in the same orientation as resveratrol,
coplanar to the oxidized isoalloxazine ring of the bound cofactor
FAD (Fig. 5). The binding of analogs 4d, 4f, 4k, 4r, 8a, and 8d does
not significantly alter the conformation of the active site residues
compared to the resveratrol-bound structure. As with resveratrol,
the (Z)-analogues show water mediated hydrogen bonds from
the 40-hydroxyl group of the ligand to the hydroxyl group of
Thr71, a tight hydrogen bond from the 5-hydroxyl to Asn161,
and a hydrogen bond from the 3-hydroxyl to the carbonyl oxygen
of Gly174.17 The 5-hydroxyls of the (Z)-configured analogues also
form a hydrogen bond to an ordered active site water molecule.
In some cases, such as 8a (Fig. 5E) and 8d (Fig. 5F), a network of
water molecules within the active site can extend to the substitu-
tion at the central olefin.
Examination of the X-ray crystal structures of the (Z)-config-
ured resveratrol analogues show that they bind in identical confor-
mations. The substitution of methyl ethers for phenols, such as in
analogue 4b, could change this preferred binding orientation. In
support of this, we did not observe strong electron density of 4b
in the QR2 active site, suggesting that the ligand was only present
at partial occupancy. This also supports our observations regarding
the series of analogues 4f, 4i, and 4k (Fig. 3). Our most active inhib-
itor, 4f, has a Z geometry and has hydroxyl substituents that hydro-
gen-bond key residues and structural waters in the QR2 active site.
The inhibitor 4i, which differs from 4f only by substitution of
methyl ethers for the hydroxyl groups of 4f, did not show potent
enough inhibition of QR2 to make determination of an IC50 feasible,
suggesting that increasing the size of the 40-, 3-, and 5-substituents
is not readily accommodated by the QR2 active site.
Most surprisingly, the E isomer of 4i, 4k, is a potent inhibitor of
QR2 and binds in a completely different orientation than the other
analogues where only one aryl ring occupies the same molecular
space as the other Z analogues (Fig. 5E). Examination of the binding
orientation of 4k shows that it does not form a direct hydrogen
bond to the network of active site water molecules that hydrogen
bond to the side chain of Thr71. Instead, an additional water mol-
ecule is present in the active site and is positioned where the 40-hy-
droxyl group of the (Z)-configured resveratrol analogues usually
resides, forming a water-mediated hydrogen bond to the side chain
of Asn161. Taking together the structure of 4k in the active site and
the partial occupancy observed for the 4b analogue, we hypothe-
size that, for the QR2 active site to accommodate resveratrol ana-
logues with bulkier substituents, the molecules must rotate 90
from their preferred binding orientation to allow at least one aryl
ring to stack on the isoalloxazine ring (Fig. 6A). Whether this rota-
tion will be accommodated by the QR2 active site depends on the
other substituents on the analogs and whether water molecules
can aid in the binding process.
The two most active benzanilide analogues, 8a and 8d (Fig. 5E
and F, respectively), orient their hydroxyl substituents in identical
locations (Fig. 6B), taking advantage of the same hydrogen bond
network. The carbonyl groups of the amide core of each analogue
are positioned to interact with the solvent exposed region of the
active site, avoiding the hydrophobic interior, again both utilizing
almost identical water molecules.
3. Conclusions
In conclusion, two sets of resveratrol analogue libraries were
designed, synthesized and tested for inhibition of QR2. Twenty-
four of the seventy-eight first generation resveratrol analogues
were found to potently inhibit QR2 and, of those twenty-four ana-
logues, ten were more potent QR2 inhibitors than resveratrol. Our
goal of identifying analogues that were both more potent than res-
veratrol and lacking the metabolically sensitive 3- and 40-hydroxyl
groups was achieved with the identification of five analogues—1h,
1i, 1j, 1r, and 1v—from the first-generation library. A second-gen-
eration library of 47 resveratrol analogues was designed to probe
the effects of substitution on the central alkene. Nine of the sec-
ond-generation resveratrol analogues were found to inhibit QR2.
Two of the analogues, 4d and 4f, had comparable IC50 values to that
of resveratrol while the remaining seven analogues were slightly
weaker inhibitors of QR2 in comparison to resveratrol. Because of
the unique substitutions made at the central alkene, X-ray crystal
structures of six of the nine inhibitors in complex with QR2 were
determined. From the series of crystal structures obtained, we
Figure 4. Resveratrol-QR2 complex (PDB: 1SG0). Resveratrol is shown in green, colored by atom type, and shown in ball and stick representation. Water molecules are shown
as red spheres. Hydrogen bonds are shown as grey dashes labeled with the distance in Ångstroms (Å). (A) X-ray structure of QR2 in complex with resveratrol displaying
hydrogen bond network, (B) Resveratrol in binding cavity of QR2, where QR2 is shown in grey surface representation and colored according to atom type.17
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learned that all of the Z-configured resveratrol analogues share a
common binding orientation within the active site of QR2. Addi-
tionally, the analogues all utilize the same ordered, active site
water molecules to form water-mediated hydrogen bonds to the
same residues within the QR2 active site, Asn161, Gly174 and
Thr71. We also identified a novel binding orientation of the E-
configured resveratrol analogue 4k, which is the first example of
an E-configured resveratrol analogue bound in the QR2 active site.
Future investigations will focus on the identification of additional
E-configured resveratrol analogues that lack the metabolically sen-




All reagents (chemicals) were purchased from Sigma or Acros
and used without further purification. Infrared spectra were ob-
tained using a ThermoNicolet Nexus 470 FT-IR spectrometer with
OMNIC software package. Mass spectral analyses were performed
using a Waters Micromass ZQ with ESI-MS injection port utilizing
MassLynx V4.1 software package. Analytical thin-layer chromatog-
raphy was performed on Sorbent Technologies Glass Backed Silica
Gel HL TLC Plates w/UV254. Flash chromatography was performed
with Sorbent Technologies 200–400 mesh silica gel. 1H NMR spec-
tra were obtained at 300 or 400 MHz and 13C NMR spectra were
obtained at 75 or 100 MHz, using Varian Inova300 and Bruker
ARX400 spectrometers, respectively. E/Z isomerism was deter-
mined by Nuclear Overhauser Effect experiments. All compounds
were purified by flash chromatography to >90% purity by 1H
NMR (see Supplementary data).
4.2. Synthesis
4.2.1. 3,5-Diisopropoxybenzaldehyde (2)
A mixture of 3,5-dihydroxybenzoic acid (1.00 g, 6.49 mmol),
potassium carbonate (4.04 g, 29.2 mmol) and isopropyl bromide
(3.65 mL, 38.93 mmol) in 12 mL dimethylformamide was heated
to reflux for 4 days. After cooling to room temperature, 6 mL water
and 6 mL 2 M hydrochloric acid were added to dissolve the carbon-
ate and acidify the reaction mixture. The aqueous layer was ex-
tracted with ethyl acetate (3  20 mL) and the combined organic
layers were dried over magnesium sulfate, filtered and concen-
trated to yield 3,5-diisopropoxybenzoic acid as a clear oil that
was used without further purification.
A 0.54 M solution of DIBAL-H in dichloromethane (4.66 mL,
2.52 mmol) was added to a solution of 3,5-diisopropoxybenzoic
acid (282 mg, 1.01 mmol) in toluene (5 mL) at 78 C. The reaction
mixture was allowed to stir for 45 min at that temperature before
quenching with 5% aqueous hydrochloric acid (1 mL). After warm-
ing to room temperature, the reaction mixture was diluted with
water and the aqueous layer was extracted with ethyl acetate
(3  5 mL), the combined organic layers were dried over magne-
sium sulfate, filtered and concentrated to yield a mixture of
3,5-diisopropoxybenzaldehyde and (3,5-diisopropoxyphe-
nyl)methanol in 97% combined yield. 3,5-Diisopropoxybenzalde-
hyde: 1H NMR (400 MHz, CDCl3) d (ppm): 9.77 (1H, s), 6.86 (2H,
d, J = 2.31), 6.57 (1H, t, J = 2.31), 4.48 (2H, m, J = 6.15), 1.24 (6H,
d, J = 6.16). 13C NMR (100 MHz, CDCl3) d (ppm): 191.72, 159.44,
110.10, 108.33, 70.03, 21.72.
4.2.2. 2-(4-Methoxyphenyl)acetonitrile (3)
Triphenyl phosphine (1.14 g, 4.34 mmol) was added portion-
wise to a solution of (4-methoxyphenyl)methanol (300 mg,
2.17 mmol) and carbon tetrabromide (1.22 g, 3.69 mmol) in anhy-
drous dichloromethane (7.2 mL) at 0 C. The reaction mixture was
stirred at that temperature for 20 min then concentrated to yield a
viscous oil which was dissolved in 10 mL of 50% hexanes 50% ethyl
acetate. The precipitate was filtered off and the filtrate concen-
trated. The residue was taken up in dimethylformamide (7.2 mL)
and potassium cyanide (0.99 g, 15.2 mmol) was added. The reac-
tion mixture was allowed to stir for 90 min before quenching with
saturated aqueous sodium bicarbonate (10 mL). The aqueous layer
was extracted with ethyl acetate (3  10 mL) and the combined or-
ganic layers were washed with brine, dried over magnesium sul-
fate, filtered and concentrated. The crude product was purified
by flash chromatography using 20% ethyl acetate 80% hexanes to
yield the pure product 3 in 45% yield. 1H NMR (300 MHz, CDCl3)
d (ppm): 7.19 (2H, d, J = 8.38), 6.86 (2H, d, J = 8.38), 3.74 (3H, s),
3.61 (2H, s). 13C NMR (75 MHz, CDCl3) d (ppm): 159.15, 129.01,
121.89, 118.42, 114.35, 55.18, 22.50.
4.2.3. General procedure for Aldol condensation (4a–4c)
Aqueous 40% potassium hydroxide (0.23 mL/mmol nitrile) was
diluted with absolute ethanol (0.46 mL/mmol nitrile) and added
Table 3
X-ray data collection and refinement statistics
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a = b = c (degrees) 90 90 90 90 90 90 90
Resolution (Å) 50–1.40 50–1.45 50–1.45 50–1.55 50–1.63 50–1.45 50–1.40
Reflections observed 436515 402271 389780 349634 287051 437831 441401
Unique reflections 85793 90632 84618 72933 62952 86788 98717
Rmerge (%) 58.7 (5.1) 54.4 (5.6) 50.2 (5.2) 53.0 (6.6) 54.9 (7.8) 46.1 (5.7) 50.3 (5.2)
I/r 33.1 (2.5) 28.0 (2.9) 28.3 (2.9) 27.1 (2.6) 17.4 (2.0) 31.7 (3.0) 31.4 (2.5)
% Completeness 85.9 (85.8) 99.8 (99.8) 94.0 (98.7) 98.9 (98.1) 98.4 (97.6) 96.8 (99.8) 99.4 (98.6)
Refinement
Resolution range (Å) (1.40–1.42) (1.45–1.48) (1.45–1.48) (1.55–1.58) (1.63–1.66) (1.45–1.48) (1.40–1.42)
Reflections in working
set
81481 86029 80331 69206 59715 82382 93724
Reflections in test set 5532 5778 5840 3672 3968 5772 6413
Rwork (%) 16.3 15.4 16.7 16.8 16.4 16.4 16.6
Rfree (%) 19.0 18.0 19.2 18.9 19.3 18.7 18.8
Average B-factor (Å2) 14.0 13.8 13.8 12.9 11.7 14.0 14.1
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at room temperature to a solution of the appropriate aldehyde
(1.1 equiv) and nitrile (1.0 equiv) in absolute ethanol (0.35 mL/
mmol nitrile). The reaction was then allowed to stir at room tem-
perature for 12–24 h before concentrating. The resulting yellow
residue was taken up in water and ethyl acetate and dilute hydro-
chloric acid was added to neutralize the aqueous layer. The aque-
ous layer was then extracted with ethyl acetate and the
combined organic layers were washed with brine, dried over mag-
nesium sulfate, filtered and concentrated to yield the crude prod-
uct. Purification by flash chromatography yielded the pure nitrile
products in 80–95% yield.
4.2.4. (Z)-3-(3,5-Diisopropoxyphenyl)-2-(4-hydroxyphenyl)
acrylonitrile (4a)
General procedure for Aldol condensation was used in combi-
nation with 2 and 2-(4-((tert-butyldimethylsilyl)oxy)phenyl)
acetonitrile (28%). 1H NMR (300 MHz, CDCl3) d (ppm): 7.56 (2H,
d, J = 8.71), 7.31 (1H, s), 6.98 (2H, d, J = 2.15), 6.90 (2H, d,
J = 8.71), 6.50 (1H, t, J = 2.15), 5.06 (1H, s), 4.58 (2H, m, J = 6.05),




General procedure for Aldol condensation was used in combina-
tion with 3,5-dimethoxybenzaldehyde and 3 (95%). 1H NMR
(300 MHz, CDCl3) d (ppm): 7.61 (2H, d, J = 8.91), 7.34 (1H, s), 7.04
(2H, d, J = 2.13), 6.96 (2H, d, J = 8.91), 6.53 (1H, t, 2.13), 3.85 (9H,
s). 13C NMR (75 MHz, CDCl3) d (ppm): 160.73, 160.32, 139.83,
135.47, 127.16, 126.59, 118.11, 114.27, 111.14, 106.71, 102.65,
55.28. ESIMS(+) m/z 318 (M+Na).
Figure 5. X-ray crystal structures of (A) 4d, (B) 4f, (C) 4k, (D) 4r, (E) 8a, and (F) 8d in complex with QR2. Resveratrol analogues are shown in green, colored according to atom
type, and shown in ball and stick representation. Water molecules are shown as red spheres. Hydrogen bonds are shown as grey dashes with distances (Å) labeled. The FAD
cofactor is shown in grey lines and colored according to atom. Electron density omit maps (FoFc) are shown in white mesh and contoured to 3.0 r around the ligand only. The
binding orientation of each resveratrol analogue was the same in both active sites of the QR2 dimer, therefore only one active site is shown for clarity.




General procedure for Aldol condensation was used in combina-
tion with 2 and 3 (92%). 1H NMR (300 MHz, CDCl3) d (ppm): 7.56
(2H, d, J = 8.83), 7.32 (1H, s), 7.01 (2H, d, J = 1.86), 6.94 (2H, d,
J = 8.83), 6.51 (1H, t, 1.86), 4.58 (2H, m, J = 6.04), 3.81 (3H, s),
1.37 (12H, d, J = 6.04). 13C NMR (75 MHz, CDCl3) d (ppm): 160.31,
159.15, 140.24, 135.45, 127.19, 126.79, 118.08, 114.30, 110.98,
108.30, 108.24, 106.13, 70.07, 70.01, 55.25, 21.96. ESIMS(+) m/z
352 (M+H), 374 (M+Na), 390 (M+K).
4.2.7. (Z)-3-(3,5-Dihydroxyphenyl)-2-(4-hydroxyphenyl)-
acrylonitrile (4d)
A 1.0 M solution of boron tribromide in dichloromethane
(2.34 mL, 2.34 mmol) was added slowly to a solution of 4b
(138 mg, 0.46 mmol) in dichloromethane (2.3 mL) at 78 C under
nitrogen atmosphere. The reaction was allowed to stir at room
temperature for 4 h before cooling to 78 C and quenching with
an aqueous solution of saturated sodium bicarbonate (2 mL). The
reaction mixture was warmed to room temperature and the aque-
ous layer was extracted with ethyl acetate (3  2 mL). The com-
bined organic layers were washed with saturated sodium
bicarbonate (3  5 mL), water (1  5 mL), and brine (1  5 mL) be-
fore being dried over magnesium sulfate, filtered, and concen-
trated. The pure product was obtained in 80% yield after
purification by flash chromatography using 50% ethyl acetate 50%
hexanes. 1H NMR (400 MHz, CD3OD) d (ppm): 7.52 (2H, d,
J = 8.70), 7.42 (1H, s), 6.85 (2H, d, J = 8.70), 6.82 (2H, d, J = 2.02),
6.33 (1H, t, J = 2.02). 13C NMR (100 MHz, CD3OD) d (ppm):
159.85, 141.34, 137.32, 128.35, 127.07, 119.17, 116.86, 111.91,
108.56, 105.58. IR vmax 3216 (OH), 2227 (CN) cm1.
4.2.8. (E)-3-(3,5-Dihydroxyphenyl)-2-(4-
hydroxyphenyl)acrylaldehyde (4e)
A 1.0 M solution of tetrabutylammonium fluoride solution in
THF (0.15 mL, 0.15 mmol) was added to a solution of 5 (29 mg,
0.05 mmol) in THF (0.25 mL) at 0 C. The reaction was allowed to
stir overnight before quenching with saturated ammonium chlo-
ride. The aqueous layer was extracted with ethyl acetate
(3  3 mL) and the combined organic layers were washed with
brine, dried over magnesium sulfate, filtered and concentrated.
The pure product 4e was obtained in 15% yield after flash chroma-
tography using 50% ethyl acetate 50% hexanes. 1H NMR (400 MHz,
CD3OD:CDCl3 50:50) d (ppm): 9.44 (1H, s), 7.03 (1H, s), 6.81 (2H, d,
J = 8.59), 6.63 (2H, d, J = 8.59), 6.07 (2H, s). 13C NMR (100 MHz, CD3-
OD) d (ppm): 195.25, 157.48, 157.33, 151.12, 140.98, 135.65,
130.39, 123.78, 115.27, 109.10, 104.54. ESIMS(+) m/z 257 (M+H).
4.2.9. 3-(3,5-Bis((tert-butyldimethylsilyl)oxy)phenyl)-2-(4-
((tert-butyldimethylsilyl)oxy)phenyl)-acrylaldehyde (5)
Tert-Butyldimethylsilyl chloride (202 mg, 1.34 mmol) and imid-
azole (228 mg, 3.35 mmol) were added to a stirred solution of 4d
(94 mg, 0.37 mmol) in dimethylformamide (2 mL) at 0 C. The
reaction mixture was warmed to room temperature. After stirring
overnight, the reaction mixture was diluted with water and ex-
tracted with ethyl acetate (3  5 mL). The combined organic layers
were then washed with brine, dried over magnesium sulfate, fil-
tered and concentrated to yield the protected nitrile in 52% yield
after flash chromatography using 5% ethyl acetate 95% hexanes.
A 0.54 M solution of DIBAL-H in hexanes (0.31 mmol, 0.57 mL)
was added slowly to the protected nitrile (155 mg, 0.26 mmol) in
toluene (1.3 mL) at 0 C under nitrogen atmosphere. After 40 min
the reaction was quenched by addition of methanol (0.32 mL)
and water (0.31 mL), warmed to room temperature and stirred
for an additional 3 h. The reaction mixture was diluted with water
and the aqueous phase was extracted with ethyl acetate
(3  5 mL). The combined organic layers were washed with brine,
dried over magnesium sulfate, filtered and concentrated. Flash
chromatography using 5% ethyl acetate 95% hexanes yielded the
pure aldehyde product 5 in 80% yield. (Z)-5: 1H NMR (300 MHz,
CDCl3) d (ppm): 9.71 (1H, s), 7.20 (1H, s), 7.05 (2H, d, J = 8.41),
6.85 (2H, s, J = 8.41), 6.39 (2H, d, J = 2.18), 6.29 (1H, t, J = 2.18),
1.00 (12H, s), 0.92 (18H, s), 0.23 (6H, s), 0.08 (9H, s). (E)-5: 1H
NMR (300 MHz, CDCl3) d (ppm): 10.10 (1H, 1), 7.70 (1H, s), 7.39
(2H, d, J = 8.38), 6.94 (2H, d, J = 8.38), 6.50 (2H, d, J = 2.07), 6.41
(1H, t, J = 2.07), 1.00 (12H, s), 0.92 (18H, s), 0.23 (6H, s), 0.08 (9H,
s). 13C NMR (75 MHz, CDCl3) d (ppm): 192.46, 156.47, 145.57,




A 0.54 M solution of DIBAL-H in hexanes (0.7 mmol, 0.12 mL)
was added slowly to 5 (40 mg, 0.07 mmol) in toluene (.4 mL) at
78 C under nitrogen atmosphere. The reaction was allowed to
warm to room temperature and stirred for 4 h. The reaction was
quenched by addition of methanol (0.12 mL) and 0.1 N HCl
(0.12 mL) at 78 C. The reaction mixture was diluted with water
and the aqueous phase was extracted with ethyl acetate
(3  5 mL). The combined organic layers were washed with brine,
Figure 6. (A) Crystal structure of inhibitor 4k bound in the QR2 active site. QR2 is shown in grey surface representation and colored according to atom type; 4k is shown in
green ball and stick and colored according to atom. FAD and active site residue Asn161 are shown in grey ball and stick and colored according to atom. (B) Superposition of X-
ray structures of benzanilides 8a (shown in orange ball and stick) and 8d (shown in green ball and stick) in complex with QR2, where active site waters are shown as non-
bonding spheres, are colored according to ligand and are identical between the two compounds.
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dried over magnesium sulfate, filtered and concentrated. Flash
chromatography using 5% ethyl acetate 95% hexanes yielded the
pure protected alcohol in 55% yield.
The protected alcohol (15 mg, 0.04 mmol) was dissolved in
methanol (0.5 mL) and a catalytic amount of hydrochloric acid
was added. The reaction was allowed to stir until all of the starting
material had disappeared from TLC. The reaction mixture was then
concentrated. The residue was taken up in ethyl acetate and water,
and the aqueous phase was extracted with ethyl acetate (3). The
combined organic layers were washed with brine, dried over mag-
nesium sulfate, filtered and concentrated. The product 4f was ob-
tained in 35% yield after purification by flash chromatography
using 70% ethyl acetate 30% hexanes. 1H NMR (400 MHz, CD3OD)
d (ppm): 7.43 (2H, d, J = 8.64), 6.78 (2H, d, J = 8.64), 6.73 (1H, s),
6.37 (2H, d, J = 2.13), 6.19 (1H, t, J = 2.13), 4.59 (2H, s). 13C NMR
(100 MHz, CD3OD) d (ppm): 159.33, 158.05, 141.01, 140.74,
133.78, 130.22, 128.76, 116.09, 109.11, 108.50, 102.42, 101.57,
84.02, 60.22.
4.2.11. General procedure for nitrile reduction (4g, 4h)
A 0.54 M solution of DIBAL-H in hexanes (2.0 equiv) was added
slowly to a solution of the appropriate nitrile (1.0 equiv) in toluene
(0.2 M) at 78 C. The reaction mixture was stirred at that temper-
ature for 4 h before quenching with water and ethyl acetate. The
organic layer was washed (3) with dilute hydrochloric acid. The
combined aqueous layers were extracted with ethyl acetate (3)
and the combined organic layers were washed with brine, dried
over magnesium sulfate, filtered and concentrated. The desired




General procedure for nitrile reduction was used starting from
4b (67%). 1H NMR (400 MHz, CDCl3) d (ppm): 9.75 (1H, s), 7.28
(1H, s), 7.15 (2H, d, J = 8.71), 6.96 (2H, d, J = 8.71), 6.41 (3H, s),
3.83 (3H, s), 3.59 (6H, s). 13C NMR (100 MHz, CDCl3) d (ppm):
194.16, 160.36, 159.56, 149.81, 141.68, 135.80, 130.70, 125.30,
114.23, 108.37, 102.83, 55.23, 55.06.
4.2.13. (Z)-3-(3,5-Diisopropoxyphenyl)-2-(4-methoxyphenyl)acryl-
aldehyde (4h)
General procedure for nitrile reduction was used starting from
4c (80%). 1H NMR (300 MHz, CDCl3) d (ppm): 10.13 (1H, s), 7.73
(1H, s), 7.37 (2H, d, J = 8.77), 6.94 (2H, d, J = 8.77), 6.49 (3H), 4.54
(2H, m, J = 6.04), 3.84 (3H, s), 1.35 (12H, d, J = 6.04). 13C NMR
(75 MHz, CDCl3) d (ppm): 192.58, 159.69, 158.88, 145.96, 140.65,
135.82, 129.89, 128.43, 113.72, 109.81, 104.68, 70.07, 55.22, 21.94.
4.2.14. General procedure for aldehyde reduction (4i–4l)
Sodium borohydride (1.2 equiv) was added portion-wise to a
stirred solution of the appropriate aldehyde (1.0 equiv) in metha-
nol (0.2 M) at 0 C. The reaction mixture was concentrated under
reduced pressure after 30 min. The residue was dissolved in CH2Cl2
and extracted with H2O, and the aqueous layer was washed with
CH2Cl2 (3). The combined organic layers were washed with H2O
(3) and brine, dried over MgSO4, filtered and concentrated. Puri-
fication by flash chromatography afforded the pure alcohol prod-
ucts in 13–44% yield.
4.2.15. (Z)-3-(3,5-Dimethoxyphenyl)-2-(4-methoxyphenyl)prop-
2-en-1-ol (4i)
General procedure for aldehyde reduction as used from 4g
(13%). 1H NMR (300 MHz, CDCl3) d (ppm): 7.53 (2H, d, J = 8.82),
6.94 (2H, d, J = 8.82), 6.85 (1H, s), 6.57 (2H, d, J = 2.16), 6.42 (1H,
t, J = 2.16), 4.70 (2H, s), 3.84 (3H, s), 3.82 (6H, s). 13C NMR
(100 MHz, CDCl3) d (ppm): 160.63, 159.32, 139.94, 139.00,
132.70, 129.62, 127.68, 114.01, 106.80, 99.44, 60.39, 55.29.
4.2.16. (Z)-3-(3,5-Diisopropoxyphenyl)-2-(4-methoxyphenyl)-
prop-2-en-1-ol (4j)
General procedure for aldehyde reduction was used from 4h
(27%). 1H NMR (400 MHz, CDCl3) d (ppm): 7.52 (2H, d, J = 8.71),
6.93 (2H, d, J = 8.71), 6.82 (1H, s), 6.53 (2H, d, J = 2.16), 6.39 (1H,
t, J = 2.16), 4.70 (2H, s), 4.54 (2H, m, J = 6.07), 3.84 (3H, s), 1.34
(12H, d, J = 6.07). 13C NMR (100 MHz, CDCl3) d (ppm): 159.25,
158.92, 139.60, 138.86, 132.80, 129.84, 127.66, 113.98, 108.49,
102.90, 69.87, 60.39, 55.25, 22.03.
4.2.17. (E)-3-(3,5-Dimethoxyphenyl)-2-(4-methoxyphenyl)prop-
2-en-1-ol (4k)
General procedure for aldehyde reduction was used from 4g
(35%). 1H NMR (300 MHz, CDCl3) d (ppm): 7.17 (2H, d, J = 8.77),
6.88 (2H, d, J = 8.77), 6.59 (1H, s), 6.24 (1H, t, J = 2.23), 6.20 (2H,
d, J = 2.23), 4.43 (2H, s), 3.80 (3H, s), 3.56 (6H, s). 13C NMR
(75 MHz, CDCl3) d (ppm): 160.05, 158.97, 141.52, 138.37, 130.47,
129.86, 126.01, 114.09, 106.98, 99.50, 68.36, 55.17, 54.88.
4.2.18. (E)-3-(3,5-Diisopropoxyphenyl)-2-(4-
methoxyphenyl)prop-2-en-1-ol (4l)
General procedure for aldehyde reduction was used from 4h
(44%). 1H NMR (300 MHz, CDCl3) d (ppm): 7.17 (2H, d, J = 8.63),
6.88 (2H, d, J = 8.63), 6.56 (1H, s), 6.21 (1H, t, J = 2.02), 6.16 (2H,
d, J = 2.02), 4.41 (2H, s), 4.19 (2H, m, J = 6.05), 1.17 (12H, d, J = 6.05).
4.2.19. (E)-Methyl 3-(3,5-diisopropoxyphenyl)-2-(4-
methoxyphenyl)acrylate (4m)
To a stirred solution of 4h (64 mg, 0.18 mmol) in methanol
(1.8 mL) was added potassium cyanide (59 mg, 0.91 mmol) and
manganese dioxide (317 mg, 3.65 mmol). After six days, the reac-
tion mixture was diluted with dichloromethane and filtered
through a celite pad. The combined organic layers were washed
with brine, dried over magnesium sulfate, filtered and concen-
trated. Flash chromatography using 10% ethyl acetate 90% hexanes
afforded the pure product in 17% yield. 1H NMR (300 MHz, CDCl3) d
(ppm): 7.72 (1H, s), 7.16 (2H, d, J = 8.70), 6.92 (2H, d, J = 8.70), 6.29
(1H, t, J = 2.22), 6.20 (2H, d, J = 2.22), 4.16 (2H, m, J = 6.06), 3.81
(3H, s), 3.79 (3H, s), 1.17 (12H, d, J = 6.06).
4.2.20. (Z)-Methyl 3-(3,5-diisopropoxyphenyl)-2-(4-
methoxyphenyl)acrylate (4n)
See procedure for 4o (34%). 1H NMR (400 MHz, CDCl3) d (ppm):
7.37 (2H, d, 8.86), 6.91 (2H, d, J = 8.86), 6.85 (1H, s), 6.49 (2H, d,
J = 2.11), 6.38 (1H, t, J = 2.11), 4.50 (2H, m, J = 6.07), 3.83 (3H, s),
3.80 (3H, s), 1.33 (12H, d, J = 6.07). 13C NMR (100 MHz, CDCl3) d
(ppm): 170.24, 159.71, 159.02, 137.48, 134.37, 129.44, 129.23,
127.52, 114.06, 107.71, 104.14, 69.92, 55.26, 52.17, 22.03, 21.90.
4.2.21. (Z)-Methyl 3-(2-chloro-3,5-diisopropoxyphenyl)-2-(4-
methoxyphenyl)acrylate (4o)
Sodium chlorite (66 mg, 0.73 mmol) in water (0.73 mL) was
added drop-wise to a mixture of 4h (185 mg, 0.52 mmol) in aceto-
nitrile (0.54 mL), monosodium phosphate (108 mg, 0.78 mmol) in
water (0.25 mL) and 30% hydrogen peroxide (0.07 mL) at 0 C.
The reaction was then allowed to stir for 48 h at room temperature
before addition of a saturated solution of sodium thiosulfate. The
aqueous phase was then extracted with ethyl acetate (3  5 mL).
The combined organic layers were washed with brine, dried over
magnesium sulfate, filtered and concentrated to afford an
inseparable mixture of (Z)-3-(3,5-diisopropoxyphenyl)-2-(4-
methoxyphenyl)acrylic acid and (Z)-3-(2-chloro-3,5-diisopropoxy-
phenyl)-2-(4-methoxyphenyl)acrylic acid in 81–88% yield.
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The above mixture of acids was dissolved in methanol (2.33 mL)
and a catalytic amount of concentrated sulfuric acid was added.
The reaction mixture was then refluxed for 48 h, cooled to room
temperature and concentrated. The residue was taken up in ethyl
acetate and water, and the aqueous layer was extracted with ethyl
acetate (3  8 mL). The combined organic layers were washed with
brine, dried over magnesium sulfate, filtered and concentrated to
yield a mixture of 4o and 4n, which were separated by flash chro-
matography using 49% petroleum ether, 49% toluene, 1% t-butanol
to yield 4o in 34% yield and 4n in 14% yield. 1H NMR (400 MHz,
CDCl3) d (ppm): 7.42 (2H, d, J = 8.84), 7.15 (1H, s), 6.92 (2H, d,
J = 8.84), 6.55 (1H, d, J = 2.63), 6.47 (1H, d, J = 2.63), 4.51 (1H, m,
J = 6.03), 4.46 (1H, m, J = 6.05), 3.83 (3H, s), 3.71 (3H, s), 1.39 (6H,
d, J = 6.05), 1.33 (6H, d, J = 6.03). 13C NMR (100 MHz, CDCl3) d
(ppm): 169.70, 159.88, 156.63, 154.38, 136.10, 135.85, 128.97,
127.97, 127.73, 115.50, 114.03, 106.95, 104.71, 71.99, 70.39,




A 1.0 M solution of boron tribromide in dichloromethane
(0.60 mL, 0.60 mmol) was added slowly to a solution of 4o
(50 mg, 0.12 mmol) in dry dicholormethane (0.60 mL) at 78 C.
The reaction was gradually allowed to warm to room temperature.
After 6 h the reaction mixture was cooled to 78 C and quenched
with saturated sodium bicarbonate. The aqueous layer was ex-
tracted with ethyl acetate (3  5 mL) and the combined organic
layers were washed with brine, dried over magnesium sulfate, fil-
tered and concentrated. The pure product was obtained in 10%
yield after flash chromatography using 50% ethyl acetate 50% hex-
anes. 1H NMR (400 MHz, CD3OD) d (ppm): 7.80 (1H, s), 6.94 (2H, d,
J = 8.67), 6.69 (2H, d, J = 8.67), 6.26 (1H, d, J = 2.70), 5.84 (1H, d,
J = 2.70). 13C NMR (100 MHz, CD3OD) d (ppm): 170.02, 158.35,
157.17, 155.04, 137.90, 136.51, 135.48, 132.47, 128.87, 115.98,
112.88, 110.09, 104.76, 52.77.
4.2.23. (Z)-3-(3,5-Dimethoxyphenyl)-2-(4-methoxyphenyl)-
acrylamide (4q)
A mixture of 2b (45 mg, 0.15 mmol), acetaldoxime (0.02 mL,
0.30 mmol), palladium acetate (3 mg, 0.02 mmol), and triphenyl-
phosphine (8 mg, 0.03 mmol) in aqueous ethanol (0.5 mL, 1:4
water:ethanol) was heated to reflux for 3 h under nitrogen atmo-
sphere. The reaction mixture was diluted with ethanol, filtered
through a celite pad, washed with dichloromethane, and the com-
bined organic layers were concentrated. The pure product was ob-
tained in 92% yield after purification by flash chromatography
using 40% ethyl acetate 60% hexanes. 1H NMR (300 MHz, CDCl3)
d (ppm): 7.34 (2H, d, J = 8.91), 6.79 (2H, d, J = 8.91), 6.70 (1H, s),
6.57 (2H, d, J = 2.06), 6.28 (1H, t, J = 2.06), 3.86 (2H, s), 3.71 (3H,
s), 3.66 (6H, s). 13C NMR (100 MHz, CDCl3) d (ppm): 173.13,




A 1.0 M solution of boron tribromide in dichloromethane
(0.94 mL, 0.94 mmol) was added slowly to a solution of 4q
(50 mg, 0.13 mmol) in dry dicholormethane (0.60 mL) at 78 C.
The reaction was gradually allowed to warm to room temperature.
After 4 h the reaction mixture was cooled to 78 C and quenched
with saturated sodium bicarbonate. The aqueous layer was ex-
tracted with ethyl acetate (3  5 mL) and the combined organic
layers were washed with brine, dried over magnesium sulfate, fil-
tered and concentrated. The pure product was obtained in quanti-
tative yield after flash chromatography using 60% ethyl acetate 40%
hexanes. 1H NMR (400 MHz, CD3OD) d (ppm): 7.38(2H, d, J = 8.66),
6.79 (2H, d, J = 8.66), 6.70 (1H, s), 6.52 (2H, s), 6.19 (1H, s). 13C NMR
(100 MHz, CD3OD) d (ppm): 175.86, 159.43, 158.82, 139.17,
138.47, 130.03, 128.45, 126.91, 116.43, 108.12, 103.31.
4.2.25. 3-(3,5-Dimethoxyphenyl)-2-(4-methoxyphenyl)propan-
1-amine (4s)
To a mixture of 4b (20 mg, 0.07 mmol) cobalt chloride hexahy-
drate (32 mg, 0.14 mmol) in anhydrous methanol (0.5 mL) was
added sodium borohydride (26 mg, 0.68 mmol) portionwise. After
stirring overnight a second portion of sodium borohydride was
added. After 1 h, an aqueous solution of 3 N HCl was added to
the reaction mixture until it because clear in appearance. The
aqueous layer was then extracted with ether (3) to remove any
remaining nitrile. The aqueous layer was then made alkaline using
ammonium hydroxide (pH 10) and extracted with ethyl acetate
(3  5 mL). The combined organic layers were washed with brine,
dried over magnesium sulfate, filtered and concentrated. The pure
product was obtained in 64% yield after purification by flash chro-
matography using 5% methanol 95% dichloromethane. 1H NMR
(400 MHz, CDCl3) d (ppm): 7.09 (2H, d, J = 8.57), 6.84 (2H, d,
J = 8.57), 6.26 (1H, t, J = 2.17), 6.21 (2H, d, J = 2.17), 3.78 (3H, s),
3.71 (6H, s), 2.96-2.81 (5H, m). 13C NMR (100 MHz, CDCl3) d
(ppm): 160.42, 158.22, 142.46, 134.57, 128.82, 113.89, 107.01,
97.93, 55.11, 49.88, 46.82, 41.15.
4.2.26. (Z)-Methyl (2-(3,5-dimethoxyphenyl)-1-(4-
methoxyphenyl)vinyl)carbamate (4t)
Potassium hydroxide (14 mg, 0.26 mmol) was added to 4q
(32 mg, 0.10 mmol) in anhydrous methanol (1.25 mL) at room
temperature under nitrogen atmosphere. Once a clear reaction
mixture was obtained, (diacetoxyiodo)benzene (33 mg,
0.10 mmol) was added in one portion. The reaction mixture was
concentrated after 3 h and the crude residue as taken up in water
and dichloromethane. The aqueous phase was extracted with
dichloromethane (3  5 mL) and the combined organic layers were
washed with brine, dried over magnesium sulfate, filtered and con-
centrated. The pure product was obtained in 86% yield after purifi-
cation by flash chromatography using 30% ethyl acetate 70%
hexanes. 1H NMR (400 MHz, CDCl3) d (ppm): 7.44 (2H, d,
J = 8.80), 6.91 (2H, d, J = 8.80), 6.58 (2H, d, J = 2.20), 6.37 (1H, t,
J = 2.20), 6.20 (1H, s), 3.83 (3H, s), 3.78 (6H, s), 3.67 (3H, s). 13C
NMR (100 MHz, CDCl3) d (ppm): 160.84, 159.85, 154.67, 137.66,
135.13, 130.56, 127.38, 118.19, 113.72, 106.30, 99.55, 55.20, 52.51.
4.2.27. 2-(3,5-Dimethoxyphenyl)-1-(4-methoxyphenyl)-
ethanimine (4u)
A 1.0 M solution of boron tribromide in dichloromethane
(0.66 mL, 0.66 mmol) was added slowly to a solution of 4t
(30 mg, 0.09 mmol) in dichloromethane (0.5 mL) at 78 C under
nitrogen atmosphere. The reaction was allowed to stir at room
temperature for 4 h before cooling to 78 C and quenching with
an aqueous solution of saturated sodium bicarbonate (2 mL). The
reaction mixture was warmed to room temperature and the aque-
ous layer was extracted with ethyl acetate (3  2 mL). The com-
bined organic layers were washed with saturated sodium
bicarbonate (3  5 mL), water (1  5 mL), and brine (1  5 mL) be-
fore being dried over magnesium sulfate, filtered, and concen-
trated. The pure product was obtained in 77% yield after
purification by flash chromatography using 30% ethyl acetate 70%
hexanes. 1H NMR (400 MHz, CDCl3) d (ppm): 7.99 (2H, d,
J = 8.97), 6.92 (2H, d, J = 8.97), 6.43 (2H, d, J = 2.26), 6.34 (1H, t,
J = 2.26), 4.15 (2H, s), 3.85 (3H, s), 3.76 (6H, s). 13C NMR
(100 MHz, CDCl3) d (ppm): 195.94, 163.45, 160.83, 137.07,
130.90, 129.50, 113.70, 107.32, 98.76, 55.37, 55.20, 45.53.
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4.2.28. General benzanilide synthesis, Method A
The benzoyl chloride was prepared by stirring benzoic acid
(1.0 mmol) with SOCl2 (0.363 mL, 5.0 mmol) and DMF (1 drop) in
CH2Cl2 (5 ml) for overnight and evaporating the volatile materials
under reduced pressure. To the solution of benzoyl chloride in CH2-
Cl2 (5 mL) were added an aniline (1.0 mmol) and DIEA (0.871 mL,
5.0 mmol), and the reaction was stirred until no starting material
by TLC (1–24 h) at room temperature. After dilution with CH2Cl2
(30 mL), the organic layer was washed with brine (40 mL), dried
with anhydrous MgSO4, and evaporated to dryness under reduced
pressure. The residue was purified by flash column chromatogra-
phy to obtain a benzanilide.
4.2.29. General benzanilide synthesis, Method B
To the solution of benzoic acid (1.0 mmol) in CH2Cl2 (5 ml) were
added EDC (192 mg, 1.0 mmol) and DIEA (0.523 mL, 3.0 mmol),
and stirred for 5 min at room temperature. To the solution of acti-
vated benzoic acid was added an aniline (1.0 mmol) and the reac-
tion was stirred for overnight at room temperature. After dilution
with CH2Cl2 (35 mL), the organic layer was washed with brine
(40 mL), dried with anhydrous MgSO4, and evaporated to dryness
under reduced pressure. The residue was purified by flash column
chromatography to obtain a benzanilide.
4.2.30. General benzanilide synthesis, Method C
To the solution of secondary amide (0.5 mmol) in THF (5 ml)
were added NaH (25 mg, 60% in oil, 0.6 mmol) and stirred for
30 min at 0 C. MeI (0.062 mL, 1 mmol) was added dropwise to
the solution, and the reaction was stirred for overnight at room
temperature. After dilution with CH2Cl2 (40 mL), the organic layer
was washed with brine (40 mL), dried with anhydrous MgSO4, and
evaporated to dryness under reduced pressure. The residue was
purified by flash column chromatography to obtain a benzanilide.
4.2.31. General benzanilide deprotection, Method D
If R1 or R2 were protected by TBS, that were deprotected before
final column purification by TBAF treatment; the product was dis-
solved in THF (5 mL), and TBAF (1.0 mmol per protecting group)
was added and stirred for 20 min. After dilution with CH2Cl2
(30 mL), the organic layer was washed with brine (40 mL), dried
with anhydrous MgSO4, and evaporated to dryness under reduced
pressure.
4.2.32. N-(3,5-Dihydroxyphenyl)-4-hydroxybenzamide (8a)
Method B and D were used in combination with 3,5-bis(tert-
butyldimethylsilyloxy)benzoic acid and 4-(tert-butyldimethylsilyl-
oxy)aniline (79%). 1H NMR (300 MHz, (CD3)2CO) d (ppm): 7.69 (2H,
d, J = 8.7), 7.04 (2H, d, J = 1.8), 6.91 (2H, d, J = 8.7), 6.62 (1H, t,
J = 1.8). 13C NMR (75 MHz, (CD3)2CO) d (ppm): 206.88, 166.03,
158.68, 154.13, 137.68, 131.11, 122.52, 115.25, 106.12. ESIMS(+)
m/z 246 (M+H), 268 (M+Na), 284 (M+K).
4.2.33. 3,5-Dihydroxy-N-(4-hydroxyphenyl)-N-methylbenza-
mide (8b)
Method C and D were used starting from TBS protected form of
8a (38%). 1H NMR (300 MHz, (CD3)2CO) d (ppm): 7.05 (2H, d,
J = 8.1), 6.80 (2H, d, J = 8.1), 6.38 (2H, s), 6.32 (1H, s), 3.40 (3H, s).
13C NMR (75 MHz, (CD3)2CO) d (ppm): 205.98, 157.95, 155.98,
138.69, 136.84, 128.13, 115.67, 107.13, 103.57, 37.96. ESIMS(+)
m/z 260 (M+H), 282 (M+Na).
4.2.34. N-(4-Hydroxyphenyl)-3,5-dimethoxybenzamide (8c)
Method A and Dwere used in combination with 3,5-dimethoxy-
benzoic acid and 4-(tert-butyldimethylsilyloxy)aniline (90%). 1H
NMR (300 MHz, (CD3)2CO) d (ppm): 7.70 (2H, d, J = 8.7), 7.20 (2H,
d, J = 2.4), 6.91 (2H, d, J = 8.7), 6.72 (1H, t, J = 2.4), 3.89 (6H, s).
13C NMR (75 MHz, (CD3)2CO) d (ppm): 165.05, 161.01, 154.07,
137.68, 131.25, 122.32, 115.14, 105.31, 103.23, 55.06. ESIMS(+)
m/z 274 (M+H), 296 (M+Na), 312 (M+K).
4.2.35. N-(3,5-Dihydroxyphenyl)-4-hydroxybenzamide (8d)
Method B and D were used in combination with 4-(tert-butyldi-
methylsilyloxy)benzoic acid and 3,5-bis(tert-butyldimethylsilyl-
oxy)aniline (41%). 1H NMR (300 MHz, CD3OD) d (ppm): 7.86 (2H,
d, J = 9.0), 6.93 (2H, d, J = 9.0), 6.78 (2H, d, J = 1.8), 6.16 (1H, t,
J = 1.8). 13C NMR (75 MHz, CD3OD) d (ppm): 167.40, 160.89,
158.28, 140.20, 129.34, 125.78, 114.77, 99.75, 98.54. ESIMS(+) m/
z 246 (M+H), 268 (M+Na), 284 (M+K).
4.2.36. N-(3,5-Dihydroxyphenyl)-4-hydroxy-N-methylb-
enzamide (8e)
Method B and D were used in combination with 4-(tert-butyldi-
methylsilyloxy)benzoic acid and N-methyl 3,5-bis(tert-butyldi-
methylsilyloxy) aniline (11%). 1H NMR (300 MHz, CD3OD) d
(ppm): 7.31 (2H, d, J = 9.0), 6.69 (2H, d, J = 9.0), 6.19 (1H, t,
J = 1.8), 6.12 (2H, d, J = 1.8), 3.45 (3H, s). 13C NMR (75 MHz, CD3OD)
d (ppm): 171.34, 159.24, 158.82, 146.61, 130.44, 126.39, 114.12,
105.48, 100.87, 37.74. ESIMS(+) m/z 260 (M+H), 282 (M+Na), 298
(M+K).
4.2.37. N-(4-(Dimethylamino)phenyl)-4-hydroxybenzamide (8f)
Method B and D were used in combination with 4-(tert-butyldi-
methylsilyloxy)benzoic acid and 4-(N,N-dimethylamino)aniline
(46%). 1H NMR (300 MHz, CD3OD) d (ppm): 7.87 (2H, d, J = 9.6),
7.53 (2H, d, J = 9.6), 6.92 (2H, d, J = 8.7), 6.87 (2H, d, J = 8.7), 2.98
(6H, s). 13C NMR (75 MHz, CD3OD) d (ppm): 167.18, 161.34,
148.35, 129.17, 128.64, 125.35, 122.72, 114.94, 113.09, 40.04.
ESIMS(+) m/z 257 (M+H), 279 (M+Na), 295 (M+K).
4.2.38. N-(4-(Dimethylamino)phenyl)-4-methoxy-N-
methylbenzamide (8g)
Method C was used starting from 8f (12%). 1H NMR (300 MHz,
CDCl3) d (ppm): 7.34 (2H, d, J = 9), 6.96 (2H, d, J = 8.7), 6.73 (2H,
d, J = 8.7), 6.61 (2H, d, J = 9), 3.78 (3H, s), 3.48 (3H, s), 2.96 (6H,
s). 13C NMR (75 MHz, CDCl3) d (ppm): 170.30, 160.28, 148.85,
134.51, 130.88, 128.47, 127.60, 112.89, 112.61, 55.20, 40.57,
38.94. ESIMS(+) m/z 285 (M+H), 307 (M+Na).
4.2.39. N-(4-(Dimethylamino)phenyl)-3,5-dimethoxybenzamide
(8h)
Method A was used in combination with 3,5-hydroxybenzoic
acid and 4-(N,N-dimethylamino)aniline (9%). 1H NMR (300 MHz,
(CD3)2SO) d (ppm): 9.87 (1H, s), 9.60 (2H, s), 7.62 (2H, d, J = 8.7),
6.82 (2H, s), 6.76 (2H, d, J = 8.7), 6.41 (1H, s), 2.91 (6H, s). 13C
NMR (75 MHz, (CD3)2SO) d (ppm): 165.56, 158.79, 147.73,
138.02, 129.57, 122.18, 112.97, 106.18, 105.62, 40.26. ESIMS(+)
m/z 273 (M+H), 295 (M+Na), 311 (M+K).
4.2.40. N-(4-(Bimethylamino)phenyl)-3,5-dimethoxybenzamide
(8i)
Method A was used in combination with 3,5-dimethoxybenzoic
acid and 4-(N,N-dimethylamino)aniline (83%). 1H NMR (300 MHz,
CDCl3) d (ppm): 8.51 (1H, s), 7.54 (2H, d, J = 8.7), 7.03 (2H, d,
J = 2.4), 6.71 (2H, d, J = 8.7), 6.58 (1H, t, J = 2.4), 3.77 (6H, s), 2.95
(6H, s). 13C NMR (75 MHz, CDCl3) d (ppm): 165.78, 160.78,
148.09, 137.51, 127.97, 122.38, 112.95, 105.03, 103.71, 55.51,
40.91. ESIMS(+) m/z 301 (M+H), 323 (M+Na), 339 (M+K).
4.2.41. N-(4-(Dimethylamino)phenyl)-3,5-dimethoxy-N-
methylbenzamide (8j)
Method C was used from 8i (67%). 1H NMR (300 MHz, CDCl3) d
(ppm): 6.97 (2H, d, J = 9.0), 6.61 (2H, d, J = 9.0), 6.54 (2H, d, J = 1.8),
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6.38 (1H, t, J = 1.8), 3.70 (6H, s), 3.49 (3H, s), 2.96 (6H, s). 13C NMR
(75 MHz, CDCl3) d (ppm): 170.44, 159.97, 149.10, 138.21, 133.94,
127.52, 112.64, 106.71, 102.28, 55.37, 40.60, 38.66. ESIMS(+) m/z
315 (M+H), 337 (M+Na), 353 (M+K).
4.2.42. N-(3,5-Dihydroxyphenyl)-4-(dimethylamino)benzamide
(8k)
Method A and D were used in combination with 4-(N,N-dimeth-
ylamino)benzoic acid and 3,5-bis(tert-butyldimethylsilyloxy)ani-
line (54%). 1H NMR (300 MHz, (CD3)2SO) d (ppm): 7.88 (2H, d,
J = 8.7), 6.80 (2H, s), 6.78 (2H, d, J = 8.7), 5.98 (1H, s), 3.04 (6H, s).
13C NMR (75 MHz, (CD3)2SO) d (ppm): 165.56, 158.62, 152.78,
141.55, 129.62, 121.93, 111.23, 99.19, 98.29, 40.26. ESIMS(+) m/z
273 (M+H), 295 (M+Na), 311 (M+K).
4.2.43. N-(3,5-Dihydroxyphenyl)-4-(dimethylamino)-N-
methylbenzamide (8l)
Method A and D were used in combination with 4-(N,N-dimeth-
ylamino)benzoic acid and N-methyl-3,5-bis(tert-butyldimethylsi-
lyloxy)aniline (69%). 1H NMR (300 MHz, CD3OD) d (ppm): 7.34
(2H, d, J = 8.7), 6.53 (2H, d, J = 8.7), 6.21 (1H, t, J = 2.4), 6.16 (2H,
d, J = 2.4), 3.42 (3H, s), 2.91 (6H, s). 13C NMR (75 MHz, CD3OD) d
(ppm): 171.82, 158.82, 151.80, 147.14, 130.41, 121.70, 110.33,




Method A and D were used in combination with 4-(N,N-dimeth-
ylamino)benzoic acid and 4-(tert-butyldimethylsilyloxy)aniline
(81%). 1H NMR (300 MHz, (CD3)2SO) d (ppm): 7.91 (2H, d, J = 8.7),
7.59 (2H, d, J = 8.1), 6.80 (4H, d, J = 8.7), 3.05 (6H, s). 13C NMR
(75 MHz, (CD3)2SO) d (ppm): 165.24, 153.79, 152.70, 131.73,
129.45, 122.60, 121.93, 115.39, 111.29, 40.26. ESIMS(+) m/z 257
(M+H), 279 (M+Na), 295 (M+K).
4.2.45. 4-(Dimethylamino)-N-(4-hydroxyphenyl)-N-methylb-
enzamide (8n)
Method C and D was used from TBS protected 8m (51%). 1H
NMR (300 MHz, (CD3)2SO) d (ppm): 7.16 (2H, d, J = 8.7), 6.98 (2H,
d, J = 9.0), 6.70 (2H, d, J = 8.7), 6.52 (2H, d, J = 9.0), 3.13 (3H, s),
2.92 (6H, s). 13C NMR (75 MHz, (CD3)2SO) d (ppm): 169.85,
155.93, 151.21, 137.65, 130.86, 128.53, 122.97, 116.17, 110.76,
40.60, 40.32.
4.2.46. 3,5-Dihydroxy-N-(naphthalen-2-yl)benzamide (8o)
Method A and D was used in combination with 3,5-bis(tert-
butyldimethylsilyloxy)benzoic acid and 2-naphthyl amine (43%).
1H NMR (300 MHz, (CD3)2CO) d (ppm): 8.57 (1H, s), 7.94–7.85
(4H, m), 7.52–7.40 (4H, m), 7.05 (2H, d, J = 1.8), 6.63 (1H, t,
J = 1.8). 13C NMR (75 MHz, (CD3)2CO) d (ppm): 166.28, 158.99,
137.90, 137.28, 134.25, 130.86, 128.55, 127.80, 126.62, 125.02,
120.97, 116.88, 106.38, 105.98. ESIMS(+) m/z 280 (M+H), 302
(M+Na), 318 (M+K).
4.2.47. 3,5-Dimethoxy-N-(naphthalen-2-yl)benzamide (8p)
Method A was used in combination with 3,5-dimethoxybenzoic
acid and 2-naphthlamine (87%). 1H NMR (300 MHz, CDCl3) d
(ppm): 8.31 (1H, s), 7.78–7.62 (4H, m), 7.46–7.38 (2H, m), 7.02
(2H, d, J = 2.4), 6.55 (1H, t, J = 2.4), 3.74 (6H, s). 13C NMR
(75 MHz, CDCl3) d (ppm): 137.15, 135.57, 133.86, 130.83, 128.75,
127.80, 127.63, 126.51, 125.19, 120.50, 117.44, 108.20, 107.13,




Method A was used in combination with 3,5-dimethoxybenzoic
acid and N-methyl 2-naphthlamine (91%). 1H NMR (300 MHz,
CDCl3) d (ppm): 7.81–7.12 (3H, m), 7.56 (1H, d, J = 1.8), 7.49–7.46
(2H, m), 7.26 (1H, dd, J = 1.8, 8.7), 6.58 (2H, d, J = 2.4), 6.33 (1H, t,
J = 2.4), 3.61 (3H, s), 3.57 (6H, s). 13C NMR (75 MHz, CDCl3) d
(ppm): 170.50, 160.14, 142.34, 137.71, 133.47, 131.64, 129.20,
127.74, 126.76, 126.34, 125.21, 124.74, 106.83, 102.39, 55.25,
38.66. ESIMS(+) m/z 322 (M+H), 344 (M+Na), 360 (M+K).
4.2.49. N-(3,5-Dihydroxyphenyl)-2-naphthamide (8r)
Method A and D were used in combination with 2-naphtoic acid
and 3,5-bis(tert-butyldimethylsilyloxy)aniline (61%). 1H NMR
(300 MHz, CD3OD) d (ppm): 8.51 (1H, s), 8.09–7.99 (4H, m), 7.66
(2H, m), 6.87 (2H, d, J = 2.1), 6.19 (1H, t, J = 2.1). 13C NMR
(75 MHz, CD3OD) d (ppm): 167.66, 158.42, 140.06, 134.96,
132.65, 132.32, 128.84, 128.11, 127.85, 127.66, 127.52, 126.59,
123.89, 99.92, 99.11. ESIMS(+) m/z 280 (M+H), 302 (M+Na), 318
(M+K).
4.2.50. N-(3,5-Dihydroxyphenyl)-N-methyl-2-naphthamide (8s)
Method A and D were used in combination with 2-naphtoic acid
and N-methyl 3,5-bis(tert-butyldimethylsilyloxy) aniline (32%). 1H
NMR (300 MHz, (CD3)2CO) d (ppm): 8.09 (1H, s), 7.91–7.87 (2H, m),
7.80 (1H, d, J = 8.7), 7.61–7.52 (3H, m), 6.32 (3H, s), 3.51 (3H, s). 13C
NMR (75 MHz, (CD3)2CO) d (ppm): 170.13, 158.99, 146.69, 134.09,
133.75, 132.54, 128.75, 128.64, 127.71, 127.29, 127.24, 126.56,
125.49, 106.07, 101.35, 37.88. ESIMS(+) m/z 294 (M+H), 316
(M+Na), 332 (M+K).
4.2.51. 3,4-Dihydroxy-N-(4-hydroxyphenyl)benzamide (8t)
Method B and D were used in combination with 3,4-bis(tert-
butyldimethylsilyloxy)benzoic acid and 4-(tert-butyldimethylsilyl-
oxy)aniline (26%). 1H NMR (300 MHz, CD3OD) d (ppm): 7.47 (2H, d,
J = 8.7), 7.45 (1H, d, J = 2.4), 7.22 (1H, dd, J = 2.4, 8.4), 6.91 (1H, d,
J = 8.4), 6.85 (2H, d, J = 8.7). 13C NMR (75 MHz, CD3OD) d (ppm):
167.41, 154.21, 148.94, 145.01, 130.38, 127.38, 126.22, 123.16,




Method C and D were used starting from 8t (58%). 1H NMR
(300 MHz, CD3OD) d (ppm): 6.99 (2H, d, J = 8.7), 6.86 (1H, d,
J = 1.8), 6.75 (2H, d, J = 8.7), 6.71–6.61 (2H, m), 3.44 (3H, s). 13C
NMR (75 MHz, CD3OD) d (ppm): 171.87, 156.01, 147.00, 144.33,
136.78, 127.80, 127.01, 121.12, 115.89, 115.44, 113.98, 37.99.
ESIMS(+) m/z 260 (M+H), 282 (M+Na).
4.2.53. (Z)-Methyl N-(3,5-dihydroxyphenyl)-2-naphthimidate
(8v)
Compound 8v was prepared by O-methylation of 8r; 8r
(200 mg, 0.39 mmol) was stirred with SOCl2 (5 mL) for 3 h, and vol-
atile materials were removed by evaporation under reduced pres-
sure. MeOH (5 mL) was added to the residue and continued the
stirring for 1 h. After evaporation, method D was used to deprotect
TBS group and purified by flash column chromatography (ethyl
acetate only) to obtain a benzanilide (41 mg, 36%). 1H NMR
(300 MHz, (CD3)2SO) d (ppm): 8.59 (1H, s), 8.15–8.02 (4H, m),
7.71–7.67 (2H, m), 6.87 (2H, d, J = 2.1), 6.05 (1H, t, J = 2.1), 3.42
(3H, s). 13C NMR (75 MHz, (CD3)2SO) d (ppm): 207.05, 165.98,
158.79, 141.10, 134.70, 133.10, 132.57, 129.45, 128.39, 128.16,
127.32, 125.07, 99.33, 98.91, 31.22. ESIMS(+) m/z 332 (M+K).
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4.2.54. N-(3,5-Dihydroxyphenyl)-3,4-dimethoxybenzamide (8w)
Method A and Dwere used in combination with 3,4-dimethoxy-
aniline and 3,5-bis(tert-butyldimethylsilyloxy)benzoic acid (71%).
1H NMR (300 MHz, (CD3)2CO) d (ppm): 7.65 (1H, dd, J = 1.8, 8.4),
7.62 (1H, d, J = 1.8), 7.08 (1H, d, J = 8.4), 7.03 (2H, d, J = 2.4), 6.22
(1H, t, J = 2.4), 3.93 (6H, s). 13C NMR (75 MHz, (CD3)2CO) d (ppm):
165.30, 158.62, 152.30, 149.10, 141.13, 127.77, 120.72, 111.06,




Method A and Dwere used in combination with 3,4-dimethoxy-
benzoic acid and N-methyl 3,5-bis(tert-butyldimethylsilyloxy)ani-
line (64%). 1H NMR (300 MHz, CD3OD) d (ppm): 7.14 (1H, d), 7.01
(1H, d), 6.86 (1H, d), 6.21 (1H, s), 6.15 (2H, s), 3.83 (3H, s), 3.70
(3H, s), 3.46 (3H, s). 13C NMR (75 MHz, CD3OD) d (ppm): 170.80,
159.04, 150.70, 147.95, 146.61, 127.71, 122.32, 112.22, 110.22,
105.51, 101.01, 54.92, 37.65. ESIMS(+) m/z 304 (M+H), 326
(M+Na), 342 (M+K).
4.2.56. 3,4-Dihydroxy-N-(naphthalen-2-yl)benzamide (8y)
Method B and D were used in combination with 3,4-bis(tert-
butyldimethylsilyloxy)benzoic acid and 2-naphtyl amine (77%).
1H NMR (300 MHz, (CD3)2SO) d (ppm): 8.30 (1H, d, J = 1.8), 7.88–
7.45 (4H, m), 7.55–7.43 (4H, m), 6.96 (1H, d, J = 8.1). 13C NMR
(75 MHz, CD3OD) d (ppm): 167.72, 149.24, 145.12, 136.22,
133.89, 130.86, 128.08, 127.26, 126.17, 126.06, 124.74, 120.95,
119.85, 117.63, 114.83, 114.63. ESIMS(+) m/z 318 (M+K).
4.2.57. 3,4-Dimethoxy-N-(naphthalen-2-yl)benzamide (8z)
Method A was used in combination with 3,4-dimethoxybenzoic
acid and 2-naphtyl amine (99%). 1H NMR (300 MHz, CDCl3) d
(ppm): 7.76 (3H, m), 7.70 (1H, m), 7.55 (2H, m), 7.45 (2H, m),
6.65 (1H, d), 3.79 (3H, s), 3.76 (3H, s). 13C NMR (75 MHz, CDCl3)
d (ppm): 166.23, 151.94, 148.88, 135.94, 133.83, 130.74, 128.64,
127.71, 127.60, 127.26, 126.48, 125.13, 120.89, 120.33, 117.66,
110.70, 110.25, 55.87, 55.79.
4.3. Expression and purification of human QR2
Human QR2 was purified from 4L of Escherichia coli BL21(DE3)
grown in Luria–Bertani medium supplemented with 100 lg/mL
ampicillin as previously described.23 The concentration of purified
hQR2 was determined using BioRad Protein assay. QR2 was con-
centrated to 4 mg/mL for all kinetic and crystallization assays.
4.4. Steady-state kinetic assays and IC50 value determination
The enzymatic activity of QR2 at steady-state was determined
using two assays, where both utilized NMeH (N-methyldihydro-
nicotinamide) as the co-substrate.23,35,36 In the first assay, menadi-
one was used as the quinone substrate and QR2 activity was
monitored by the decrease in absorbance of NMeH at 360 nm.
The second assay utilized MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-
dipenyltetrazolium bromide)) as a quinone substrate and QR2
activity was monitored by the increase of the formazan product
at 612 nm. Both assays were performed at 25 C on a BioTek Syn-
ergy H1 multimode microplate reader. Reactions were carried
out in a 96-well plate to a final volume of 200 lL. Each assay mix-
ture contained 12 nM QR2, NMeH (100 lM for the first assay and
17.5 lM on the second assay), either 30 lM menadione in the first
assay or 200 lMMTT in the second assay, in a reaction buffer con-
taining 100 mM NaCl, 50 mM Tris (pH 7.5) and 0.1% Triton-X-100.
Substrates, inhibitor and buffer were added to the wells, and the
plate was shaken for 5 s using a Thermo LabSystems WellMix
microtiter plate shaker at a setting of 9–10 to mix the assay com-
ponents. With the microtiter plate still on the shaker (not shaking),
the enzyme, and associated control with no enzyme, were rapidly
pipetted into the appropriate wells using a multi-channel pipette,
and the plate was immediately shaken for 5 s to mix the enzyme
with reagents. The plate was immediately transferred to the plate
reader and the change in absorbance was monitored until the reac-
tion reached completion. Initial slopes of the reaction (DAbs/
Dtime) were measured and were used to calculate initial rates of
the reaction using a value of 7060 M1 cm1 as an extinction coef-
ficient for NMeH and 11,300 M1 cm1 as an extinction coefficient
for MTT.
Inhibitors were tested at 100 lM and compounds that showed
greater than 50% inhibition at 100 lM were assayed for their IC50
determination. The inhibition of QR2 activity by resveratrol ana-
logs were determined using the same assay conditions described
above except that inhibitor concentrations were varied from 0.2
to 100 lM. Assays at each inhibitor concentration were performed
in triplicate and the average and standard deviations in the rates
were used to determine the final IC50 values by calculating the per-
cent inhibition at each inhibitor concentration verses the negative
control with zero inhibitor. The percent inhibition data were then
plotted as a function of inhibitor concentration [I] and the data
were fit to the following equation using nonlinear regression:
Inhibition ð%Þ ¼ Inhibitionmax ð%Þ=ð1þ ½I=IC50Þ
All data were fit to the equation using the Enzyme Kinetics
Module of the program SigmaPlot from SPSS Scientific. IC50 values
are reported along with their standard error.
4.5. Crystallization and X-ray structure determination of
human QR2 in complex with inhibitors
QR2 was crystallized using our previously described meth-
ods.23,35,36 Briefly, the hanging-drop, vapor-diffusion method was
used by setting up drops adding 1 lL purified QR2 with 1 lL of res-
ervoir solution that contained between 1.3 and 1.7 M ammonium
sulfate, 0.1 M Bis–Tris buffer pH between 6.0 and 7.0, 0.1 M NaCl,
5 mM DTT and 12 lM FAD. Crystals were transferred from hang-
ing-drops to a 10 lL drop of prepared with 9 lL reservoir solution
and 1 lL stock solution of inhibitor (10 mM in 100% DMSO). Crys-
tals were soaked for 24 h, retrieved with a nylon loop, which was
then swiped through the same mother-liquor solution supple-
mented with 20% glycerol. The crystals were flash-frozen by plung-
ing into liquid nitrogen. Crystals were stored in shipping dewars
containing liquid nitrogen until X-ray data collection.
All diffraction data were collected at 100 K at the Life Sciences
Collaborative Access Team (LS-CAT) at the Advanced Photon
Source (APS) at Argonne National Laboratories. Crystals were
transferred from shipping dewars and mounted on a goniostat un-
der a stream of dry N2. X-ray data sets were collected using both
MarMosaic 300 and 225 mm CCD detectors. QR2-inhibitor com-
plexes were processed and scaled using the program HKL2000.
The crystals belonged to the primitive orthorhombic space group
P212121 with a dimer in the asymmetric unit.
The initial phases for QR2 in complex with the inhibitors were
determined by molecular replacement using PHASER in the CCP4
suite.40 The search model used was the structure of human QR2
in complex with resveratrol (PDB 1SG0).17 Molecular library files
and coordinates for the inhibitors were built using SKETCHER in
CCP4. The inhibitors were manually built into density using the
program COOT. Fourier maps were calculated and visualized using
the program COOT,41 and the structures were refined using the
program REFMAC. Water molecules were added manually to 2Fo-
Fc density peaks that were greater than 3.0 r. Iterative rounds
of refinement were continued until Rwork and Rfree values reached
6036 S. E. St. John et al. / Bioorg. Med. Chem. 21 (2013) 6022–6037
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their lowest values.42 At this point, TLS refinement was used by
submitting the coordinates to the TLS server,43–45 and then two
rounds of TLS and restrained refinement were performed in REF-
MAC to arrive at the final models, which were validated using Mol-
Probity.46 Electron density maps presented in the figures were
calculated using CCP4 and the figures were generated using the
program PyMol.
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